Expanded edition · 95 mediators and 126 cells, antibodies, complement components, acute-phase markers, biologic agents and precision therapies. Scenes 1–18 diagram all 95 in their cellular context, Scenes 19–38 add the T- and B-cell subsets, the immunoglobulins and their Fc receptors, complement, the neutrophil and the acute-phase markers, Scenes 39–43 the biologic and targeted agents that block them, and Scenes 44–47 the precision therapies and management of inborn errors of immunity; all 95 also appear in the mediator catalogue (where each is made and what it regulates), the source-cell index, the cell, antibody and complement catalogue, and the signalling tables below. Use the finder to see anything’s immediate upstream and downstream, and the what-if predictor to set levels and trace what would move.
Type a name, alias, gene or drug (e.g. IL-6, CXCL10, TSLP, Th17, IgG4, C3, Factor H, dupilumab, Xolair). All 95 mediators and all 126 cell subsets, immunoglobulins, Fc receptors, complement components, neutrophil steps, acute-phase markers, biologic agents and precision therapies can be centred here — agents by generic or trade name. The map shows the cells that make it and the mediators that act on it (left), and its receptor, cascade, effects and the mediators it acts on (right). Click any mediator box to re-centre on it; “Show in Scene” jumps to the diagram and highlights it. Solid arrows induce, dashed red blunt arrows inhibit production or block action, grey dotted arrows deliver (perforin letting granzymes in) or link to the producing cells; only interactions stated elsewhere in this atlas are listed.
Nothing selected yet.
Give one or more mediators, cell subsets, immunoglobulins or complement components a level (zero, low, normal, high, very high), then either predict what else would move, or ask what upstream cause would explain the pattern. You can also enter a biologic — dupilumab, etanercept, anakinra, tocilizumab, omalizumab, mepolizumab, rituximab, eculizumab and the rest of Scenes 39–43 — and the predictor will read it as “the patient is on this drug”: it reports what the agent blocks, what the atlas states that does to each test, and which tests it makes unreadable, before tracing the same chains. The predictor walks only the interactions this atlas states, up to three steps, and shows the chain behind every prediction so you can check it. Directions are qualitative: it says what would be pushed up or down, never by how much.
All 95 mediators, grouped by function. Made by lists the main producing cells (dominant source first); Regulates is the principal biological effect; Receptor → signalling names the receptor and the cascade class (chip colours match the cascade colours in the legend). Main scene gives the scene where the mediator is principally drawn; some also appear as outputs or cross-references in other scenes. Each mediator appears in one category only, even where it bridges two.
| Mediator | Made by | Regulates | Receptor → signalling | Main scene |
|---|---|---|---|---|
| IL-1α IL1A | Epithelial cells, keratinocytes and endothelium (stored, active precursor released on necrosis); activated macrophages | Sterile ‘first alarm’ after tissue damage; fever; endothelial adhesion molecules; induces IL-6 and chemokines | IL-1R1 + IL-1RAcP (IL-1R2 / CD121b is a membrane and soluble decoy) → MyD88 / IRAK4 / TRAF6 → NF-κB, MAPK NF-κB family | Scene 1 |
| IL-1β IL1B | Monocytes, macrophages, DCs, neutrophils (pro-IL-1β cleaved by the NLRP3 inflammasome / caspase-1) | Fever, acute-phase response (via IL-6), endothelial activation, neutrophil recruitment, Th17 differentiation | IL-1R1 + IL-1RAcP (IL-1R2 / CD121b is a membrane and soluble decoy) → MyD88 / IRAK4 / TRAF6 → NF-κB, MAPK NF-κB family | Scene 1 |
| IL-18 IL18 | Macrophages, DCs, keratinocytes, intestinal epithelium (caspase-1 processed; constitutive pro-form) | With IL-12, drives IFN-γ from NK and Th1 cells; NK cytotoxicity; held in check by IL-18BP | IL-18Rα + IL-18Rβ → MyD88 / IRAK → NF-κB NF-κB family | Scene 1, 2 |
| TNFα TNF | Macrophages, monocytes, T cells, NK cells, mast cells (preformed in granules); shed from membrane by ADAM17 | Endothelial activation, fever, cachexia, granuloma maintenance, cell death via TNFR1 | TNFR1 (p55), TNFR2 (p75) → TRADD / TRAF2 / RIPK1 → NF-κB, MAPK; or caspase-8 death NF-κB family | Scene 1 |
| TNFβ LTA (lymphotoxin-α) | Th1 cells, CD8 T cells, NK cells, B cells, ILC3 | Inflammation through the TNF receptors; as membrane LTα1β2, builds lymph nodes, Peyer’s patches and follicles | TNFR1, TNFR2, HVEM (and LTβR as LTα1β2) → TRADD / TRAF2 → NF-κB NF-κB family | Scene 1 |
| HMGB1 HMGB1 | Passively released by any necrotic cell; actively secreted by activated macrophages, monocytes, DCs and NK cells | Damage signal: macrophage TNF-α / IL-6 release, DC maturation; reduced form joins CXCL12 to recruit leukocytes | RAGE; TLR4 (disulfide form); CXCR4 when complexed with CXCL12 (reduced form) → TLR4 → MyD88 → NF-κB; RAGE → MAPK / NF-κB NF-κB family | Scene 7 |
| Mediator | Made by | Regulates | Receptor → signalling | Main scene |
|---|---|---|---|---|
| IL-33 IL33 | Airway and gut epithelium, endothelium, fibroblastic reticular cells — stored in the nucleus, released on necrosis or mechanical stress | Activates ILC2, Th2, mast cells, basophils, eosinophils and ST2+ Tregs → IL-5, IL-13; airway hyperresponsiveness | ST2 (IL1RL1) + IL-1RAcP; soluble ST2 is a decoy → MyD88 / IRAK → NF-κB, MAPK NF-κB family | Scene 7 |
| IL-17E/IL-25 IL25 | Intestinal tuft cells, airway epithelium; also Th2 cells, mast cells, eosinophils | Activates ILC2 (especially inflammatory ILC2s) and Th2 memory cells → IL-4, IL-5, IL-13; anti-helminth tuft-cell circuit | IL-17RA + IL-17RB → Act1 → TRAF6 → NF-κB NF-κB family | Scene 7 |
| TSLP TSLP | Airway, skin (keratinocyte) and gut epithelium; also mast cells, DCs, fibroblasts | Conditions DCs (OX40L, CCL17) to prime Th2; activates ILC2, mast cells and basophils; acts on itch neurons | TSLPR (CRLF2) + IL-7Rα → JAK1 + JAK2 → STAT5 JAK-STAT | Scene 7 |
| Mediator | Made by | Regulates | Receptor → signalling | Main scene |
|---|---|---|---|---|
| IL-10 IL10 | Tregs and Tr1 cells, macrophages (M2), Bregs, Th2 cells, DCs, mast cells | Shuts down macrophage / DC cytokine production and MHC II; limits Th1 and Th17 inflammation; IgG4 switching | IL-10R1 + IL-10R2 → JAK1 / TYK2 → STAT3 → suppressive gene programme JAK-STAT | Scene 1 |
| IL-1RA IL1RN | Monocytes, macrophages, neutrophils, hepatocytes (acute-phase), epithelium | Blocks IL-1α and IL-1β at IL-1R1 — the fastest brake on IL-1 inflammation | IL-1R1 (occupies without recruiting IL-1RAcP) → Competitive block — no signal Antagonist / decoy | Scene 1 |
| IL-35 IL12A (p35) + EBI3 | Regulatory T cells (firmly in mice; inducible ‘iTr35’ in humans), regulatory B cells | Suppresses effector T-cell proliferation and Th17; converts conventional T cells into IL-35-producing iTr35 cells; expands Bregs | IL-12Rβ2 + gp130 (also homodimers of either chain) → JAK1 / JAK2 → STAT1:STAT4 heterodimer JAK-STAT | Scene 9 |
| Mediator | Made by | Regulates | Receptor → signalling | Main scene |
|---|---|---|---|---|
| IL-12p40 IL12B (p40 subunit; p40 homodimer ‘p80’) | Activated macrophages, monocytes, DCs, neutrophils — made in large excess over IL-12p70 | Shared subunit of IL-12 (p35+p40) and IL-23 (p19+p40); free p40 / p80 dampens both (shown mainly in mice; weak in humans) | IL-12Rβ1 (as free p40 or p40 homodimer) → Occupies IL-12Rβ1 without STAT activation — competitive antagonist of IL-12 / IL-23 (mainly in mice) Antagonist / decoy | Scene 9 |
| IL-12p70 IL12A + IL12B | DCs, macrophages, monocytes, neutrophils (after TLR / CD40 signals) | Th1 differentiation (T-bet), IFN-γ production by NK and T cells, cytotoxicity | IL-12Rβ1 + IL-12Rβ2 → JAK2 / TYK2 → STAT4 JAK-STAT | Scene 2 |
| IL-27 IL27 (p28) + EBI3 | DCs, macrophages, monocytes | Early: T-bet and Th1 commitment; late: IL-10 from Tr1 cells, restrains Th17 and Th2 | IL-27Rα (WSX-1) + gp130 → JAK1 / JAK2 / TYK2 → STAT1 then STAT3 JAK-STAT | Scene 2 |
| IFNγ IFNG (type II IFN) | Th1 cells, CD8 T cells, NK and NKT cells, ILC1 | Macrophage activation (MHC II, microbicidal NO / ROS), IL-12 amplification, CXCL9/10/11, suppresses Th2 / Th17 | IFNGR1 + IFNGR2 → JAK1 / JAK2 → STAT1 homodimer (GAF) JAK-STAT | Scene 2 |
| Mediator | Made by | Regulates | Receptor → signalling | Main scene |
|---|---|---|---|---|
| IFNα2 IFNA2 (type I IFN) | Plasmacytoid DCs (dominant), any virus-infected cell, monocytes | Antiviral ISGs, MHC I up-regulation, NK activation, DC maturation, B-cell responses | IFNAR1 + IFNAR2 → JAK1 / TYK2 → ISGF3 (STAT1:STAT2:IRF9) JAK-STAT | Scene 5 |
| IFNβ IFNB1 (type I IFN) | Fibroblasts, epithelial cells, macrophages and DCs — the first IFN made after IRF3 activation; also pDCs | Antiviral ISGs; primes IRF7 to amplify IFN-α production; antiproliferative and immunomodulatory effects | IFNAR1 + IFNAR2 (highest-affinity type I IFN) → JAK1 / TYK2 → ISGF3 → ISGs incl. IRF7 JAK-STAT | Scene 8 |
| IFNω IFNW1 (type I IFN) | Leukocytes — pDCs and monocytes (co-produced with IFN-α) | Antiviral ISGs, with the same receptor and programme as IFN-α | IFNAR1 + IFNAR2 → JAK1 / TYK2 → ISGF3 JAK-STAT | Scene 8 |
| IL-28A IFNL2 (IFN-λ2, type III IFN) | Epithelial cells (airway, gut), hepatocytes, pDCs and DCs | Antiviral ISGs restricted to barrier epithelium, hepatocytes and a few leukocytes (neutrophils, pDCs) — protection with less systemic inflammation | IFNLR1 + IL-10R2 → JAK1 / TYK2 → ISGF3 JAK-STAT | Scene 8 |
| IL-29 IFNL1 (IFN-λ1, type III IFN) | Epithelial cells, hepatocytes, pDCs and DCs (IFNL1 is a pseudogene in mice) | Same barrier-restricted antiviral programme as IL-28A | IFNLR1 + IL-10R2 → JAK1 / TYK2 → ISGF3 JAK-STAT | Scene 8 |
| Mediator | Made by | Regulates | Receptor → signalling | Main scene |
|---|---|---|---|---|
| IL-4 IL4 | Th2 and Tfh cells, basophils, mast cells, eosinophils, NKT cells | Th2 differentiation (GATA3), IgE and IgG4 class switching, alternatively activated macrophages, VCAM-1, suppresses Th1 | Type I: IL-4Rα + γc; type II: IL-4Rα + IL-13Rα1 → JAK1 / JAK3 (type I) or JAK1 / JAK2 / TYK2 (type II) → STAT6 JAK-STAT | Scene 3 |
| IL-5 IL5 | ILC2 (major), Th2 cells, mast cells, eosinophils | Eosinophil production, release from marrow, survival and activation | IL-5Rα + βc → JAK1 / JAK2 → STAT5 (also STAT1/3) JAK-STAT | Scene 3 |
| IL-9 IL9 | Th9 and Th2 cells, ILC2, mast cells | Mast-cell expansion and survival, mucus production, ILC2 survival | IL-9R + γc → JAK1 / JAK3 → STAT5 (also STAT1/3) JAK-STAT | Scene 3 |
| IL-13 IL13 | Th2 cells, ILC2, mast cells, basophils, NKT cells | Goblet-cell mucus, airway hyperresponsiveness, epithelial eotaxin-3 and periostin, fibrosis, barrier disruption | IL-4Rα + IL-13Rα1 (IL-13Rα2 is a decoy) → JAK1 / JAK2 / TYK2 → STAT6 JAK-STAT | Scene 3 |
| IL-31 IL31 | Th2 cells (skin-homing), mast cells, macrophages, DCs | Itch via sensory (DRG) neurons; keratinocyte differentiation and barrier | IL-31RA + OSMRβ → JAK1 / JAK2 → STAT3 (also STAT1/5) JAK-STAT | Scene 3 |
| Mediator | Made by | Regulates | Receptor → signalling | Main scene |
|---|---|---|---|---|
| IL-17A IL17A | Th17 cells, γδ T cells, ILC3, MAIT cells, Tc17 cells | Epithelial and fibroblast CXCL1/5/8, G-CSF, antimicrobial peptides → neutrophilic inflammation; anti-Candida defence | IL-17RA + IL-17RC → Act1 → TRAF6 → NF-κB, C/EBPβ NF-κB family | Scene 4 |
| IL-17F IL17F | Th17 cells, γδ T cells, ILC3, MAIT cells; some epithelial cells | Same programme as IL-17A but weaker: neutrophil chemokines (CXCL1, CXCL5), G-CSF, β-defensins; mucosal anti-Candida / anti-Staphylococcus defence | IL-17RA + IL-17RC (as homodimer or IL-17A/F heterodimer) → Act1 → TRAF6 → NF-κB, C/EBPβ NF-κB family | Scene 10 |
| IL-21 IL21 | Tfh cells (major), Th17 cells, NKT cells | Germinal-centre B cells and plasma-cell differentiation; autocrine Th17 amplification (proposed; intact Th17 responses in IL-21- and IL-21R-deficient mice); CD8 and NK cytotoxicity | IL-21R + γc → JAK1 / JAK3 → STAT3 (also STAT1) JAK-STAT | Scene 4 |
| IL-22 IL22 | Th22 and Th17 cells, ILC3, γδ T cells | Epithelial antimicrobial peptides, regeneration and barrier repair; hepatocyte acute-phase proteins; keratinocyte hyperplasia | IL-22R1 + IL-10R2 (IL-22BP is a soluble decoy) → JAK1 / TYK2 → STAT3 JAK-STAT | Scene 4 |
| IL-23 IL23A (p19) + IL12B (p40) | DCs and macrophages (especially in skin and gut) | Expands and stabilizes Th17 and ILC3; IL-17 and IL-22 production | IL-23R + IL-12Rβ1 → JAK2 / TYK2 → STAT3 (also STAT4, weakly) JAK-STAT | Scene 2, 4 |
| IL-20 IL20 | Keratinocytes, monocytes, macrophages, DCs | Keratinocyte proliferation and antimicrobial-peptide expression (epidermal hyperplasia); osteoclast formation | IL-20R1 + IL-20R2 (type I) or IL-22R1 + IL-20R2 (type II) → JAK1 / TYK2 → STAT3 JAK-STAT | Scene 10 |
| IL-24 IL24 (MDA-7) | Keratinocytes, Th2 and Th17 cells, monocytes, melanocytes | Keratinocyte proliferation; IL-13-driven IL-24 lowers filaggrin (barrier defect in atopic dermatitis); tumour-suppressive | IL-20R1 + IL-20R2 or IL-22R1 + IL-20R2 → JAK1 / TYK2 → STAT3 JAK-STAT | Scene 10 |
| Mediator | Made by | Regulates | Receptor → signalling | Main scene |
|---|---|---|---|---|
| IL-2 IL2 | Activated CD4 (and CD8) T cells; small amounts from DCs and NKT cells | T-cell proliferation, Treg maintenance (CD25), NK activation, activation-induced cell death | IL-2Rα (CD25) + IL-2Rβ + γc → JAK1 / JAK3 → STAT5 JAK-STAT | Scene 5 |
| IL-7 IL7 | Thymic and bone-marrow stroma, lymph-node FRCs, intestinal epithelium, keratinocytes | T-cell development, naive and memory T-cell survival, ILC development | IL-7Rα + γc → JAK1 / JAK3 → STAT5 JAK-STAT | Scene 5 |
| IL-15 IL15 | Monocytes, macrophages, DCs, stromal and epithelial cells (trans-presented on IL-15Rα) | NK, NKT, memory CD8 and intra-epithelial lymphocyte survival and proliferation | IL-2Rβ + γc on the responding cell (IL-15 trans-presented on IL-15Rα) → JAK1 / JAK3 → STAT5 JAK-STAT | Scene 5 |
| Mediator | Made by | Regulates | Receptor → signalling | Main scene |
|---|---|---|---|---|
| IL-6 IL6 | Macrophages, DCs, T cells, fibroblasts, endothelium, adipocytes, muscle | Acute-phase proteins (CRP, fibrinogen, hepcidin), fever, Th17 (with TGF-β), plasma-cell differentiation | IL-6Rα (membrane or soluble ‘trans-signalling’) + gp130 → JAK1 / JAK2 / TYK2 → STAT3 JAK-STAT | Scene 4, 5 |
| IL-11 IL11 | Fibroblasts (TGF-β-induced, major), bone-marrow stroma, epithelial cells, osteoblasts | Fibroblast activation and fibrosis (autocrine), megakaryocyte maturation, bone remodelling, mucosal protection | IL-11Rα + gp130 homodimer → JAK1 (JAK2, TYK2) → STAT3; fibrotic programme largely ERK-dependent JAK-STAT | Scene 10 |
| LIF LIF (leukemia inhibitory factor) | Activated T cells, monocytes, fibroblasts, astrocytes, endometrium, bone-marrow stroma | Mouse ES-cell self-renewal, embryo implantation, acute-phase proteins, neuronal survival, platelet formation | LIFR + gp130 → JAK1 (JAK2, TYK2) → STAT3 JAK-STAT | Scene 10 |
| Mediator | Made by | Regulates | Receptor → signalling | Main scene |
|---|---|---|---|---|
| IL-3 IL3 | Activated T cells (Th2), mast cells, basophils, NK cells | Multilineage progenitor growth; basophil and mast-cell growth and priming (histamine release); pDC survival | IL-3Rα (CD123) + βc → JAK2 → STAT5 JAK-STAT | Scene 11 |
| GM-CSF CSF2 | T cells (Th17 / ThGM), macrophages, endothelium, fibroblasts, alveolar epithelium | Granulocyte and macrophage production, alveolar-macrophage maturation (surfactant clearance), inflammatory DCs | GM-CSFRα + βc → JAK2 → STAT5 JAK-STAT | Scene 5 |
| G-CSF CSF3 | Monocytes, macrophages, endothelium, fibroblasts, epithelium (strongly IL-17-induced) | Neutrophil production, release from marrow and survival; mobilizes stem cells | G-CSFR (CSF3R) homodimer → JAK1 / JAK2 → STAT3 (also STAT5) JAK-STAT | Scene 11 |
| M-CSF CSF1 | Fibroblasts, osteoblasts, endothelium, bone-marrow stroma, macrophages (constant circulating level) | Monocyte / macrophage survival, proliferation and differentiation; osteoclasts (with RANKL); tissue-resident macrophages | CSF1R (c-FMS) → Receptor tyrosine kinase → PI3K / AKT, ERK Receptor tyrosine kinase | Scene 11 |
| IL-34 IL34 | Keratinocytes, neurons, splenic red-pulp stroma | Development and maintenance of Langerhans cells and microglia | CSF1R (also PTPRZ1, syndecan-1) → Receptor tyrosine kinase → PI3K / AKT, ERK Receptor tyrosine kinase | Scene 11 |
| SCF KITLG (stem cell factor, KIT ligand) | Bone-marrow stroma and endothelium, fibroblasts, keratinocytes, airway epithelium and smooth muscle | Stem-cell maintenance; mast-cell development, survival and activation; melanocytes and germ cells | KIT (CD117) → Receptor tyrosine kinase → PI3K / AKT, MAPK, (STAT) Receptor tyrosine kinase | Scene 11 |
| Flt-3 Ligand FLT3LG | Bone-marrow stroma, T cells, endothelium (membrane and soluble forms) | Dendritic-cell development (cDC and pDC), early progenitor expansion, NK cells | FLT3 (CD135) → Receptor tyrosine kinase → PI3K / AKT, RAS / MAPK, STAT5 Receptor tyrosine kinase | Scene 11 |
| TPO THPO (thrombopoietin) | Liver hepatocytes (constant production), kidney, marrow stroma | Megakaryocyte growth and platelet production; stem-cell quiescence; plasma level set by platelet MPL clearance | MPL → JAK2 → STAT5 (also STAT3) JAK-STAT | Scene 11 |
| Mediator | Made by | Regulates | Receptor → signalling | Main scene |
|---|---|---|---|---|
| EGF EGF | Salivary and Brunner’s glands, kidney, platelets, macrophages; abundant in saliva, milk and urine | Epithelial proliferation and migration, wound healing, gut mucosal repair; airway goblet-cell (MUC5AC) mucus | EGFR (ErbB1) → Receptor tyrosine kinase → RAS / MAPK, PI3K / AKT, PLCγ Receptor tyrosine kinase | Scene 12 |
| TGFα TGFA | Macrophages, keratinocytes, epithelial cells, eosinophils (membrane precursor shed by ADAM17) | Keratinocyte and epithelial proliferation, wound re-epithelialization, airway mucous metaplasia | EGFR (ErbB1) → Receptor tyrosine kinase → RAS / MAPK, PI3K / AKT Receptor tyrosine kinase | Scene 12 |
| FGF-2 FGF2 (basic FGF) | Fibroblasts, endothelium, macrophages, mast cells, smooth muscle (released on injury — no signal peptide) | Angiogenesis, fibroblast proliferation, wound healing, airway smooth-muscle growth | FGFR1–4 + heparan sulfate → Receptor tyrosine kinase → RAS / MAPK, PI3K, PLCγ Receptor tyrosine kinase | Scene 12 |
| PDGF-AA PDGFA homodimer | Platelets (α-granules), macrophages, epithelial cells, astrocytes, smooth muscle | Fibroblast and oligodendrocyte-precursor proliferation; alveolar myofibroblast development | PDGFRα homodimer → Receptor tyrosine kinase → PI3K, PLCγ, RAS / MAPK Receptor tyrosine kinase | Scene 12 |
| PDGF-AB/BB PDGFA/PDGFB heterodimer; PDGFB homodimer | Platelets (major), macrophages, endothelium, smooth muscle | Pericyte and smooth-muscle recruitment to vessels; fibroblast chemotaxis and proliferation; wound healing; airway remodelling | PDGFRαα, PDGFRαβ, PDGFRββ (BB binds all three; AB binds αα and αβ) → Receptor tyrosine kinase → PI3K, PLCγ, RAS / MAPK Receptor tyrosine kinase | Scene 12 |
| VEGF-A VEGFA | Hypoxic epithelial and tumour cells (HIF-1α), macrophages, keratinocytes, mast cells, eosinophils, neutrophils, platelets | Angiogenesis, vascular permeability (oedema), endothelial survival; airway vascular remodelling | VEGFR2 (KDR) + neuropilin-1; VEGFR1 (FLT1) as a high-affinity sink → Receptor tyrosine kinase → PLCγ / ERK, PI3K / AKT / eNOS Receptor tyrosine kinase | Scene 12 |
| Mediator | Made by | Regulates | Receptor → signalling | Main scene |
|---|---|---|---|---|
| BAFF TNFSF13B (BLyS) | Monocytes, macrophages, DCs, neutrophils, lymphoid stromal cells, epithelium (strongly interferon-induced) | Survival of transitional and mature naive B cells; class switching via TACI; excess BAFF rescues autoreactive B cells | BAFF-R (BR3), TACI, BCMA → TRAF3 degradation → NIK → non-canonical NF-κB (p52 / RelB) NF-κB family | Scene 13 |
| APRIL TNFSF13 | Monocytes, macrophages, DCs, neutrophils, eosinophils and osteoclasts in the marrow plasma-cell niche, gut epithelium | Long-lived plasma-cell survival (BCMA); T-independent IgA class switching (TACI) | TACI, BCMA (plus heparan sulfate proteoglycans) → TRAF → canonical and non-canonical NF-κB NF-κB family | Scene 13 |
| sCD40L CD40LG (soluble CD154) | Activated CD4 T cells (shed from the membrane) and platelets (source of most circulating sCD40L); mast cells, basophils | Platelet activation marker, endothelial activation and thrombus stability. Class switching and germinal-centre formation are functions of MEMBRANE CD40L on the T cell, not of the soluble molecule, which is a weak agonist and mostly platelet-derived — a serum level does not report B-cell helper function | CD40 (also αIIbβ3 and Mac-1 integrins) → TRAF2/3/5/6 → canonical and non-canonical NF-κB NF-κB family | Scene 13 |
| sCD137 TNFRSF9 (soluble 4-1BB) | Activated T cells and NK cells (alternatively spliced), some tumours | Dampens 4-1BB co-stimulation of CD8 T cells; serum marker of T-cell activation | Binds 4-1BBL (CD137L) — decoy → No signal; blocks 4-1BB co-stimulation Antagonist / decoy | Scene 9 |
| Mediator | Made by | Regulates | Receptor → signalling | Main scene |
|---|---|---|---|---|
| sFasL FASLG (soluble CD95L) | Shed (metalloproteinases) from activated CTLs, NK cells and Th1 cells; constitutive at immune-privileged sites | Contraction of activated lymphocyte clones, removal of autoreactive lymphocytes; soluble form mainly chemotactic / non-apoptotic | Fas (CD95) → FADD → caspase-8 → caspase-3 (soluble form is a weak killer) Death receptor | Scene 14 |
| sFas FAS (soluble CD95) | Activated lymphocytes and many tissues (exon-skipping splice variant) | Inhibits FasL-induced apoptosis | Binds FasL — decoy → No signal; blocks Fas-mediated apoptosis Antagonist / decoy | Scene 9 |
| TRAIL TNFSF10 (Apo2L) | NK cells (especially liver), CTLs, pDCs, monocytes, neutrophils — strongly interferon-induced | Kills virus-infected and transformed cells; NK immune surveillance; limits autoimmunity | DR4 (TRAIL-R1), DR5 (TRAIL-R2); decoys DcR1, DcR2, OPG → FADD → caspase-8 → caspase-3; also NF-κB Death receptor | Scene 14 |
| Perforin PRF1 | CD8 CTLs, NK cells, NKT and γδ T cells, CD4 CTLs | Target-cell killing; removes antigen-presenting cells and so ends T-cell / macrophage activation | Inserts into the target-cell membrane (Ca²⁺-dependent) → Forms pores → delivers granzymes Cytotoxic granule | Scene 14 |
| Granzyme A GZMA | CTLs, NK cells, γδ T cells (one of the two most abundant, with granzyme B) | Caspase-independent target death — mechanism uncertain: mitochondrial damage, SET-complex cleavage with single-strand nicks, and gasdermin-B pyroptosis in GSDMB+ human epithelium have all been proposed and are disputed; reported extracellular induction of IL-1β, IL-6 and TNF-α from monocytes is contested (endotoxin in recombinant preparations) | Enters through perforin pores (extracellular actions via unknown receptors) → Cleaves SET complex → single-strand DNA nicks (caspase-independent); cleaves gasdermin B Cytotoxic granule | Scene 14 |
| Granzyme B GZMB | CTLs, NK cells; also pDCs, B cells, basophils, mast cells, keratinocytes | Rapid apoptosis of infected / tumour cells; extracellularly degrades matrix and barrier proteins | Enters through perforin pores → Cleaves BID and caspase-3/7 → mitochondrial apoptosis Cytotoxic granule | Scene 14 |
| Mediator | Made by | Regulates | Receptor → signalling | Main scene |
|---|---|---|---|---|
| IL-8 CXCL8 | Monocytes, macrophages, epithelium, endothelium, fibroblasts, keratinocytes, neutrophils (IL-1 / TNF / IL-17-induced) | Neutrophil chemotaxis, adhesion and degranulation; angiogenesis | CXCR1, CXCR2 → Gαi → PI3K, Rho GTPases, Ca²⁺ flux Chemokine GPCR | Scene 6 |
| GROα CXCL1 | Epithelium, keratinocytes, macrophages, endothelium, fibroblasts (strongly IL-17-induced) | Neutrophil recruitment; angiogenesis; oligodendrocyte-precursor signalling | CXCR2 → Gαi → PI3K, Rho GTPases, Ca²⁺ flux Chemokine GPCR | Scene 6 |
| ENA-78 CXCL5 | Type II alveolar epithelium, platelets, monocytes, endothelium, fibroblasts (IL-1 / TNF / IL-17-induced) | Neutrophil recruitment and angiogenesis; tunes plasma CXCL1/CXCL8 availability via the DARC (ACKR1) sink | CXCR2 → Gαi → PI3K, Rho GTPases, Ca²⁺ flux Chemokine GPCR | Scene 15 |
| GCP-2 CXCL6 | Fibroblasts, airway and gut epithelium, macrophages, chondrocytes (IL-1 / TNF-induced) | Neutrophil chemotaxis and degranulation; antimicrobial activity; angiogenesis | CXCR1, CXCR2 → Gαi → PI3K, Rho GTPases, Ca²⁺ flux Chemokine GPCR | Scene 15 |
| Mediator | Made by | Regulates | Receptor → signalling | Main scene |
|---|---|---|---|---|
| IP-10 CXCL10 | Monocytes, endothelium, keratinocytes, fibroblasts, epithelium — induced by IFN-γ and type I IFN | Recruits Th1 cells, CTLs and NK cells; angiostatic | CXCR3 → Gαi → PI3K, Ca²⁺ flux Chemokine GPCR | Scene 6 |
| MIG CXCL9 | Macrophages, DCs, endothelium, keratinocytes — predominantly IFN-γ-induced | Recruits Th1 cells, CTLs and NK cells into inflamed tissue; angiostatic | CXCR3 → Gαi → PI3K, Ca²⁺ flux Chemokine GPCR | Scene 15 |
| I-TAC CXCL11 | Monocytes, endothelium, keratinocytes, astrocytes — induced by IFN-γ plus type I IFN | Most potent CXCR3 agonist; effector T-cell recruitment | CXCR3 (highest affinity) → Gαi → PI3K, Ca²⁺ flux; ACKR3 = scavenger (no G-protein signal) Chemokine GPCR | Scene 15 |
| Mediator | Made by | Regulates | Receptor → signalling | Main scene |
|---|---|---|---|---|
| MCP-1 CCL2 | Monocytes, macrophages, endothelium, fibroblasts, epithelium, smooth muscle | Monocyte egress from marrow and recruitment; memory T and NK cells; basophil histamine release | CCR2 → Gαi → PI3K, Ca²⁺ flux Chemokine GPCR | Scene 6 |
| MCP-2 CCL8 | Fibroblasts, monocytes, endothelium (interferon-induced) | Recruits monocytes, T cells, NK cells, eosinophils, basophils; in mouse skin draws IL-5+ Th2 cells via CCR8 | CCR1, CCR2, CCR3, CCR5 (CCR8 in mice) → Gαi → PI3K, Ca²⁺ flux Chemokine GPCR | Scene 16 |
| MCP-3 CCL7 | Monocytes, fibroblasts, platelets, mast cells, keratinocytes | Broad recruiter: monocyte marrow egress (with CCL2), eosinophils, basophils, DCs, T and NK cells | CCR1, CCR2, CCR3 (CCR5 antagonist) → Gαi → PI3K, Ca²⁺ flux Chemokine GPCR | Scene 16 |
| MIP-1α CCL3 | Macrophages, DCs, T cells, NK cells, neutrophils, mast cells | Recruits monocytes, T cells, NK cells, DCs and eosinophils; osteoclast activation; inhibits stem-cell proliferation | CCR1, CCR5 → Gαi → PI3K, Ca²⁺ flux Chemokine GPCR | Scene 6 |
| MIP-1β CCL4 | Macrophages, DCs, CD8 T cells, NK cells | Recruits CCR5+ T cells, NK cells and monocytes; blocks R5 HIV entry | CCR5 → Gαi → PI3K, Ca²⁺ flux Chemokine GPCR | Scene 6 |
| MIP-1δ CCL15 (leukotactin-1, HCC-2) | Monocytes, macrophages, intestinal and lung epithelium | Recruits monocytes, neutrophils, lymphocytes and eosinophils; potency rises after protease trimming of the N-terminus | CCR1, CCR3 → Gαi → PI3K, Ca²⁺ flux Chemokine GPCR | Scene 16 |
| MPIF-1 CCL23 (MIP-3, CKβ8) | Monocytes, macrophages and DCs (boosted by IL-4 / IL-13) | Recruits monocytes and resting T cells; inhibits myeloid progenitor proliferation (its namesake); angiogenic | CCR1 → Gαi → PI3K, Ca²⁺ flux Chemokine GPCR | Scene 16 |
| RANTES CCL5 | Activated T cells (late), platelets (α-granules), epithelium, endothelium, fibroblasts, macrophages | Recruits T cells, monocytes, eosinophils, basophils, NK cells and DCs | CCR1, CCR3, CCR5 → Gαi → PI3K, Ca²⁺ flux Chemokine GPCR | Scene 6 |
| Mediator | Made by | Regulates | Receptor → signalling | Main scene |
|---|---|---|---|---|
| Eotaxin CCL11 | Airway epithelium, fibroblasts, smooth muscle, endothelium, eosinophils (IL-4 / IL-13 / TNF-induced) | Eosinophil, basophil and Th2 recruitment; with IL-5, eosinophil release from marrow | CCR3 → Gαi → PI3K, Ca²⁺ flux Chemokine GPCR | Scene 6 |
| Eotaxin-2 CCL24 | Activated (IL-4-conditioned) monocytes and macrophages, DCs, airway epithelium, fibroblasts | Eosinophil and basophil chemotaxis; resting T cells | CCR3 → Gαi → PI3K, Ca²⁺ flux Chemokine GPCR | Scene 17 |
| Eotaxin-3 CCL26 | Epithelium (oesophageal, airway), keratinocytes, endothelium — strongly IL-4 / IL-13 / STAT6-induced | Eosinophil and basophil recruitment; the dominant epithelial eotaxin in chronic Th2 inflammation | CCR3 (also a CX3CR1 agonist and a CCR1, CCR2, CCR5 antagonist) → Gαi → PI3K, Ca²⁺ flux Chemokine GPCR | Scene 17 |
| MCP-4 CCL13 | Endothelium, airway epithelium, fibroblasts, monocytes (IL-1 / TNF plus IL-4 / IL-13) | Eosinophil, basophil, monocyte and T-cell chemotaxis | CCR1, CCR2, CCR3 → Gαi → PI3K, Ca²⁺ flux Chemokine GPCR | Scene 17 |
| TARC CCL17 | DCs (incl. Langerhans and TSLP-conditioned DCs), keratinocytes, endothelium, bronchial epithelium; Reed–Sternberg cells | Recruits CCR4+ Th2, Treg and skin-homing (CLA+) T cells | CCR4 → Gαi → PI3K, Ca²⁺ flux Chemokine GPCR | Scene 17 |
| MDC CCL22 | DCs, macrophages (IL-4-conditioned), activated B cells | Recruits Th2 and Treg cells; Treg–DC contacts; Treg recruitment into tumours | CCR4 → Gαi → PI3K, Ca²⁺ flux Chemokine GPCR | Scene 17 |
| I-309 CCL1 | Activated monocytes / macrophages, mast cells, activated T cells (Th2), endothelium | Recruits CCR8+ Tregs (especially in skin and tumours), Th2 cells and monocytes; enhances Treg suppression | CCR8 → Gαi → PI3K, Ca²⁺ flux Chemokine GPCR | Scene 17 |
| IL-16 IL16 (lymphocyte chemoattractant factor) | CD8 T cells (preformed, caspase-3 processed), CD4 T cells, mast cells, eosinophils, airway epithelium, B cells | Chemoattractant for CD4+ T cells, monocytes and eosinophils; primes CD4 T cells (CD25); competes with HIV for CD4 | CD4 (with CD9) — not a GPCR → CD4-associated Lck signalling → migration, IL-2Rα (CD25) expression Other (CD4) | Scene 17 |
| Mediator | Made by | Regulates | Receptor → signalling | Main scene |
|---|---|---|---|---|
| SDF-1 CXCL12 | Bone-marrow CXCL12-abundant reticular (CAR) cells, osteoblasts, endothelium, lymph-node stroma | Stem-cell retention and homing, B-cell development, plasma-cell niches, germinal-centre dark zone | CXCR4 (ACKR3 = scavenger) → Gαi → PI3K, Ca²⁺ flux Chemokine GPCR | Scene 6 |
| 6Ckine CCL21 (SLC) | Lymph-node high endothelial venules and T-zone fibroblastic reticular cells; lymphatic endothelium | Entry of naive / central-memory T cells and mature DCs into lymph-node T zones; DC migration along lymphatics | CCR7 → Gαi → PI3K, Ca²⁺ flux; integrin activation Chemokine GPCR | Scene 18 |
| MIP-3β CCL19 (ELC) | Lymph-node T-zone fibroblastic reticular cells, mature DCs | T-cell / DC encounters in the T zone (with CCL21); unlike CCL21 it triggers CCR7 internalization | CCR7 → Gαi → PI3K, Ca²⁺ flux Chemokine GPCR | Scene 18 |
| BCA-1 CXCL13 (BLC) | Follicular DCs and marginal reticular cells; human Tfh cells; stroma of ectopic lymphoid follicles | Homing of B cells and Tfh cells to follicles; germinal-centre organization; ectopic lymphoid structures | CXCR5 → Gαi → PI3K, Ca²⁺ flux Chemokine GPCR | Scene 18 |
| MIP-3α CCL20 (LARC) | Epithelium (gut follicle-associated, skin keratinocytes, airway) induced by IL-1β / TNF / IL-17; Th17 cells | Recruits CCR6+ Th17, Treg, immature DC and B cells to epithelia and Peyer’s patches | CCR6 (its only chemokine receptor; β-defensin-2 is also reported to bind CCR6) → Gαi → PI3K, Ca²⁺ flux Chemokine GPCR | Scene 18 |
| CTACK CCL27 | Keratinocytes (constitutive; increased by TNF-α / IL-1β) | Skin homing of CLA+ CCR10+ memory T cells, including skin Tregs | CCR10 → Gαi → PI3K, Ca²⁺ flux Chemokine GPCR | Scene 18 |
| CCL28 CCL28 (MEC) | Mucosal and glandular epithelium (salivary, colon, airway, lactating mammary gland) | Homing of IgA plasmablasts to mucosa and milk; CCR3+ eosinophils; direct antimicrobial activity | CCR10, CCR3 → Gαi → PI3K, Ca²⁺ flux Chemokine GPCR | Scene 18 |
| Lymphotactin XCL1 | Activated CD8 T cells, NK cells, NKT and γδ T cells | Draws XCR1+ cross-presenting cDC1 to CD8 T cells, strengthening cross-priming; thymic Treg development | XCR1 → Gαi → PI3K, Ca²⁺ flux Chemokine GPCR | Scene 18 |
| Fractalkine CX3CL1 | Inflamed endothelium (TNF / IL-1 / IFN-γ-induced), neurons, epithelium, DCs | Firm capture and recruitment of CX3CR1+ patrolling monocytes, NK and effector CD8 T cells; neuron–microglia signalling | CX3CR1 → Gαi + direct adhesion (membrane-anchored on a mucin stalk; ADAM10/17 shed) Chemokine GPCR | Scene 18 |
The 126 entities added in Scenes 19–47: every T- and B-cell subset, the nine immunoglobulin isotypes and their Fc receptors, the complement components, regulators and receptors, and the steps of the neutrophil life cycle from marrow to resolution, and the acute-phase markers. Made / induced by is what generates or produces it; Function and clinical correlate is what it does and what happens when it fails; Receptor → signalling names the receptor and cascade; Detail carries markers, homing, typical levels and cytokine control. Every level is a typical adult figure for orientation only — reference ranges are laboratory-specific and strongly age-specific, and paediatric values differ sharply from adult ones.
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| Th1 CD4 helper 1 CD4 effector subset | Naive CD4 T cell driven by IL-12 (+ IL-18) from macrophages and DC1s during intracellular infection | Macrophage activation, IgG1 and IgG3 class switching, delayed-type hypersensitivity Mendelian susceptibility to mycobacterial disease (IL12B, IL12RB1, IFNGR1/2, STAT1); driver of granulomatous inflammation | IL-12R (IL-12Rβ1 + IL-12Rβ2); IFN-γR; CXCR3 for tissue entry → STAT4 (IL-12) and STAT1 (IFN-γ) → T-bet | Defining factor: T-bet (TBX21), with STAT4 / STAT1 Markers: CD4, CXCR3, CCR5, IL-12Rβ2, IL-18R Homing: CXCR3, CCR5 → inflamed Th1 tissue Makes: IFNγ, TNFα, TNFβ, IL-2, IL-10 | Scene 19 |
| Th2 CD4 helper 2 CD4 effector subset | Naive CD4 T cell driven by IL-4 (with TSLP-, IL-33- or IL-25-conditioned DCs) during allergen or helminth exposure | IgE class switching, eosinophilia, mucus, smooth-muscle and barrier changes of allergic disease Atopic dermatitis, allergic asthma, food allergy, eosinophilic oesophagitis; Th2A frequency falls with successful oral or sublingual immunotherapy and with naturally acquired tolerance; target of dupilumab (IL-4Rα) and anti-IL-5 agents | IL-4R (IL-4Rα + γc); ST2 and IL-17RB on memory Th2; CCR4 and CCR3 for tissue entry → STAT6 (IL-4) → GATA3; STAT5 (IL-2) supports it | Defining factor: GATA3, with STAT6 / STAT5 Markers: CD4, CRTH2 (DP2), CCR4, ST2, IL-17RB; the allergen-specific pathogenic effector "Th2A" subset is CRTH2+ CD161+ CD27− IL-17RB+ with high CD49d Homing: CCR4, CCR3, CRTH2 → allergic tissue, skin and airway Makes: IL-4, IL-5, IL-13, IL-9, IL-31, IL-10, GM-CSF | Scene 19 |
| Th17 CD4 helper 17 CD4 effector subset | Naive CD4 T cell driven in humans mainly by IL-1β with IL-6 and IL-23 (TGF-β is permissive at low dose; its obligate role is established in mouse but contested in humans), then stabilized by IL-23 and its own IL-21 | Neutrophil recruitment and antifungal/antibacterial defence at barriers; autoimmune tissue inflammation STAT3 LOF (hyper-IgE), IL17RA / IL17RC / IL17F / ACT1 (TRAF3IP2) and RORC defects and STAT1 GOF cause chronic mucocutaneous candidiasis (RORC also brings mycobacterial susceptibility); CARD9 deficiency causes invasive and CNS fungal disease; in APECED (AIRE) neutralizing anti-IL-17 and anti-IL-22 autoantibodies produce the same candidiasis; target of anti-IL-17 and anti-IL-23 agents | IL-6R, IL-23R, IL-21R, IL-1R1; CCR6 for epithelial homing → STAT3 → RORγt | Defining factor: RORγt (RORC), with STAT3 Markers: CD4, CCR6, IL-23R, CD161 Homing: CCR6 → epithelium, gut and skin (CCL20) Makes: IL-17A, IL-17F, IL-22, IL-21, GM-CSF, TNFα | Scene 19 |
| Th9 CD4 helper 9 CD4 effector subset | Naive CD4 T cell driven by IL-4 plus TGF-β (IL-25 and TSLP enhance it) | Mast-cell accumulation and IL-9-dependent allergic inflammation; antihelminth and antitumour effects shown in mouse models. A differentiation state rather than a stable lineage; IL-9 output is lost on restimulation Contributes to asthma and food-allergy mast-cell burden; no monogenic human disease defined | IL-4R, TGF-βR, IL-2R → STAT6 + SMAD → PU.1, IRF4 | Defining factor: PU.1 (SPI1) with IRF4, BATF and GATA3 Markers: No defining surface phenotype in humans; identified by IL-9 secretion; GATA3 is required alongside PU.1, IRF4 and BATF, although PU.1 blocks the full Th2 programme Homing: CCR3, CCR6 → airway and gut mucosa Makes: IL-9, IL-10, IL-21 | Scene 19 |
| Th22 CD4 helper 22 CD4 effector subset | Naive CD4 T cell driven by IL-6 and TNF-α with aryl-hydrocarbon-receptor ligands, in skin-draining nodes | Keratinocyte antimicrobial peptides, proliferation and wound repair without the IL-17 neutrophil programme Expanded in psoriasis and in atopic dermatitis (IL-22 correlates with severity) | IL-6R, TNFR; CCR4 + CCR10 for skin homing → STAT3 with AHR | Defining factor: AHR (required for IL-22 but not lineage-restricted) with STAT3; no master transcription factor; best regarded as a differentiation state Markers: CD4, CCR10 with CCR4/CCR6, no IL-17A Homing: CCR10 with CCR4 → skin Makes: IL-22, TNFα | Scene 19 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| Tfh follicular helper T cell CD4 helper for B cells | Naive CD4 T cell primed by dendritic cells (in humans mainly by IL-12 with TGF-β and IL-23, whereas IL-6 is the dominant inducer in mouse; IL-21 then provides autocrine amplification), then retained in the follicle by B-cell ICOS-L and by follicular-dendritic-cell CXCL13 | Germinal-centre formation, affinity maturation and class switching; its IL-21 and IL-4 determine the isotype CD40LG deficiency (X-linked hyper-IgM), ICOS, CD40, IL21 and IL21R defects abolish or severely impair germinal centres; NFKB1/NFKB2 and activated-PI3K-delta syndrome dysregulate Tfh; circulating Tfh expanded in autoantibody disease | IL-6R, IL-21R, ICOS, CD40L on its surface; CXCR5 for follicle entry → STAT3 with STAT4 (human IL-12-driven) → Bcl-6 | Defining factor: Bcl-6, with STAT3 Markers: CD4, CXCR5, PD-1, ICOS, Bcl-6, CD57 on germinal-centre Tfh, low CCR7 Homing: CXCR5 → B-cell follicle (CXCL13), CCR7 low Makes: IL-21, IL-4, sCD40L, IL-10, BCA-1 | Scene 20 |
| Tfr follicular regulatory T cell Regulatory subset | Treg that acquires CXCR5 and enters the follicle; thymic derivation and Bcl-6 dependence are established in mouse, while human follicular Tregs express Bcl-6 weakly and blood "circulating Tfr" are largely not germinal-centre-derived | Limits germinal-centre size and output; restraint of autoantibody (and of IgE, shown in mouse) is mediated by CTLA-4, IL-10 and IL-2 consumption CTLA-4 haploinsufficiency and LRBA deficiency, in which follicular regulation fails, cause germinal-centre hyperplasia with autoantibodies; FOXP3 mutation (IPEX) eliminates the entire Treg compartment | IL-2R (CD25), CTLA-4, PD-1; CXCR5 → FoxP3 with Bcl-6 | Defining factor: FoxP3 with Bcl-6 Markers: CD4, CD25, FoxP3, CXCR5, PD-1 Homing: CXCR5 → germinal centre Makes: IL-10, IL-35 | Scene 20 |
| nTreg thymic (natural) regulatory T cell Regulatory subset | Selected in the thymus on self antigen with IL-2; maintained peripherally by IL-2 | Dominant peripheral tolerance: suppresses effector T cells, B cells and antigen-presenting cells through CTLA-4-mediated CD80/CD86 transendocytosis, IL-2 consumption by high-affinity CD25, IL-10 and TGF-β, CD39/CD73 adenosine generation, and granzyme-mediated killing FOXP3 mutation causes IPEX; CD25 (IL2RA), CTLA-4, LRBA, STAT5B, IL2RB, BACH2 and DEF6 defects cause Treg-deficient autoimmunity with enteropathy | IL-2R (CD25, high affinity), CTLA-4, TGF-βR; CCR4, CCR8 for tissue entry → STAT5 (IL-2) → FoxP3 stability | Defining factor: FoxP3 (demethylated TSDR), with STAT5, Helios Markers: CD4, CD25 high, CD127 low, FoxP3, CTLA-4 Homing: CCR4, CCR8 → skin and inflamed tissue; CCR7 for nodes Makes: IL-10, IL-35 | Scene 20 |
| pTreg / iTreg peripherally induced regulatory T cell Regulatory subset | Naive CD4 T cell converted in the gut and other tissues by TGF-β with retinoic acid, IL-2 and short-chain fatty acids | Tolerance to food and microbial antigens at mucosal surfaces. TGF-β-induced FOXP3 in human cells is often transient and not necessarily suppressive, so a FoxP3-positive cell is not necessarily regulatory Central to oral tolerance and to the proposed mechanism of oral immunotherapy | TGF-βR, IL-2R, retinoic-acid receptor; CCR9 and α4β7 for gut homing → SMAD2/3 with STAT5 → FoxP3 | Defining factor: FoxP3 with an incompletely demethylated TSDR Markers: CD4, FoxP3, α4β7, CCR9; Helios is often low but is a disputed marker of peripheral origin Homing: α4β7 and CCR9 → gut lamina propria Makes: IL-10, IL-35 | Scene 20 |
| Tr1 type 1 regulatory T cell (FoxP3-negative) Regulatory subset | Repeated antigen exposure with IL-27 and IL-10 (tolerogenic DCs) | IL-10-dependent suppression without FoxP3; granzyme-mediated killing of APCs IL10, IL10RA and IL10RB defects cause very-early-onset inflammatory bowel disease; Tr1 induction is a goal of allergen immunotherapy | IL-10R, IL-27R (WSX-1 + gp130); LAG-3, CD49b and CTLA-4 on its surface → STAT1 and STAT3 (IL-27, IL-10) → c-Maf, Blimp-1 | Defining factor: c-Maf with Blimp-1 (no FoxP3) Markers: CD4, IL-10 high with IFN-γ (the defining human cytokine pattern); LAG-3 with CD49b is the proposed Tr1 signature but both are induced on activated conventional CD4 cells, so it is not specific in humans Homing: CCR5, CXCR3 and gut homing receptors → inflamed mucosa Makes: IL-10, IFNγ, Granzyme B | Scene 20 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| CD8 Tc1 (CTL) cytotoxic T lymphocyte, type 1 CD8 effector subset | Naive CD8 T cell primed by cross-presenting cDC1 with IL-12 and type I interferon, expanded by IL-2 and IL-15 | Kills virus-infected and tumour cells; provides IFN-γ to the Th1 axis Perforin (PRF1), UNC13D, STX11 and STXBP2 defects cause familial HLH; CD8 CTLs are the effectors of checkpoint-inhibitor responses | TCR with CD8; IL-2R, IL-15R, IL-12R; CXCR3 and CCR5 for tissue entry → STAT4 / STAT5 → T-bet, Eomes, Runx3 | Defining factor: T-bet with Eomes and Runx3 Markers: CD8, CXCR3, CD107a on degranulation, granzyme/perforin loaded Homing: CXCR3, CCR5 → infected tissue Makes: IFNγ, TNFα, Perforin, Granzyme A, Granzyme B, sFasL, Lymphotactin | Scene 21 |
| CD8 Tc2 / Tc17 type 2 and type 17 cytotoxic CD8 subsets CD8 effector subset | CD8 T cell primed in IL-4-rich (Tc2) or IL-6 + IL-23-rich (Tc17) conditions | Tc2 contributes IL-4, IL-5 and IL-13 in allergic tissue; Tc17 contributes IL-17A with weaker cytotoxicity Tc2 cells are found in atopic dermatitis and eosinophilic oesophagitis; Tc17 in psoriasis | TCR with CD8; IL-4R (Tc2) or IL-23R and IL-6R (Tc17) → STAT6 → GATA3 (Tc2); STAT3 → RORγt (Tc17) | Defining factor: GATA3 (Tc2) or RORγt (Tc17) Markers: CD8 with CRTH2 (Tc2) or CCR6 and CD161 (Tc17) Homing: CRTH2 and CCR4 (Tc2); CCR6 (Tc17) Makes: IL-4, IL-5, IL-13, IL-17A, IL-22, GM-CSF, Granzyme B | Scene 21 |
| CD8 Tscm / Tcm stem-cell-like and central-memory CD8 T cells CD8 memory subset | Survive after infection on IL-7 and IL-15, without antigen | Long-lived recall capacity: proliferation and replenishment of the effector pool on re-exposure IL7R defects cause T−B+NK+ SCID; the memory pool on which vaccine responses depend | IL-7R (CD127), IL-2Rβ + γc for IL-15; CCR7 and CD62L for node homing → STAT5 (IL-7, IL-15) → Bcl-2, Tcf-1 | Defining factor: Tcf-1 (TCF7) with Bcl-6, Id3 Markers: Tcm: CD8, CD45RO+, CCR7+, CD62L+, CD127+. Tscm: CD45RA+ CD45RO− CCR7+ CD62L+ CD27+ with CD95+ and CD122+, a naive-like surface phenotype with memory function Homing: CCR7 and CD62L → lymph node Makes: IL-2, IFNγ | Scene 21 |
| CD8 Tem / Temra effector-memory and terminally differentiated CD8 T cells CD8 memory subset | Repeated or persistent antigen; maintained by IL-15 | Immediate cytotoxic effector function in blood and tissue, with limited proliferation Accumulate with CMV carriage and age; Temra expansion is a marker of immune senescence | IL-15 (trans-presented) and IL-18R; CX3CR1 and CCR5; loss of CCR7 → STAT5 (IL-15) with T-bet high | Defining factor: T-bet high, Tcf-1 low Markers: CD8, CD45RA re-expression (Temra), CD57, CD28 low, CX3CR1 Homing: CX3CR1 and CCR5; no CCR7 → blood and tissue Makes: IFNγ, Perforin, Granzyme B, TNFα | Scene 21 |
| CD8 Trm tissue-resident memory CD8 T cell CD8 memory subset | Effector CD8 T cell retained in tissue by TGF-β and local IL-15 | Local first-line defence at skin, lung and gut; rapid IFN-γ and granule release without recirculating Mediate fixed-drug eruption and recurrent herpes lesions; contribute to mucosal protection after infection and vaccination, as shown chiefly in mouse models | TGF-βR, IL-15R; CD103 (αEβ7) and CD69 mediate tissue retention → SMAD with STAT5; Hobit and Blimp-1 | Defining factor: Runx3 with Blimp-1 and KLF2 downregulation; Hobit (ZNF683) is the mouse residency determinant and is variably expressed in human Trm Markers: CD8, CD69 (the most consistent human marker), CD103 on many but not all (liver and some lung Trm are CD103−), CD49a, CXCR6, low S1PR1 / KLF2 Homing: retained by CD69 and CD103; CXCR6; S1PR1 low → tissue residence Makes: IFNγ, Granzyme B, TNFα | Scene 21 |
| Treg (CD8) CD8 regulatory T cell Regulatory subset | CD8 T cell exposed to IL-10 and TGF-β or to Qa-1/HLA-E-restricted self peptide | Suppresses effector T cells and follicular responses, partly by killing activated targets Human biology remains incompletely defined; of interest in autoimmunity and transplantation | IL-10R, TGF-βR; HLA-E-restricted TCR on the best-defined human subset → STAT3 (IL-10) and SMAD2/3 (TGF-β) | Defining factor: FoxP3 or Helios (subset-dependent) Markers: Human: CD8+CD28− suppressors, HLA-E-restricted CD8 Tregs, or KIR+ CD8 T cells; FoxP3 in a minority. CD8+CD122+ is the mouse-defined population Homing: CCR7 and CXCR5 on the follicular-suppressing subset Makes: IL-10, Granzyme B | Scene 21 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| iNKT invariant natural killer T cell Innate-like T cell | Thymic selection on CD1d-lipid by double-positive thymocytes with IL-15; activated within hours by CD1d-lipid plus IL-12 and IL-18 | Very rapid cytokine release that shapes the response before conventional T cells arrive; activates dendritic cells. IL-17A derives only from a rare NKT17 subset, prominent in mouse Reduced in some primary immunodeficiencies (e.g. XLP, SAP/SH2D1A deficiency); iNKT-derived IL-4 has been proposed, chiefly on mouse evidence, to contribute to early allergic sensitization | Invariant TCR (Vα24-Jα18) on CD1d-lipid; IL-12R, IL-18R, IL-25R on subsets → TCR with STAT4 (IL-12); PLZF-dependent development | Defining factor: PLZF (ZBTB16), with T-bet, GATA3 or RORγt by subset Markers: Vα24-Jα18 TCR, CD1d-tetramer+, CD161, often CD4− CD8− Homing: CXCR6 → liver sinusoids; CCR4 and CCR6 to tissue Makes: IFNγ, IL-4, IL-13, IL-2, TNFα, IL-10, GM-CSF, sCD40L, Granzyme B | Scene 22 |
| MAIT mucosal-associated invariant T cell Innate-like T cell | Selected on MR1-riboflavin metabolites; expanded by microbial exposure and maintained by IL-7 and IL-18 | Antibacterial and antifungal defence at mucosa; can respond to IL-12 + IL-18 without a TCR signal Depleted in HIV and in cystic-fibrosis airways; low MAIT numbers accompany several inborn errors of immunity | Semi-invariant TCR (Vα7.2) on MR1; IL-12R, IL-18R, IL-7R, IL-23R; CCR6 and CXCR6 → TCR with STAT4 / STAT3; PLZF-dependent development | Defining factor: PLZF with RORγt and T-bet Markers: Vα7.2 TCR, CD161 high, CD26 high, MR1-tetramer+ Homing: CCR6 and CXCR6 → gut, lung and liver Makes: IFNγ, TNFα, IL-17A, IL-22, Granzyme B | Scene 22 |
| γδ T cell gamma-delta T cell Innate-like T cell | Thymic development without MHC restriction; peripheral Vγ9Vδ2 cells respond to phosphoantigens with IL-2, IL-15, IL-18 or IL-23 | Early IFN-γ or IL-17 at epithelial surfaces; cytotoxicity against stressed cells; keratinocyte repair Expanded in CMV infection and in some leukaemias; in mouse, γδ T cells are a major early IL-17 source before Th17 cells appear, whereas human γδ cells produce IL-17 only rarely (chiefly tissue Vδ1) and are dominated by IFN-γ and cytotoxic output | γδ TCR engaging BTN2A1 directly, with phosphoantigen-sensing BTN3A1 as obligatory co-ligand (Vγ9Vδ2); NKG2D; IL-23R, IL-1R1 on the IL-17-producing subset → TCR with STAT3 (IL-23) or STAT4 (IL-12/IL-18) | Defining factor: RORγt (IL-17 subset) or T-bet (IFN-γ subset) Markers: TCR γδ, Vδ2 (blood) or Vδ1 (tissue), NKG2D, CD27 (which separates functional subsets) Homing: CCR6 and CCR2 (IL-17 subset); skin and gut epithelium (Vδ1) Makes: IFNγ, IL-17A, IL-17F, TNFβ, Perforin, Granzyme B, IL-22 | Scene 22 |
| NK cell natural killer cell — the prototype cytotoxic group 1 ILC, shown for comparison with innate-like T cells Innate effector | Marrow development on IL-15 with Flt-3L and SCF; activated by IL-12, IL-18 and type I interferon | Kills cells lacking MHC class I or coated with IgG (CD16-mediated); provides early IFN-γ Classical and functional NK deficiency (GATA2, MCM4, FCGR3A) predisposes to severe herpesvirus disease; CD16 links NK killing to IgG | IL-15R (trans-presented), IL-12R, IL-18R; CD16 (FcγRIIIa) for antibody-dependent killing; NKG2D → STAT5 (IL-15) and STAT4 (IL-12) → T-bet, Eomes | Defining factor: T-bet with Eomes, on an ID2 and NFIL3-dependent ILC programme Markers: CD56, CD16, NKp46, no CD3 Homing: CXCR3 and CX3CR1 (CD56dim blood); CCR7 and CXCR4 (CD56bright, nodes and marrow) Makes: IFNγ, TNFα, Perforin, Granzyme A, Granzyme B, Lymphotactin, GM-CSF | Scene 22 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| Transitional B cell T1 / T2 transitional B cell B-cell developmental stage | Immature B cell leaving the marrow; survival depends on tonic BCR signalling plus BAFF | Last checkpoint against autoreactivity before the naive pool; T2 cells can enter follicles Expanded in common variable immunodeficiency and after rituximab; reduced BAFF-R function blocks the transitional-to-naive step | BCR (IgM high, IgD rising from low to high); BAFF-R; CD21 low → BAFF-R → non-canonical NF-κB (NIK); BCR → NF-κB, PI3K | Defining factor: Remains BCR-dependent; no change in lineage master TF Markers: CD19, CD24 high, CD38 high, CD10+, IgM high, IgD low (T1), becoming IgD+ (T2) Homing: spleen (via blood), then follicle on CXCR5 | Scene 24 |
| Naive follicular B cell mature naive B cell (IgM+ IgD+) B-cell subset | Survival is maintained by BAFF through BAFF-R; CXCL13 retains the cell in the follicle | The pool from which T-dependent germinal-centre responses arise Target of anti-CD20 therapy; excess BAFF permits survival of autoreactive naive cells (belimumab target) | BCR (IgM + IgD); BAFF-R, TACI; CD40; CXCR5, CCR7 → BAFF-R → non-canonical NF-κB; CD40 → canonical NF-κB | Defining factor: Pax5 with EBF1 (B-lineage identity) Markers: CD19, CD20, CD27−, IgM+, IgD+, CD21+, CD23+ Homing: lymph-node and splenic follicles (CXCR5 → CXCL13) | Scene 24 |
| Marginal-zone B cell splenic marginal-zone B cell B-cell subset | Splenic population generated under Notch2/DLL1 signalling (established in mouse) with BAFF; responds to polysaccharide with little or no T-cell help. Human marginal-zone B cells carry mutated immunoglobulin V genes and overlap substantially with the IgM+IgD+CD27+ IgM-memory compartment, so a purely germinal-centre-independent origin is not established | Rapid T-independent IgM (and some IgG2) against encapsulated bacteria Absent or non-functional after splenectomy and immature in young children, with resulting susceptibility to pneumococcus and poor polysaccharide vaccine responses | BCR with TLRs and complement receptor CD21 (CR2); TACI for APRIL and BAFF → BCR + TLR + CR2 co-signal → NF-κB; TACI → NF-κB | Defining factor: Pax5 with a Notch2-driven programme (mouse-established) Markers: CD19, CD27+, IgM high, IgD low, CD21 high, CD1c+ Homing: splenic marginal zone (S1PR1 vs CXCR5 shuttling) Makes: IL-10 | Scene 24 |
| B-1 cell B-1a / B-1b cell (innate-like) B-cell subset | Self-renewing population of fetal/neonatal origin supported by IL-5; all of these features are established in mouse, and no equivalent human self-renewing cavity pool has been defined | Spontaneous "natural" polyreactive IgM and some IgA, without immunization Human counterpart remains debated; the source of natural IgM, including isohaemagglutinins | BCR (polyreactive, germline-near); IL-5R; TLRs → BCR tonic signalling with TLR → NF-κB; IL-5R → STAT5 | Defining factor: Pax5 with high Bhlhe41 (mouse-defined) Markers: Mouse: CD19 high, CD5+ (B-1a), CD43+, IgM high, IgD low. A proposed human equivalent (CD20+CD27+CD43+CD70−) is contested; human CD5+ B cells are activated or transitional cells and do not correspond to mouse B-1a Homing (mouse): pleural and peritoneal cavities and gut lamina propria; no human cavity pool defined Makes: IL-10 | Scene 24 |
| Germinal-centre B cell dark-zone and light-zone GC B cell B-cell subset | Antigen plus Tfh help (CD40L and IL-21) after follicular entry; CXCL12 (dark zone) and CXCL13 (light zone) position it | Somatic hypermutation in the dark zone, selection on follicular-dendritic-cell antigen in the light zone, and class switching AICDA and UNG defects cause hyper-IgM with giant germinal centres; the cell of origin of most B-cell lymphomas | CD40 for T help; IL-21R; BCR for antigen capture; CXCR4 (dark zone) and CXCR5 (light zone) → CD40 → NF-κB; IL-21R → STAT3; AID (AICDA) mediates somatic hypermutation and class switching | Defining factor: Bcl-6, which blocks differentiation during somatic hypermutation; exit results from mutual antagonism with Blimp-1 and a rise in IRF4 Markers: CD19, CD38+, CD10+, IgD−, CD77 (dark zone), Fas/CD95+ Homing: germinal centre; shuttling between dark and light zones on CXCR4 and CXCR5 | Scene 25 |
| Memory B cell class-switched and IgM memory B cell B-cell subset | Germinal-centre output with lower Tfh help and intermediate affinity; maintained without antigen | Rapid, high-affinity recall: re-enters germinal centres or becomes a plasmablast within days Switched memory (CD27+IgD−) counts classify CVID (EUROclass), where severely reduced switched memory B cells are associated with splenomegaly and granulomatous disease and an expanded CD21low subset with splenomegaly; DN2 cells expand in lupus and chronic infection; IgM memory loss follows splenectomy | BCR (switched IgG/IgA/IgE or IgM); CD40; TACI; BAFF-R → BCR with enhanced signalling (CD27, switched Ig tail) → NF-κB, PI3K | Defining factor: Loss of Bcl-6; Bach2 prevents differentiation into a plasma cell Markers: CD19, CD27+, IgD− (switched) or IgM+IgD+ CD27+ (IgM memory); CD21low CD38low and T-bet+ CD11c+ IgD−CD27− "double-negative" (DN2) cells are the two clinically tracked abnormal compartments Homing: blood, spleen and marginal zone; mucosa for IgA memory | Scene 25 |
| Plasmablast short-lived antibody-secreting cell Antibody-secreting cell | Strong BCR plus CD40L, IL-21 and IL-6; extrafollicular or germinal-centre derived | The early antibody response, days after exposure; the cells remain proliferative and migratory Blood plasmablast counts rise about a week after vaccination; expanded in IgG4-related disease | IL-6R, IL-21R; CXCR4 for migration to marrow and inflamed tissue; CXCR5 is lost → STAT3 (IL-6, IL-21) → Blimp-1, XBP1 secretory programme | Defining factor: Blimp-1 (PRDM1) and IRF4, with XBP1 Markers: CD19 low or positive, CD20−, CD27 high, CD38 high, CD138 variable, Ki-67+ Homing: medullary cords, then marrow or mucosa on CXCR4 Makes: IgM, IgG1, IgA1, IgE | Scene 25 |
| Long-lived plasma cell bone-marrow (and mucosal) plasma cell Antibody-secreting cell | Germinal-centre derived; survival niche of CXCL12+ stromal cells with APRIL, BAFF and IL-6 | Maintains serum antibody titres for years without antigen; the source of steady-state IgG Not depleted by anti-CD20 (no CD20), so titres persist after rituximab; anti-BCMA agents target it in myeloma | BCMA (APRIL, BAFF), IL-6R; CXCR4 retains the cell in the niche → BCMA → NF-κB survival; IL-6R → STAT3; no surface BCR signalling | Defining factor: Blimp-1 with XBP1 (Pax5 off) Markers: CD38 high, CD138+, CD20−, surface Ig low; the long-lived, titre-maintaining marrow fraction is CD19-negative, while CD19+ plasma cells are shorter-lived Homing: bone-marrow survival niche; mucosal lamina propria for IgA Makes: IgG1, IgG2, IgG3, IgG4, IgA1, IgA2 | Scene 25 |
| Regulatory B cell (Breg) IL-10-producing regulatory B cell Regulatory subset | BCR plus CD40 and TLR signals with IL-21, IL-6 and IFN-α; found among transitional, memory and plasmablast-like cells | Suppresses Th1 and Th17 responses and supports Tregs, mainly through IL-10 (and IL-35) Reduced IL-10+ B cells in several autoimmune diseases; the allergen-specific human BR1 population (IL-10+ CD73− CD25+ CD71+) preferentially secretes IgG4 and expands during successful allergen immunotherapy and in beekeepers | CD40, TLRs, IL-21R; CD1d high on the transitional subset → CD40 and TLR → NF-κB → IL-10; STAT3 | Defining factor: No unique master TF; defined by IL-10 output Markers: Human: CD19+CD24 high CD38 high transitional, or CD24 high CD27+ memory Homing: spleen, blood, inflamed tissue Makes: IL-10, IL-35, Granzyme B | Scene 24 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| IgM IGHM; pentamer (with J chain) in serum, monomer on the B-cell surface Immunoglobulin | Naive and marginal-zone B cells, B-1 cells and plasmablasts, without class switching; T-independent responses included | First antibody of a primary response; agglutination and the strongest classical-complement activator; natural antibodies including isohaemagglutinins Normal or raised in the class-switch-recombination defects still termed hyper-IgM syndromes (CD40LG, CD40, AICDA, UNG), in which IgM is often not elevated and the historical designation is misleading; absent or low, together with IgG, in agammaglobulinaemia; selective IgM deficiency is rare | Fcμ receptor (FCMR, on lymphocytes), Fcα/μR; pIgR carries pentameric IgM across mucosa; C1q is engaged only after antigen binding bends the pentamer out of its planar (star) form into the staple conformation → Switch signal: none required (default isotype) | Level / assay: Typical adult serum 0.4–2.3 g/L; the only isotype produced in quantity by the newborn (cord IgM above ~0.2 g/L suggests intrauterine infection) Serum half-life about 5 days by turnover studies, although some texts give up to 10 Classical pathway: strongest activator; one surface-bound pentamer in the staple conformation can fix C1 | Scene 26, 27 |
| IgD IGHD; monomer, mostly membrane-bound Immunoglobulin | Co-expressed with IgM on naive B cells by alternative splicing; a small amount is secreted, mainly by upper-airway plasma cells after class switching from IgM to IgD | Marks the mature naive B cell; secreted IgD sensitizes basophils and mast cells and contributes to upper-airway immunity Very high IgD with periodic fever suggests mevalonate-kinase deficiency (hyper-IgD syndrome), where the raised IgD is a marker rather than the cause | IgD receptor on basophils (galectin-9 has been proposed); no dedicated classical Fc receptor family → Switch signal: non-canonical class switch from Sμ to the σδ switch-like region in tonsil and upper-airway mucosa; AID-dependent, largely T-independent, promoted by IL-2 and IL-21 with APRIL or BAFF through TACI | Level / assay: Trace: mean adult serum about 0.03 g/L with a laboratory upper limit around 0.15 g/L, often undetectable; not useful as a routine quantitative test Serum half-life about 3 days Does not activate complement | Scene 26, 27 |
| IgG1 IGHG1 Immunoglobulin | Class-switched plasmablasts and long-lived plasma cells after T-dependent protein antigen; IL-21 with CD40L drives the switch | Dominant IgG of protein and vaccine responses; opsonization, toxin and virus neutralization, ADCC Low IgG1 lowers total IgG; the main isotype measured in replacement therapy and in vaccine-response testing; crosses the placenta most efficiently | FcγRI (CD64, high affinity), FcγRIIa/IIb, FcγRIIIa; FcRn recycling and placental transfer → Switch signal: IL-21 and IFN-γ with CD40L | Level / assay: Typical adult serum 4.9–11.4 g/L (about 60–65% of total IgG) Serum half-life about 21 days (FcRn-dependent) Classical pathway: good activator (second only to IgG3) | Scene 26, 27 |
| IgG2 IGHG2 Immunoglobulin | Plasma cells responding to polysaccharide, largely from marginal-zone and IgM-memory B cells | Antibody against encapsulated bacteria (pneumococcal and Haemophilus polysaccharide) Selective IgG2 deficiency and poor polysaccharide responses present as recurrent sinopulmonary infection; an IgG2 level normal for age is required before a specific antibody deficiency is diagnosed | FcγRIIa (especially the H131 allotype); poor binding to FcγRI and FcγRIIIa; FcRn recycling → Switch signal: T-independent polysaccharide with TACI (APRIL/BAFF); IFN-γ contributes | Level / assay: Typical adult serum 1.5–6.4 g/L (about 20–30% of total IgG); the last subclass to mature; it is low through early childhood and continues to rise through adolescence, so an age-specific rather than an adult range is required. Polysaccharide antibody responses, rather than the IgG2 level itself, mature first: they are poor before about 2 years and mature over the next few years Serum half-life about 21 days Classical pathway: weak activator | Scene 26, 27 |
| IgG3 IGHG3 Immunoglobulin | Class-switched plasma cells early in protein and viral responses; the first IgG subclass in the switch order | The most potent IgG for complement activation and FcγR engagement; strong antiviral activity Isolated IgG3 deficiency is reported with recurrent respiratory infection but is a finding of limited significance in isolation; its short half-life causes levels to fluctuate | FcγRI, FcγRIIa, FcγRIIIa (highest affinity of the subclasses); arginine at position 435 in the Fc, and not the long hinge, lowers FcRn affinity and shortens the half-life, and His435 allotypes behave like IgG1 → Switch signal: IFN-γ with CD40L (and IL-21) | Level / assay: Typical adult serum 0.2–1.1 g/L (about 5–8% of total IgG) Serum half-life about 7 days, shorter than the other subclasses because Arg435 in its Fc binds FcRn with lower affinity Classical pathway: strongest IgG activator | Scene 26, 27 |
| IgG4 IGHG4 Immunoglobulin | Plasma cells after prolonged or repeated antigen exposure with IL-4, IL-13 and especially IL-10 (and IL-21): the "modified Th2" setting | Non-inflammatory blocking antibody: exchanges half-molecules so it becomes functionally monovalent and cannot cross-link Rises during successful allergen immunotherapy and in beekeepers and cat-owners as a blocking antibody; serum IgG4 is not raised in all patients with IgG4-related disease: in a cohort of 125 patients only 51% of those with active disease had an elevated level, so a normal level does not exclude it; the raised IgG4 is probably a consequence of the chronic Th2 and IL-10 milieu rather than the driver of tissue injury | FcγRIIb (inhibitory) preferentially and FcγRI with intermediate affinity; measurable but weak at FcγRIIa, poor at FcγRIIIa; FcRn recycling → Switch signal: IL-4 / IL-13 with IL-10 and CD40L | Level / assay: Typical adult serum 0.08–1.4 g/L (about 1–4% of total IgG); the widest and most skewed of the subclass ranges Serum half-life about 21 days Does not activate complement (and blocks activation by other isotypes on the same antigen) | Scene 26, 27 |
| IgA1 IGHA1; monomer in serum, dimer with J chain at mucosa Immunoglobulin | Plasma cells in marrow and in systemic lymphoid tissue (serum IgA) and in upper-airway mucosa; TGF-β with APRIL, BAFF and IL-21 drives the switch | The dominant serum IgA and the main IgA of upper airway and nasal mucosa; neutralizes without inflammation Selective IgA deficiency (total IgA under 0.07 g/L with normal IgG and IgM, over age 4) is the most common primary immunodeficiency; most patients with low serum IgA, with or without IgG anti-IgA antibodies, receive intravenous immunoglobulin without difficulty, although IgE anti-IgA antibodies have been associated with anaphylaxis and IgG anti-IgA antibodies with complement-mediated reactions, and a low or absent IgA in the setting of low IgG is not a contraindication to immunoglobulin replacement | FcαRI (CD89) on neutrophils, monocytes and eosinophils; pIgR transports the dimer across epithelium as secretory IgA; Fcα/μR → Switch signal: TGF-β with APRIL / BAFF (TACI) and IL-21; retinoic acid in the gut | Level / assay: About 85–90% of serum IgA; total serum IgA typically 0.7–4.0 g/L in adults and much lower through early childhood Serum half-life about 6 days Does not activate the classical pathway; aggregated IgA can engage the alternative pathway weakly | Scene 26, 27 |
| IgA2 IGHA2; dimer with J chain at mucosa Immunoglobulin | Mucosal plasma cells, especially in the colon and in secretions, under TGF-β with APRIL and retinoic acid | The protease-resistant mucosal IgA: its shorter hinge resists bacterial IgA1 proteases, so it dominates in the lower gut Secretory IgA is the antibody of mucosal tolerance and protection; most IgA-deficient patients remain asymptomatic because IgM compensates at mucosal surfaces | FcαRI (CD89); pIgR for transport into secretions; binds the secretory component → Switch signal: TGF-β with APRIL / BAFF (TACI); gut retinoic acid favours IgA2 | Level / assay: About 10–15% of serum IgA, but the majority (about 60%) of colonic secretory IgA Serum half-life about 6 days Does not activate the classical pathway; whether aggregated IgA2 engages the alternative pathway is not established; it is reported for aggregated IgA generally, whereas some sources report IgA1 as positive and IgA2 as negative | Scene 26, 27 |
| IgE IGHE Immunoglobulin | Plasma cells after IL-4 or IL-13 with CD40L (Tfh or Th2 help); often by sequential switching through IgG1 | Sensitizes mast cells and basophils for immediate hypersensitivity; defence against helminths Very high IgE with eczema and infection suggests hyper-IgE syndrome (STAT3, DOCK8, PGM3, ZNF341, ERBIN, IL6ST / IL6R), and other causes of very high IgE include Netherton syndrome (SPINK5), Wiskott–Aldrich syndrome, Omenn or hypomorphic RAG disease, IPEX and CARD11 defects; omalizumab binds free IgE and lowers FcεRI density; total IgE is required for dosing in the indications dosed by IgE and body weight (such as allergic asthma and nasal polyps), whereas dosing in chronic spontaneous urticaria is fixed and independent of IgE | FcεRI (high affinity) as the four-chain receptor on mast cells and basophils, and as a three-chain form on monocytes, dendritic and Langerhans cells and some eosinophils, where it drives IgE-facilitated antigen presentation; FcεRII (CD23, low affinity) on B cells, which regulates IgE production → Switch signal: IL-4 or IL-13 with CD40L (STAT6 → ε germline transcript) | Level / assay: Typical adult total IgE 0–100 kU/L (about 0.0002 g/L, roughly 240 µg/L); the least abundant isotype. Cord-blood total IgE is usually under 0.5 kU/L (median about 0.3 kU/L in one large series); maternal blood contamination of a cord sample is excluded by measuring cord IgA, which does not cross the placenta, rather than inferred from the IgE value. Values rise through childhood, so age-specific ranges are required Serum half-life about 2 days free, but around two weeks once bound to FcεRI on tissue mast cells Does not activate complement | Scene 26, 27 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| FcγRI (CD64) FCGR1A — the only high-affinity IgG receptor Fc receptor | Monocytes, macrophages and dendritic cells constitutively; neutrophils only after induction by IFN-γ or G-CSF | Binds monomeric IgG1 and IgG3 (and IgG4) with high affinity, so it is occupied by circulating IgG at rest; phagocytosis, ADCC and antigen presentation Neutrophil CD64 rises within hours of bacterial infection and is used as a sepsis marker, especially in neonates | IgG1 and IgG3 ≫ IgG4; does not bind IgG2 → ITAM on the associated FcRγ chain → Syk → PI3K, PLCγ → phagocytosis and oxidative burst | Scene 28 | |
| FcγRIIa (CD32a) FCGR2A — activating, with the H131/R131 polymorphism Fc receptor | Neutrophils, monocytes, macrophages, platelets, eosinophils | The main phagocytic receptor for IgG-opsonized particles; the H131 allotype is the only human FcγR that binds IgG2 efficiently The R131 allotype mediates poor uptake of IgG2-opsonized pneumococcus and is associated with invasive pneumococcal disease; FcγRIIa on platelets mediates heparin-induced thrombocytopenia | Immune-complexed IgG1, IgG2 (H131 allotype), IgG3 → ITAM within its own cytoplasmic tail → Syk → phagocytosis, degranulation, NET formation | Scene 28 | |
| FcγRIIb (CD32b) FCGR2B — the only inhibitory Fc receptor Fc receptor | B cells (the only FcγR they express), mast cells and basophils, macrophages, neutrophils, eosinophils, dendritic cells; the B1 form on B cells and mast cells, the B2 form on the myeloid cells | Raises the activation threshold: co-ligated with the BCR by IgG immune complexes it inhibits B-cell activation, so IgG exerts negative feedback on its own production Loss of FcγRIIb function predisposes to lupus; its engagement is a proposed component of the mechanism of high-dose IVIG | IgG immune complexes (preferentially IgG1 and IgG4) → ITIM → SHIP-1 → blocks PI3K and calcium signalling | Scene 28 | |
| FcγRIII (CD16) FCGR3A (CD16a, transmembrane) and FCGR3B (CD16b, GPI-anchored) Fc receptor | CD16a on NK cells, macrophages and monocyte subsets; CD16b on neutrophils only | CD16a is the ADCC receptor: IgG-coated targets are killed by NK cells. CD16b is the most abundant neutrophil Fc receptor and captures immune complexes FCGR3A V158F has been associated with response to rituximab and other IgG1 antibody therapies in some, but not all, studies; CD16a deficiency causes severe herpesvirus disease with normal NK numbers; CD16b is shed on neutrophil activation | IgG1 and IgG3 (the V158 allotype of CD16a binds more strongly) → CD16a: ITAM through FcRγ or CD3ζ → NK degranulation. CD16b: GPI-anchored, signals with CR3 | Scene 28 | |
| FcεRI MS4A2 / FCER1A — the high-affinity IgE receptor Fc receptor | Mast cells and basophils as a four-chain αβγ2 receptor; dendritic cells, monocytes and eosinophils as a three-chain αγ2 form | Retains IgE on the cell surface for weeks; allergen cross-linking of bound IgE triggers immediate degranulation (histamine, tryptase) and then leukotrienes, prostaglandins and Th2 cytokines The receptor of immediate hypersensitivity, and therefore of anaphylaxis and of the skin-prick and basophil activation tests; omalizumab lowers free IgE, and FcεRI density falls in parallel, which accounts for an onset of action over weeks | Monomeric IgE with very high affinity (KD ~10⁻¹⁰ M); it binds free IgE, and receptor density follows the IgE level → ITAM → Lyn and Syk → PLCγ and calcium flux → degranulation within minutes | Scene 28 | |
| FcεRII (CD23) FCER2 — the low-affinity IgE receptor (a C-type lectin, not an Ig-superfamily FcR) Fc receptor | B cells, follicular dendritic cells, monocytes, eosinophils, airway epithelium | Regulates the quantity of IgE produced and transports IgE-bound allergen for presentation; the soluble shed form can raise or lower IgE production depending on the site of cleavage Lumiliximab (anti-CD23) has been evaluated in clinical trials in asthma; the soluble form rises in allergic disease and chronic lymphocytic leukaemia | IgE with low affinity (and CD21) → Not an ITAM receptor: acts by antigen capture, trafficking and feedback on IgE synthesis. IL-4 raises CD23 on B cells, which is the same signal that drives the IgE switch itself (Scene 26) | Scene 28 | |
| FcαRI (CD89) FCAR — the myeloid IgA receptor Fc receptor | Neutrophils (the dominant site), monocytes, macrophages, eosinophils | Confers effector function on IgA: complexed IgA triggers phagocytosis, respiratory burst and neutrophil extracellular traps, while monomeric IgA through the same receptor is inhibitory IgA immune complexes acting on CD89 drive the neutrophil injury of IgA vasculitis (Henoch–Schönlein purpura) and IgA nephropathy | IgA1 and IgA2 in complexes (monomeric IgA delivers an inhibitory signal) → ITAM on the associated FcRγ chain → Syk; monomeric binding instead produces inhibitory ITAM signalling | Scene 28 | |
| FcRn and pIgR FCGRT (with β2-microglobulin) and PIGR — the transport receptors Fc receptor | FcRn on endothelium, monocytes, syncytiotrophoblast and epithelium; pIgR on the basolateral face of mucosal and glandular epithelium | FcRn rescues IgG and albumin from lysosomal degradation, which accounts for the three-week half-life of IgG, and transports maternal IgG across the placenta. pIgR transports dimeric IgA (and pentameric IgM) into secretions, with the secretory component remaining attached FcRn accounts for third-trimester placental IgG transfer and for the IgG half-life that determines IVIG dosing intervals; FcRn blockers (efgartigimod) shorten IgG half-life in autoantibody disease; pIgR delivers the secretory IgA that is absent from serum-only measurements | FcRn binds the IgG Fc at acidic pH and releases it at neutral pH; pIgR binds the J chain of dimeric IgA and pentameric IgM → Receptor-mediated recycling and transcytosis, not a signalling cascade | Scene 28 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| C1q C1QA / C1QB / C1QC (with C1r and C1s forms C1) Complement | Monocytes, macrophages and dendritic cells (the main source; not mainly hepatocytes); immature DCs produce large amounts | Recognition unit of the classical pathway: binds the Fc of bound IgM and IgG (IgG3 > IgG1 >> IgG2, with IgG4 not fixing C1q), CRP and apoptotic-cell surfaces C1q deficiency confers the highest penetrance of lupus of any single-gene defect (around 90% in reported cases, although series are ascertainment-biased and a minority present with pyogenic infection alone), through failed apoptotic-cell clearance; acquired low C1q in hypocomplementaemic urticarial vasculitis | Binds surface-bound antibody and directly to apoptotic cells; signals through LAIR-1, calreticulin/CD91 and gC1qR (C1QBP); the former "C1qRp" (CD93) is no longer regarded as a C1q receptor → Conformational change activates C1r → C1s | Level / assay: About 0.1 g/L: clinical laboratory ranges are approximately 0.05–0.25 g/L, whereas complement-biochemistry tables quote 70–80 mg/L; measured when CH50 is absent Cytokine control: Production falls with IL-6 and rises with IFN-γ in monocytes; glucocorticoids raise it | Scene 29 |
| C1r / C1s C1R / C1S serine proteases Complement | Hepatocytes, with monocytes and fibroblasts | The catalytic component of C1: activated C1s cleaves C4 and then C2 C1r or C1s deficiency causes lupus-like disease; heterozygous C1R or C1S variants, presumed gain-of-function, cause periodontal Ehlers–Danlos syndrome | Held in the C1 complex as C1q with C1r₂C1s₂, assembled calcium-dependently; blocked by C1 inhibitor → Serine-protease cleavage of C4 → C4b + C4a, then C2 | Level / assay: Measured only indirectly (CH50 and component assays) Cytokine control: Hepatic production rises in the acute-phase response (IL-6) | Scene 29 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| MBL MBL2 (mannose-binding lectin) Complement | Hepatocytes (an acute-phase protein) | Pattern recognition for mannose and N-acetylglucosamine on microbial surfaces; activates MASPs MBL deficiency is a weak modifier rather than a disease in its own right; it is most relevant in combination with another defect, chemotherapy or infancy | Binds microbial carbohydrate; circulates in complex with MASP-1, MASP-2 and MASP-3 → MBL–MASP-2 cleaves C4 and C2 → the same C4b2a convertase | Level / assay: Typical adult serum 0.5–3 mg/L but genotype-driven and very wide: about 5–10% of individuals have levels low enough to be classified as deficient, and more have low-intermediate levels, usually without disease Cytokine control: Acute-phase: production rises with IL-6 and IL-1 | Scene 29 |
| MASP-2 MASP2 (MBL-associated serine protease 2); with MASP-1 and the ficolins/collectins Complement | Hepatocytes | The C4-cleaving protease of the lectin pathway, activated after MBL or ficolin binds a microbial surface MASP-2 is encoded by MASP2, whereas the related MASP-1 and MASP-3 are encoded by MASP1; MASP-3 is the protease that activates pro-factor D, and MASP1 or COLEC11 (collectin-11) mutations cause 3MC syndrome. MASP-2 deficiency is reported with pneumococcal infection and inflammatory disease but is often clinically silent; ficolin-3 deficiency is more consistently associated with infection | Carried on MBL, ficolin-1/2/3 and collectin-11 → Cleaves C4 then C2 → C4b2a (MASP-1 assists by cleaving C2 and activating MASP-2) | Level / assay: Measured by lectin-pathway functional assay rather than by concentration Cytokine control: Hepatic acute-phase production with IL-6 | Scene 29 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| C4 C4A and C4B (two loci, copy-number variable) Complement | Hepatocytes mainly; also monocytes and macrophages | Cleaved by C1s or MASP-2 to C4b, which binds the surface covalently and, with C2a, forms the classical/lectin C3 convertase Low C4 with low C3 suggests classical-pathway consumption (lupus, cryoglobulinaemia, immune-complex disease); low C4 with normal C3 is the characteristic hereditary-angioedema pattern; C4A null alleles associate with lupus | C4b binds covalently to the activating surface; recognized by CR1 and inactivated by factor I with C4BP or MCP → C4 → C4b + C4a; C4b + C2a = C3 convertase (C4b2a). C4a is not a true anaphylatoxin (it binds neither C3aR nor C5aR1) but it is not inert: it signals through PAR1 and PAR4 on endothelium and platelets, raising permeability and linking complement to clotting | Level / assay: Typical adult serum 0.1–0.4 g/L; falls early in classical-pathway consumption Cytokine control: Hepatic acute-phase protein: production rises with IL-6 and IFN-γ | Scene 29 |
| C2 C2 serine protease Complement | Hepatocytes; also monocytes and macrophages | Cleaved on C4b to C2a, the catalytic subunit of the classical/lectin C3 convertase The most common classical-pathway deficiency in individuals of European ancestry (about 1 in 20,000, mostly type I from a 28-base-pair deletion): pneumococcal sepsis in childhood and lupus-like disease, although around half of those affected remain asymptomatic and the lupus risk is far lower than with C1q or C4 deficiency | Binds C4b on the surface; decayed by DAF (CD55), CR1 and C4BP → C2 → C2a (with C4b) + C2b. Naming: by the current consensus C2a is the larger catalytic fragment and the enzyme is C4b2a; some literature follows the general a-small / b-large rule and writes C4b2b for the same convertase | Level / assay: Typical adult serum about 0.02 g/L; absent in C2 deficiency with a very low CH50 Cytokine control: Hepatic production rises with IFN-γ and in the acute-phase response | Scene 29 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| C3 C3 (the hub of all three pathways) Complement | Hepatocytes (over 90% of plasma C3); also monocytes, macrophages, endothelium and epithelium locally | The central component: cleaved to C3b (opsonin, convertase component) and C3a (anaphylatoxin); spontaneous tick-over initiates the alternative pathway Low C3 with normal C4 indicates alternative-pathway activation (C3 nephritic factor, factor H or I defect, post-infectious glomerulonephritis); complete C3 deficiency causes severe pyogenic infection and immune-complex disease | C3b binds surfaces covalently and is recognized by CR1 (CD35) and by CRIg, the receptor on Kupffer and other tissue-resident macrophages that clears blood-borne opsonized organisms in the liver, binds C3b and iC3b, and additionally inhibits the alternative pathway; once factor I has cleaved it, iC3b is the ligand for CR3 and CR4; C3dg/C3d is recognized by CR2 on B cells and follicular dendritic cells → C3 → C3b + C3a; C3b + Bb = alternative C3 convertase (amplification loop) | Level / assay: Typical adult serum 0.9–1.8 g/L; with C4, the most commonly measured complement protein Cytokine control: Hepatic acute-phase protein: IL-6, IL-1 and TNF raise production, so C3 can appear normal during consumption | Scene 29, 30 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| C3a C3a anaphylatoxin (C3a des-Arg after carboxypeptidase N) Complement | Released on cleavage of C3, at the site of activation | Mast-cell and basophil activation, smooth-muscle contraction and vascular permeability; also a chemoattractant for eosinophils and mast cells Contributes to the vascular leak of sepsis and of transfusion and dialysis-membrane reactions | C3aR on mast cells, basophils, eosinophils, monocytes and epithelium; C3aR is also expressed on human neutrophils, but C3a, unlike C5a, is not an effective neutrophil chemoattractant, and in mouse models C3aR signalling restrains neutrophil mobilisation. C3a des-Arg is inactive at C3aR (it is acylation-stimulating protein, a metabolic mediator), whereas C5a des-Arg retains partial activity → C3aR is a Gi-coupled GPCR, like the chemokine receptors of Scene 6 | Level / assay: Measured as C3a des-Arg in activation studies, not in routine care; rises with any activation, including in vitro activation in an incorrectly handled sample Cytokine control: Not transcriptionally regulated: its level follows C3 cleavage | Scene 29, 30 |
| C5a C5a anaphylatoxin (C5a des-Arg after carboxypeptidase N) Complement | Released when the C5 convertase cleaves C5 at the activating surface | The most potent complement anaphylatoxin: neutrophil chemoattraction, adhesion, degranulation and oxidative burst; mast-cell activation; endothelial permeability A major driver of neutrophil injury in sepsis and ANCA-associated vasculitis (avacopan blocks C5aR1); eculizumab prevents its formation by blocking C5 cleavage | C5aR1 (CD88) on neutrophils, monocytes, mast cells and epithelium; C5aR2 (C5L2) modulates the response → C5aR1 is a Gi-coupled GPCR → PI3K, Rho, Ca²⁺ flux, as for the neutrophil chemokine receptors | Level / assay: Measured as C5a des-Arg in research settings; terminal-pathway activation is screened functionally (CH50/AH50) instead Cytokine control: Not transcriptionally regulated: follows C5 cleavage | Scene 30, 33 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| Factor B CFB Complement | Hepatocytes; also monocytes and macrophages | Binds surface C3b and is cleaved by factor D to Bb, forming the alternative C3 convertase C3bBb Gain-of-function CFB variants cause atypical haemolytic uraemic syndrome and C3 glomerulopathy by stabilizing the convertase; complete deficiency is very rare (a few reported individuals) and causes Neisseria and pyogenic infection. Irrespective of the initiating pathway, the alternative-pathway amplification loop generates the large majority of C3b and of downstream C5b-9, so proximal inhibitors (iptacopan at factor B, pegcetacoplan at C3) also attenuate classical activation | Binds C3b on the activating surface; the convertase is stabilized by properdin → C3bB → C3bBb + Ba (factor D cleaves it) | Level / assay: Typical adult serum about 0.2–0.4 g/L Cytokine control: Hepatic acute-phase protein: production rises with IL-6, IL-1, TNF and IFN-γ | Scene 30 |
| Factor D CFD (adipsin) Complement | Adipocytes are the dominant source (it is adipsin); also monocytes | The rate-limiting enzyme of the alternative pathway: cleaves factor B only when B is bound to C3b Factor D deficiency causes recurrent Neisseria infection with a normal CH50 and an absent AH50; danicopan (Voydeya) inhibits factor D as an add-on for extravascular haemolysis in PNH, alongside iptacopan at factor B and pegcetacoplan at C3 | Acts on C3b-bound factor B; circulates in active form, pro-factor D having been cleaved by MASP-3 (with MASP-1) → Cleaves C3bB → C3bBb | Level / assay: Typical adult serum about 1–2 mg/L; the lowest-concentration complement enzyme, and it is catalytically self-inhibited until it engages C3b-bound factor B; both properties account for its rate-limiting role Cytokine control: TNF-α suppresses CFD transcription in cultured adipocytes, but circulating factor D correlates with fat mass and is higher, not lower, in obesity; it falls with lipoatrophy and weight loss | Scene 30 |
| Properdin CFP (factor P) — the only positive regulator Complement | Neutrophils (released from secondary granules), monocytes and T cells | Stabilizes the alternative C3 convertase five- to ten-fold, extending its half-life; the only positive complement regulator. Its established role is stabilization of a convertase that has already formed; a primary surface-recognition role is debated X-linked properdin deficiency predisposes to fulminant meningococcal disease, often fatal in a first episode. Because the disorder is X-linked, the maternal line should be evaluated: the patient should be vaccinated, maternal male relatives tested and carrier females identified, who can have intermediate levels and rarely symptomatic disease | Binds and stabilizes surface C3bBb → Extends the half-life of C3bBb (and C3bBbC3b) | Level / assay: Typical adult serum about 5–25 mg/L. Deficiency occurs in three types: I (absent), II (low) and III (dysfunctional with a normal antigenic level), so a normal concentration does not exclude it Cytokine control: Released from neutrophil granules on activation rather than transcriptionally controlled | Scene 30 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| C5 C5 Complement | Hepatocytes; also macrophages | Cleaved by the C5 convertase into C5a and C5b; C5b initiates membrane-attack-complex assembly C5 deficiency causes recurrent Neisseria infection; eculizumab and ravulizumab block C5 cleavage and create the same acquired risk, so both MenACWY and MenB vaccination are required at least two weeks before the first dose, risk is reduced rather than abolished (non-groupable Neisseria included) and many centres add continuous antibacterial prophylaxis | C5b binds C6 to begin the terminal pathway → The C5 convertase is the C3 convertase plus an additional C3b, forming C4b2a3b (classical/lectin) or C3bBb3b (alternative), which repositions C5; C5 → C5b + C5a, and C5b6789 = MAC | Level / assay: Typical adult serum about 0.07–0.09 g/L; deficiency presents as an absent CH50 and AH50 with normal C3 and C4 Cytokine control: Hepatic acute-phase production with IL-6 | Scene 30 |
| C6 / C7 / C8 / C9 (MAC) C6, C7, C8A/B/G, C9 — the membrane attack complex Complement | Hepatocytes mainly | Assemble on C5b into the C5b-9 pore that lyses Neisseria and other susceptible cells; sublytic MAC also activates endothelium and the NLRP3 inflammasome Terminal-pathway (C5–C9) and properdin deficiencies predispose to recurrent Neisseria meningitidis disease, often with unusual serogroups; CH50 and AH50 should be tested in any patient with a second meningococcal episode. C9 deficiency is common in Japan and relatively mild because C5b-8 retains some lytic activity, and complete C6 deficiency is the more frequent terminal-component defect in individuals of African ancestry | Inserts directly into the lipid bilayer; blocked by CD59 on host cells → C5b + C6 + C7 → membrane insertion; C8 then multiple C9 form the pore | Level / assay: Screened functionally, and the pair of assays localizes the defect: an absent CH50 with a normal AH50 indicates a C1, C2 or C4 defect; a normal CH50 with an absent AH50 indicates a factor D, factor B or properdin defect; and absence of both indicates a C3 or terminal-component defect. Complement function is labile in vitro, so a spuriously absent CH50 usually reflects delayed separation or warm storage rather than deficiency; serum should be separated promptly and stored at −70 °C Cytokine control: Hepatic production rises modestly in the acute-phase response | Scene 30 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| C1 inhibitor SERPING1 (C1-INH) Complement | Hepatocytes mainly; also monocytes and endothelium | Serpin that inactivates C1r/C1s and MASP-1/2, and is the principal inhibitor of plasma kallikrein and factor XIIa; its loss therefore causes bradykinin angioedema rather than a complement-deficiency syndrome Hereditary angioedema types I and II: low C4 between attacks is the best screening test, with a normal C3; acquired C1-INH deficiency (low C1q) accompanies lymphoproliferative disease. Hereditary angioedema with normal C1-INH (F12, PLG, ANGPT1, KNG1, MYOF) is a recognized diagnostic difficulty, since C4 and C1-INH are both normal and the low-C4 screen is uninformative. Attacks do not respond to antihistamines, corticosteroids or adrenaline: on-demand treatment includes C1-INH concentrate, icatibant and ecallantide (marketed in the United States but not in Canada), and first-line long-term prophylaxis includes plasma-derived C1-INH concentrate, lanadelumab and berotralstat, with danazol a second-line option that is not recommended in children and adolescents before Tanner stage V | Covalently traps the target proteases → Inhibits C1r, C1s, MASP-1, MASP-2, kallikrein, factor XIIa | Level / assay: Typical adult antigenic level 0.15–0.35 g/L with function above about 68% of normal; a function under 50% supports hereditary angioedema and 50–68% is indeterminate and should be repeated. Type II disease has a normal antigenic level and low function, so the functional assay is always required Cytokine control: Hepatic production rises with IFN-γ; attenuated androgens raise C1-INH and C4 levels by an incompletely understood mechanism (the basis of danazol prophylaxis) | Scene 31 |
| Factor H CFH (with the CFHR proteins) Complement | Hepatocytes mainly; also retinal pigment epithelium, endothelium and platelets locally | The principal fluid-phase and host-surface inhibitor of the alternative pathway: accelerates decay of C3bBb and acts as a cofactor for factor I to cleave C3b; it recognizes host sialic acid and glycosaminoglycans, which is the basis on which host surfaces are spared Loss-of-function CFH variants and anti-factor-H autoantibodies (often with CFHR1/3 deletion) cause atypical haemolytic uraemic syndrome; the Y402H variant is a major age-related macular degeneration risk allele; complete deficiency results in complete consumption of C3. The phenotype follows the genotype: aHUS mutations cluster in the C-terminal surface-recognition domains (SCR19-20), while C3 glomerulopathy follows loss of N-terminal regulatory function or CFH–CFHR hybrid genes. Eculizumab is first-line for aHUS, and anti-factor-H-antibody disease additionally requires plasma exchange and immunosuppression | Binds C3b with host surface polyanions → Decay acceleration of C3bBb plus factor-I cofactor activity | Level / assay: Typical adult serum 0.2–0.7 g/L; measured with C3, factor I and anti-factor-H antibodies when C3 is low in isolation Cytokine control: Hepatic production rises with IFN-γ and IL-6 | Scene 31 |
| Factor I CFI Complement | Hepatocytes; also monocytes and endothelium | The protease that permanently inactivates C3b to iC3b and C4b to C4c/C4d, using factor H, C4BP, CR1 or MCP as cofactor Factor I deficiency results in C3 depletion (secondary C3 deficiency) and susceptibility to pyogenic infection; partial defects cause atypical haemolytic uraemic syndrome | Requires a cofactor for activity; iC3b remains a CR3 ligand, so cleavage converts activation into opsonization → C3b → iC3b with factor H, MCP or CR1; the second cleavage of iC3b to C3c plus C3dg (the CR2 ligand) requires CR1 specifically; factor H and MCP cannot serve as cofactors for it | Level / assay: Typical adult serum 0.03–0.06 g/L Cytokine control: Hepatic acute-phase production with IL-6 and IFN-γ | Scene 31 |
| C4BP / MCP / DAF C4BPA (C4b-binding protein), CD46 (MCP), CD55 (DAF) Complement | C4BP from hepatocytes; MCP (CD46) and DAF (CD55) on almost every host cell membrane | Prevent activation on host surfaces: C4BP is the cofactor for C4b (weakly for C3b) and MCP for both C3b and C4b; DAF dissociates both C3 convertases CD46 loss of function causes atypical haemolytic uraemic syndrome; an acquired somatic PIGA mutation in an expanded haematopoietic stem-cell clone eliminates DAF and CD59 together in paroxysmal nocturnal haemoglobinuria, where the haemolysis is predominantly CD59-dependent; isolated inherited CD55 loss instead causes CHAPLE disease (protein-losing enteropathy with thrombosis), treated with terminal-pathway blockade (pozelimab). CD46-associated aHUS has the best renal and post-transplant prognosis of the aHUS genotypes | Membrane-anchored (MCP is transmembrane, DAF is GPI-anchored); CD46 is also the receptor for vaccine and laboratory-adapted measles strains (wild-type measles uses CD150/SLAM and nectin-4) and a T-cell co-stimulatory receptor → Decay acceleration (DAF) and factor-I cofactor activity (C4BP, MCP) | Level / assay: Membrane regulators are measured by flow cytometry (the PNH panel), not by serum level Cytokine control: CD46 and CD55 expression rises on activated endothelium and epithelium | Scene 31 |
| CD59 CD59 (protectin, MAC-inhibitory protein) Complement | GPI-anchored on essentially all host cells, including red cells | Blocks C9 recruitment so the membrane attack complex cannot complete on host membranes Isolated inherited CD59 deficiency causes haemolysis with childhood neuropathy; with CD55 loss in PNH it causes the intravascular haemolysis that eculizumab prevents | Binds C8 and C9 within the forming complex → Prevents conversion of C5b-8 to a C5b-9 pore | Level / assay: Measured by flow cytometry (FLAER / CD55 and CD59 on red cells and granulocytes) Cytokine control: Expression rises on endothelium after inflammatory stimuli | Scene 31 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| CR1 (CD35) CR1 — complement receptor 1 Complement | Erythrocytes (the largest pool), neutrophils, monocytes, macrophages, B cells, follicular dendritic cells, podocytes | Immune-complex clearance: red-cell CR1 transports C3b/C4b-coated complexes to liver and spleen; on phagocytes it binds C3b and C4b for ingestion; it is also a factor-I cofactor and decay accelerator Low erythrocyte CR1 impairs immune-complex clearance in lupus; CR1 is the Plasmodium falciparum rosetting receptor | Binds C3b and C4b; low-affinity iC3b binding is reported in the primary literature but disputed, and iC3b is the established ligand of CR3, CR4 and CRIg → Phagocytosis with FcγR co-signalling; regulator activity on the same molecule | Level / assay: Red-cell CR1 copy number is measured in research settings; low in lupus, partly acquired Cytokine control: Neutrophil surface CR1 rises rapidly on degranulation after C5a, GM-CSF or TNF | Scene 32 |
| CR2 (CD21) CR2 — complement receptor 2 Complement | B cells and follicular dendritic cells | Lowers the B-cell activation threshold by one to three orders of magnitude in model systems (reported 10- to 1000-fold): C3d on antigen co-ligates CR2 with the BCR (the CD19/CD21/CD81 complex); FDC CR2 retains antigen in germinal centres Human CR2 deficiency is very rare: the first reported patient presented with CVID-like hypogammaglobulinaemia and poor vaccine responses, and a second had a milder phenotype; CD21 is the Epstein–Barr-virus receptor, which links complement to EBV entry | Binds C3dg and C3d, and iC3b (the end-products of C3b breakdown) → CD19 phosphorylation → PI3K with BCR signalling | Level / assay: Assessed by flow cytometry; CD21-low B cells are a recognized CVID phenotype Cytokine control: IL-21 with TLR9 and chronic B-cell-receptor stimulation drives the CD21-low phenotype | Scene 32 |
| CR3 / CR4 ITGAM/ITGB2 (CD11b/CD18, Mac-1) and ITGAX/ITGB2 (CD11c/CD18) Complement | Neutrophils, monocytes, macrophages, NK cells, dendritic cells (CR4) | The main phagocytic receptor for iC3b-opsonized particles; also the neutrophil adhesion integrin for firm arrest on endothelium CD18 deficiency (leukocyte adhesion deficiency type 1) causes delayed cord separation, absent pus formation, severe bacterial infection with a high blood neutrophil count; the ITGAM R77H variant is an established lupus risk allele | Binds iC3b, and also ICAM-1, fibrinogen and β-glucan; fibrinogen is a CR3 ligand, through which the acute-phase protein of Scene 36 engages this receptor → Inside-out activation by C5a and chemokines; outside-in signalling → phagocytosis, oxidative burst | Level / assay: Measured as CD18/CD11b expression by flow cytometry in the evaluation of leukocyte adhesion deficiency Cytokine control: Surface CR3 rises within minutes of C5a, IL-8, TNF or GM-CSF exposure as granules mobilize | Scene 32, 33 |
| C3aR / C5aR1 C3AR1 and C5AR1 (CD88); with C5aR2 (C5L2) Complement | Neutrophils, monocytes, macrophages, mast cells, basophils, eosinophils; also epithelium and endothelium | Convert complement activation into cell behaviour: chemotaxis, adhesion, degranulation and oxidative burst, and mast-cell mediator release Avacopan (C5aR1 antagonist) is approved for ANCA-associated vasculitis; C5aR1 blockade spares the membrane-attack complex, unlike anti-C5 | Bind C3a and C5a respectively; C5aR2 is non-G-protein-coupled and modulates signalling → Gi-coupled GPCRs → PI3K, Rho GTPases, Ca²⁺ flux (the same signalling pathway as the chemokine receptors of Scene 6) | Level / assay: Not a serum measurement; receptor expression falls on neutrophils during sepsis Cytokine control: C5aR1 expression rises on epithelium and endothelium with IL-1, TNF and IFN-γ | Scene 32, 33 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| Granulopoiesis marrow production of neutrophils (myeloblast to segmented neutrophil) Neutrophil | Bone marrow: GMP progenitors under G-CSF, with GM-CSF, IL-3 and SCF; IL-17 and IL-23 raise G-CSF when neutrophils are consumed | Determines the size of the marrow pool: about 6 days from myeloblast to mature neutrophil by modern labelling studies (classical kinetic estimates put the whole sequence nearer 10–14 days), shortened by G-CSF (measured postmitotic marrow transit from about 6.4 to 2.9 days; textbooks commonly quote 1–3 days) ELANE (most common), HAX1, G6PC3, SRP54, GFI1, JAGN1, VPS45 and gain-of-function WAS (X-linked neutropenia) cause severe congenital neutropenia with promyelocyte maturation arrest in the marrow, usually G-CSF-responsive; acquired CSF3R truncation and RUNX1 mutations identify patients who progress to MDS or AML: cumulative incidence about 22% at 15 years on G-CSF (SCNIR), the annual risk plateauing near 2.3%/year after 10 years, so counts and marrow are monitored | G-CSFR (CSF3R) on progenitors; KIT for SCF; GM-CSFR → G-CSFR → JAK2 / STAT3 (with STAT5) → proliferation and maturation | Defining factor: C/EBPα for steady state, C/EBPβ for emergency granulopoiesis; Gfi-1, PU.1 | Scene 33 |
| Marrow retention and release the CXCR4 / CXCR2 balance that holds or frees neutrophils Neutrophil | Marrow stroma produces CXCL12 (SDF-1), which retains CXCR4+ neutrophils; G-CSF lowers CXCL12 and raises CXCR2 ligands (IL-8, GRO-α, ENA-78), releasing them | Regulates the blood count from minute to minute: roughly 90% of the body’s neutrophils reside in the marrow reserve, and only a few per cent circulate WHIM syndrome (gain-of-function CXCR4) retains neutrophils in the marrow, causing myelokathexis with warts and hypogammaglobulinaemia; mavorixafor, an oral CXCR4 antagonist approved by the FDA in 2024 for WHIM from age 12 (not approved in Canada), raises neutrophil and lymphocyte counts, and plerixafor releases them acutely; steroid-induced neutrophilia from demargination and release is the commonly encountered counterpart | CXCR4 (retention) opposed by CXCR2 (release) on the neutrophil surface → Both are Gi-coupled GPCRs (Scene 6); the balance between the two determines whether the cell is retained or released | Defining factor: Not transcription-factor driven: a receptor-balance switch | Scene 33 |
| Recruitment to tissue rolling, arrest and transmigration Neutrophil | Endothelium activated by TNF-α and IL-1β expresses E- and P-selectin and the chemokines IL-8, GRO-α and ENA-78; C5a is generated by complement activation | Recruits neutrophils from blood within minutes: selectin rolling, chemokine- and C5a-triggered integrin activation, firm arrest, then crawling and diapedesis LAD-1 (ITGB2/CD18) causes delayed cord separation and infection without pus formation; LAD-2 (SLC35C1) adds the growth and developmental delay and Bombay (hh) phenotype of a glycosylation disorder and responds partially to oral fucose; LAD-3 (FERMT3, kindlin-3) adds a Glanzmann-like bleeding diathesis, the clinical discriminator. In all three the blood neutrophil count is elevated because the cells cannot leave the circulation | PSGL-1 and L-selectin for rolling; CXCR1, CXCR2 and C5aR1 for activation; LFA-1 (CD11a/CD18) and Mac-1 / CR3 (CD11b/CD18) for arrest → GPCR → inside-out integrin activation → firm adhesion; outside-in signalling for crawling | Defining factor: Not applicable: a surface-receptor cascade | Scene 33 |
| Resolution and clearance apoptosis, efferocytosis and the end of the response Neutrophil | Neutrophils die by apoptosis after roughly a day in blood (circulating half-life about 8–19 hours; published estimates range from ~6 hours to several days) and longer in tissue; GM-CSF, G-CSF and IL-8 delay it, whereas loss of survival signal and phagocytosis accelerate it | Macrophages ingest apoptotic neutrophils (efferocytosis), which switches the macrophage to a TGF-β and IL-10 programme and terminates recruitment, while the eicosanoid class switch to lipoxins, resolvins and protectins actively terminates the response; when few apoptotic neutrophils are cleared in tissue, macrophage IL-23 production rises and induces IL-17 (largely from γδ T, ILC3 and MAIT cells), which in turn raises G-CSF Failed apoptotic-cell clearance (C1q deficiency) causes lupus; the IL-23 / IL-17 / G-CSF loop accounts for the rise in G-CSF in neutropenia and for the mild reduction in neutrophil counts with anti-IL-17 agents | Phosphatidylserine on the apoptotic neutrophil recognized by macrophage MerTK (bridged by Gas6 and protein S) and by scavenger receptors; C1q and C3b bridge separately to CR1, CR3 and calreticulin-LRP1 → Efferocytosis → macrophage IL-10 and TGF-β, suppressing IL-23 | Defining factor: Not applicable Makes: IL-10 | Scene 33, 34 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| Phagocytosis and killing opsonin-dependent ingestion, oxidative burst and granules Neutrophil | Opsonins determine which targets are ingested: IgG through FcγRIIa and FcγRIIIb, and C3b/iC3b through CR1 and CR3; IFN-γ and GM-CSF prime the burst | Ingests opsonized organisms into a phagosome, assembles NADPH oxidase for superoxide, and discharges primary (myeloperoxidase, elastase), secondary (lactoferrin) and tertiary (gelatinase, MMP-9) granules into it Chronic granulomatous disease (CYBB, NCF1, NCF2, CYBA, NCF4, CYBC1/EROS) abolishes the burst and predisposes to Staphylococcus aureus, Serratia, Burkholderia cepacia complex, Nocardia and Aspergillus infection with sterile granulomas and colitis (the former catalase-positive rule has been experimentally refuted). Dihydrorhodamine flow cytometry is the diagnostic test and identifies X-linked carriers by its bimodal pattern; residual oxidase activity predicts survival. Myeloperoxidase deficiency is usually benign but gives a falsely abnormal DHR result, because dihydrorhodamine oxidation is itself MPO-dependent; the NBT test remains normal | FcγRIIa (CD32a), FcγRIIIb (CD16b, GPI-anchored and lacking an ITAM; it signals through FcγRIIa and CR3), FcγRI (CD64, induced by IFN-γ or G-CSF), FcαRI (CD89) for IgA, CR1 (CD35), CR3 (CD11b/CD18), C5aR1, fMLP receptor → ITAM → Syk → PI3K and PKC → p47phox, p67phox, p40phox and Rac2 assemble on the membrane flavocytochrome gp91phox (NOX2) with p22phox | Defining factor: Granule contents are preformed and require no transcription; the cytokine output below is transcriptionally induced and modest relative to that of a monocyte Makes: IL-8, TNFα, BAFF, IL-1RA, IL-1β | Scene 34 |
| NET formation neutrophil extracellular traps Neutrophil | Triggered by immobilized antigen, PMA, IL-8, C5a, activated platelets and some bacteria; in many settings it requires NADPH-oxidase-derived ROS and PAD4-driven histone citrullination | Releases chromatin bearing elastase, myeloperoxidase and histones, which traps extracellular organisms; also a source of autoantigen and a driver of thrombosis NETs externalize MPO and PR3 (the ANCA antigens) and DNA and nucleosomes in lupus, whereas citrullinated histones from the same process are a source of the ACPA antigens of rheumatoid arthritis; NET clearance depends on DNase I and DNASE1L3, and DNASE1L3 loss causes lupus and hypocomplementaemic urticarial vasculitis. NOX2-deficient (CGD) neutrophils form NETs poorly, a defect corrected by gene therapy. NETs also contribute to immunothrombosis in sepsis and severe COVID-19 | Downstream of FcγR, CR3, C5aR1 and TLR signalling → ROS and PAD4 → chromatin decondensation → extracellular release | Defining factor: Not applicable | Scene 34 |
| Opsonin recognition what decides whether a neutrophil ingests something Neutrophil | Opsonins deposited by the adaptive and innate systems: IgG1 and IgG3 (and IgA1 in complexes) from plasma cells, and C3b and iC3b from complement activation | Binds opsonized organisms and extends the membrane around them; unopsonized organisms are largely not recognized, so antibody and complement determine which organisms a neutrophil can kill Neutrophil CD64 rises within hours of bacterial infection and is used as a sepsis marker, especially in neonates; IgA complexes acting on CD89 drive the neutrophil injury of IgA vasculitis | FcγRIIa (CD32a), FcγRIIIb (CD16b, GPI-anchored and lacking an ITAM; it signals through FcγRIIa and CR3), FcγRI (CD64, induced by IFN-γ or G-CSF), FcαRI (CD89) for IgA, CR1 (CD35) for C3b, CR3 (CD11b/CD18) for iC3b → ITAM → Syk → PI3K and PKC; C5a and chemokines activate CR3 by inside-out signalling | Defining factor: Not transcription-dependent: the receptors are constitutively expressed on the surface | Scene 34 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| CRP C-reactive protein (CRP); a pentameric short pentraxin Acute-phase | Hepatocytes almost exclusively, driven by IL-6 through STAT3 with IL-1β as a co-signal; transcription rises within hours of the stimulus | Binds phosphocholine exposed on damaged membranes, on apoptotic cells and on the pneumococcal C-polysaccharide, then activates the classical complement pathway through C1q and opsonizes the target for FcγRI and FcγRIIa; it is an antibody-independent opsonin A CRP over about 100 mg/L favours bacterial infection or an abscess, and viral illness is usually lower, but no cut-off separates them reliably and the threshold is population-specific: paediatric febrile-infant rules use the markers only as components of a complete rule. Step-by-Step classifies an infant as low risk only if the child appears well, is older than 21 days, has a negative urine leukocyte esterase, PCT under 0.5 µg/L, CRP 20 mg/L or below and ANC 10 ×10⁹/L or below, so the CRP and PCT thresholds alone do not stratify risk; neonatal sepsis screens use 10 mg/L. Because CRP lags the stimulus by hours, a low value sampled early does not exclude bacterial infection. Newborns have a physiological rise over the first 24–48 hours of life, parallel to PCT, and that response is gestational-age dependent (preterm infants mount a lower and shorter rise), so a neonatal CRP requires both an hour-of-life and a gestation-matched reference. Negative findings are equally informative: CRP remains relatively low in many lupus flares (serositis excepted), which assists in distinguishing flare from infection; it cannot rise during IL-6 blockade, in IL6R or STAT3 defects, or in liver failure, so a normal CRP in those settings provides no information about infection | Recognized by C1q (classical pathway) and by FcγRI and FcγRIIa on phagocytes → IL-6 → JAK1 → STAT3 on the CRP promoter, with NF-κB from IL-1β | Level / assay: Typical adult under about 5 mg/L (laboratories quote 3, 5 or 8); high-sensitivity CRP is the same analyte on a lower-range assay, interpreted as under 1 (low), 1–3 (average) and over 3 mg/L (high) for cardiovascular risk; the 2003 AHA/CDC statement that defined those bands specifies the average of two samples about two weeks apart and regards a value over 10 mg/L as an indication to seek an acute cause rather than as a risk category Half-life about 19 hours and constant, so the level reflects the current rate of synthesis: it begins to rise by 4–6 hours, doubles roughly every 8 hours, peaks at 36–50 hours, and falls rapidly once the stimulus ceases Cytokine control: IL-6 is the dominant driver (with IL-1β); IL-6 blockade with tocilizumab or sarilumab abolishes the CRP response | Scene 35, 36 |
| SAA serum amyloid A (SAA1/SAA2) Acute-phase | Hepatocytes under IL-1β, IL-6 and TNF-α together | An apolipoprotein that redistributes cholesterol during inflammation and recruits monocytes; chronically raised SAA is the precursor protein of AA amyloid, which deposits in kidney, gut and liver The clinically relevant marker in the periodic fevers: sustained SAA elevation in untreated familial Mediterranean fever, TRAPS or CAPS causes AA amyloidosis, so where the assay is available it is used to confirm that colchicine or anti-IL-1 treatment is adequate between attacks; a normal CRP between attacks does not establish that inflammation is controlled | Binds HDL; signals through FPR2 and TLR2 on monocytes → NF-κB and STAT3 on the SAA promoters | Level / assay: Typical adult under about 10 mg/L, but the assay is not universally available Among the fastest of the acute-phase rises: up to about 1000-fold within roughly 24 hours, as can CRP, and on serial measurement it rises earlier and falls more rapidly than CRP (human SAA half-life figures are not well established, so the comparison is kinetic rather than pharmacokinetic) Cytokine control: Driven by IL-1β, IL-6 and TNF-α; anti-IL-1 treatment lowers it markedly in the inflammasome diseases | Scene 35, 36 |
| Fibrinogen fibrinogen (FGA / FGB / FGG) — a type 2 acute-phase protein Acute-phase | Hepatocytes under IL-6 through STAT3; a type 2 acute-phase protein, driven by IL-6-family (gp130) signals alone: IL-1β and TNF-α do not add to the IL-6 effect and IL-1β negatively modulates it, unlike CRP, SAA and complement C3, which are type 1 and respond to both. Human haptoglobin is type 2 with fibrinogen, so IL-1β also adds little to it; the type 1 / type 2 distinction is species-dependent and the rat assignments do not apply to humans. A two- to four-fold rise over days rather than hours | The clotting substrate for thrombin, and the principal protein causing red cells to form rouleaux, which is the phenomenon measured by the ESR Because fibrinogen determines the ESR, any condition in which it is consumed or not produced (disseminated intravascular coagulation, liver failure, congenital hypo- or dysfibrinogenaemia, thrombolysis) can suppress the ESR despite active inflammation | Binds integrin αIIbβ3 on platelets and CR3 (CD11b/CD18) on neutrophils → IL-6 → STAT3 on the fibrinogen genes | Level / assay: Typical adult 2–4 g/L; rises to 6–10 g/L in sustained inflammation; neonatal values are lower than adult, and in a child with systemic JIA a fibrinogen of ≤3.6 g/L is classified as abnormally low in the 2016 MAS criteria because the acute-phase response would be expected to have raised it Slow: rises over 24–48 hours and falls over days to weeks, which accounts for the lag of the ESR behind the CRP in both directions Cytokine control: IL-6-driven, so IL-6 blockade lowers fibrinogen and with it the ESR. At the hepatocyte IL-1β does not add to the IL-6 signal and transiently antagonises it at the promoter, but this does not reverse the clinical direction: because IL-1β drives IL-6, IL-1 blockade also lowers fibrinogen (canakinumab reduced fibrinogen as well as IL-6 and CRP in the CANTOS phase IIb trial), so a falling fibrinogen on anti-IL-1 treatment is expected and not paradoxical | Scene 35, 36, 37 |
| Procalcitonin procalcitonin (PCT), the prohormone of calcitonin (CALCA) Acute-phase | Normally only thyroid C cells, which cleave it to calcitonin; in systemic bacterial infection almost every parenchymal tissue transcribes CALCA under IL-1β, TNF-α and IL-6 and releases the uncleaved prohormone | No established physiological role at these concentrations; it is used as a marker because bacterial products induce it whereas interferon suppresses it Discriminates bacterial from viral infection better than CRP and is the only marker in this group that IL-6 blockade does not abolish, so it remains interpretable on tocilizumab. It is also raised without infection after major surgery, trauma, burns, cardiac arrest and in medullary thyroid carcinoma | No defined receptor for the prohormone → NF-κB from TLR and IL-1 signalling; type I and type II interferon suppress it | Level / assay: Typical adult under 0.1 µg/L; above about 0.5 µg/L suggests bacterial infection and above 2 µg/L suggests sepsis. Healthy newborns have a large physiological peak at about 24 hours of life (roughly the 18–36 hour window); the 95th centile reaches roughly 20 µg/L in term infants, far above the adult bacterial cut-off, and values return to the adult range by about 48–72 hours on the classic term nomograms, although some series show a slower fall. The fall is later still in preterm infants, in whom values are interpreted against a gestation- and hour-matched nomogram; their peak is reported between 24 and 48 hours (averaging about 36) in preterm reference series, although Chiesa 2011 found an earlier one. It is agreed that the peak resolves more slowly at lower gestational ages; the peak magnitude is disputed, since preterm series report peaks both above and below the term value, with the lowest values in the lowest-birth-weight infants, while their CRP response is correspondingly lower and shorter, so gestational age as well as hour of life must be matched. Within that window PCT must therefore be interpreted against an hour-of-life nomogram and not the adult cut-offs Half-life about 24 hours; it rises within 3–6 hours and peaks at about 6–24 hours, so it rises earlier than CRP and falls predictably when the infection is treated Cytokine control: Induced by IL-1β, TNF-α and IL-6; suppressed by IFN-γ and type I interferon, which accounts for comparatively low values in viral illness | Scene 35, 36 |
| Haptoglobin haptoglobin (HP) Acute-phase | Hepatocytes under IL-6 through STAT3; a type 2 reactant in humans; a modest two- to three-fold rise | Binds free haemoglobin released from lysed red cells and delivers it to macrophage CD163 for clearance The two effects oppose each other: haemolysis consumes haptoglobin whereas inflammation raises its synthesis, so a normal haptoglobin in an inflamed patient does not exclude haemolysis | Haptoglobin–haemoglobin complexes are cleared by CD163 on macrophages → STAT3 and NF-κB on the HP promoter | Level / assay: Typical adult 0.3–2.0 g/L. Age caveat: newborns usually have no measurable haptoglobin and a low value is physiological through the first 3–6 months, with adult levels reached around 6 months, so haptoglobin cannot be used to assess haemolysis in young infants Rises over 24–48 hours; falls within hours during brisk haemolysis as it is consumed Cytokine control: IL-6-driven | Scene 35 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| Albumin albumin (ALB) — a negative acute-phase reactant Acute-phase | Hepatocytes; IL-6 and TNF-α suppress transcription, so the level falls as the positive reactants rise, and capillary leak and expanded plasma volume lower it further | Oncotic pressure and carriage of drugs, calcium, bilirubin and hormones; its fall during inflammation is a marker of the response, not of nutrition alone A low albumin in an inflamed patient is usually the acute-phase response rather than malnutrition; causes of true protein loss (nephrotic syndrome, protein-losing enteropathy, including the CD55 deficiency of CHAPLE disease) should be excluded before it is attributed to nutrition | No receptor relevant here; FcRn recycles albumin alongside IgG → IL-6 and TNF-α suppress the ALB promoter | Level / assay: Typical adult 35–50 g/L. The effect of age is contrary to expectation: values in term and preterm neonates are lower (term 24–40 g/L in the first week, preterm from about 21 g/L), but from mid-infancy through childhood albumin is at or slightly above the adult interval (about 39–50 g/L), so a borderline-low albumin in a 4-year-old is not an age effect Long (about 20 days), so a fall is slow and a rise after recovery is slower Cytokine control: Suppressed by IL-6 and TNF-α | Scene 35 |
| Transferrin and transthyretin transferrin (TF) and transthyretin / prealbumin (TTR) — negative reactants Acute-phase | Hepatocytes; both are suppressed by IL-6 and TNF-α during inflammation | Transferrin carries iron to the transferrin receptor; transthyretin carries thyroxine and retinol-binding protein. Both fall in inflammation, which distorts the panels in which they are included A low transferrin during inflammation is not iron overload, and a low transthyretin is not by itself evidence of malnutrition; both reflect the inflammation. When ferritin is uninterpretable, the soluble transferrin receptor (or the sTfR/log-ferritin index) remains a valid measure: transferrin saturation is itself lowered by inflammation, so a low saturation does not establish iron deficiency | Transferrin is recognized by TfR1 (CD71) on erythroid precursors and activated lymphocytes → IL-6 and TNF-α suppress both promoters | Level / assay: Transferrin typically 2.0–3.6 g/L in adults but lower in the neonate (mean about 2.0–2.15 g/L, roughly 1.3–2.8 g/L), exceeding the adult mean by about 10 months and remaining at or slightly above adult values for the rest of childhood; transthyretin typically 0.14–0.35 g/L in adults, about 0.11–0.26 g/L from one month to 12 years and 0.13–0.32 g/L in adolescence, with a wide newborn interval (0.07–0.39 g/L) Transferrin about 8 days; transthyretin about 2 days, which accounts for its being the most rapidly falling of the negative reactants Cytokine control: Suppressed by IL-6 and TNF-α | Scene 35, 38 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| Ferritin ferritin (FTL / FTH1), the iron-storage protein Acute-phase | Hepatocytes and macrophages; IL-6 and IL-1β raise transcription, and iron raises translation through the iron-responsive element | Stores iron in a non-toxic form within cells; the serum form is a secondary marker that rises both with iron stores and with inflammation, which accounts for the difficulty of its interpretation A normal or high ferritin does not exclude iron deficiency when CRP is raised; transferrin saturation is not a suitable alternative, because it is lowered by inflammation independently, and the soluble transferrin receptor or the sTfR/log-ferritin index, interpreted against a paediatric interval, is used instead. A very high ferritin should prompt consideration of haemophagocytosis, macrophage activation syndrome, Still disease, iron overload or liver injury rather than being interpreted as replete iron stores | Serum ferritin is largely iron-poor L-chain; scavenger receptor SCARA5 (L-ferritin) and TfR1 (CD71), the human H-ferritin receptor, bind ferritin; the murine H-ferritin receptor TIM-2 has no human ortholog → STAT3 and NF-κB on the ferritin genes; IRP1/IRP2 control translation | Level / assay: Wide and laboratory-specific; WHO defines under 12 µg/L below 5 years and under 15 µg/L from 5 years as depleted stores, and under 30 µg/L below five years and under 70 µg/L from five years when inflammation is present (the WHO recommendation text says 30 in children and 70 in adults, but the WHO cut-off table bands the 70 µg/L figure from five years up, adolescents included). The ASH 2026 guideline (Powers, Blood Adv) raises the non-inflamed cutoffs: 20 µg/L or below from 9 months to 4 years (replacing 12), 20 µg/L by indirect evidence from 4 years to adolescence, and 30 µg/L or below in adolescents and adults, including menstruating and pregnant individuals; in adults with anaemia of inflammation it suggests ferritin under 100 µg/L or a transferrin saturation under 20%. It makes no recommendation for children with inflammation, so the WHO 30 µg/L figure continues to apply in that setting; ferritin is very high in the first weeks of life (roughly 150–950 µg/L in the first month) and then falls below the adult interval for the rest of childhood (about 6–110 µg/L from 6 months to adolescence, laboratory-dependent), so it must be interpreted against an age-banded interval in both directions: a value normal for an adult can represent depletion in a neonate, whereas an adult low-normal value may be normal for a 3-year-old. Clinically relevant thresholds: ferritin of 500 µg/L or more is one of the eight HLH-2004 criteria (sensitive, poorly specific); in systemic JIA the 2016 EULAR/ACR/PRINTO criteria classify MAS on ferritin >684 µg/L plus two of platelets ≤181 ×10⁹/L, AST >48 U/L, triglycerides >1.76 mmol/L or fibrinogen ≤3.6 g/L; these criteria apply only to a febrile child with known or suspected systemic JIA, and classify rather than diagnose (sensitivity 0.73, specificity 0.99); and among children whose ferritin was already above 500 µg/L at a single paediatric centre, a ferritin over 10,000 µg/L was 90% sensitive and 96% specific for HLH (Allen 2008, 10 HLH cases in 330 patients); the denominator was selected, so the specificity does not apply to an unselected febrile child, in whom sepsis, haematological malignancy, renal failure and hepatocellular injury account for many values above that level. Values in the tens of thousands are common in MAS but are not the classification threshold Rises over 24–48 hours with inflammation and falls over days to weeks Cytokine control: IL-6 and IL-1β raise it independently of iron stores | Scene 35, 38 |
| Hepcidin hepcidin (HAMP) Acute-phase | Hepatocytes under IL-6 through STAT3, with the BMP6–SMAD pathway sensing iron stores | The principal iron-regulatory hormone: it degrades ferroportin on enterocytes and macrophages, so dietary iron absorption ceases and iron is sequestered within macrophages, which is the mechanism of the anaemia of inflammation Accounts for the laboratory pattern of anaemia of inflammation (low serum iron, low transferrin saturation, low or normal transferrin and a normal or high ferritin) and for the poor response to oral iron until the inflammation is treated | Binds and degrades ferroportin (SLC40A1) → IL-6 → STAT3 and BMP6 → SMAD1/5/8 on the HAMP promoter | Level / assay: No universally standardised assay or reference range; interpreted in research and specialist settings rather than routinely Short, with a rise within hours of an IL-6 signal Cytokine control: IL-6 is the inflammatory driver; erythropoietic drive through erythroferrone suppresses it | Scene 35, 38 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| ESR erythrocyte sedimentation rate (Westergren method) — a physical index, not a protein Acute-phase | Not synthesised: it is the distance red cells fall in a vertical tube in one hour, and it rises when plasma proteins (chiefly fibrinogen, and to a lesser extent immunoglobulins) bridge red cells into rouleaux that sediment more rapidly | Measures the net effect of fibrinogen and immunoglobulin on red-cell aggregation, so it is an indirect and slow index of inflammation rather than a mediator The ESR is interpreted together with the CRP and not as a substitute for it. A high CRP with a normal ESR suggests early inflammation; a high ESR with a normal CRP suggests resolving inflammation, a paraprotein or polyclonal hypergammaglobulinaemia, or anaemia. Raised without inflammation by anaemia, pregnancy, female sex, older age, obesity and renal failure; lowered by polycythaemia, severe hypofibrinogenaemia, and red-cell shape changes such as sickle cells, spherocytes and marked microcytosis. An ESR over 100 mm/h suggests infection, myeloma or another malignancy, giant-cell arteritis, tuberculosis or nephrotic-range renal disease in adults; in children the same value more often indicates osteomyelitis or septic arthritis, Kawasaki disease, systemic JIA and inflammatory bowel disease rather than myeloma or giant-cell arteritis | No receptor: a laboratory measurement → Depends on fibrinogen (IL-6-driven) and on immunoglobulin concentration | Level / assay: Age- and sex-dependent: Westergren upper limits in adults are under about 15 mm/h for men and 20 mm/h for women below 50 years, rising to about 20 and 30 mm/h over 50, which is approximated by the adult age correction (age ÷ 2 for men, (age + 10) ÷ 2 for women). That formula does not apply to children: paediatric limits are about 0–13 mm/h to age 12 (newborns 0–2 mm/h), with adult limits from around puberty Rises over 24–48 hours and falls over days to weeks, lagging the CRP in both directions because it follows fibrinogen Cytokine control: Only indirectly: IL-6 raises fibrinogen, which raises the ESR; IL-6 blockade lowers both | Scene 36, 37 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| Omalizumab omalizumab (Xolair) — humanised anti-IgE IgG1 Biologic or targeted agent | Administered therapeutically; not produced endogenously | Binds the Cε3 domain of free IgE at the site used by FcεRI, so IgE can no longer bind to mast cells and basophils; receptor-bound IgE is not displaced, so the effect results from the slow loss of surface IgE as receptors turn over, and FcεRI density on basophils and mast cells falls over weeks Carries a boxed warning for anaphylaxis, which has occurred after a first dose and after more than a year of uneventful treatment: it is administered in a healthcare setting with observation, and for the food-allergy indication an adrenaline auto-injector is prescribed. Licensed for allergic asthma from 6 years, chronic spontaneous urticaria from 12 years, chronic rhinosinusitis with nasal polyps in adults, and, in the USA only, for IgE-mediated food allergy from one year, where it raises the reaction threshold rather than conferring tolerance, so avoidance continues. Also used off-label as adjunctive cover during oral immunotherapy build-up. | IgE → Free IgE falls within hours; surface FcεRI density falls over 1–3 months, which accounts for the delay between dosing and clinical effect | What it does to the tests: Total IgE rises, often several-fold, and remains elevated for a year or more: the assay measures omalizumab–IgE complexes as well as free IgE, so a rising total IgE on treatment is expected and is not treatment failure. Free IgE is the analyte that falls, and it is not routinely available. Blood eosinophils fall modestly. Skin prick tests and basophil activation tests become unreliable while surface IgE is depleted, and specific IgE in serum is unaffected by the drug but is interpreted against a distorted total. Made uninterpretable: Total IgE and skin prick testing. For asthma, nasal polyps and food allergy the dose and interval are determined from the pre-treatment total IgE and body weight, so the baseline must be recorded before the first dose and a total IgE measured on treatment cannot be used to revise the dose. Chronic spontaneous urticaria is the exception: dosing is fixed at 150 or 300 mg every four weeks and requires neither value, so treatment should not be delayed to obtain them. If skin testing is required, it must precede treatment or follow a washout of several months. Canada and the United States: Canada (Xolair, PM Feb 2025; biosimilar Omlyclo): allergic asthma from 6 years, chronic idiopathic urticaria from 12 years, nasal polyps in adults. Asthma dosing is a two-variable lookup on pre-treatment total IgE × weight, 75–375 mg q2w or q4w; the adolescent table starts at 20 kg. United States: the same three indications at the same ages, and the 6–11-year asthma table is identical cell for cell, but the adolescent table starts at 30 kg and adds IgE-mediated food allergy from 1 year (75–600 mg, 10–12 kg upward, IgE 30–1850 IU/mL). Different: food allergy is not authorised in Canada for either Xolair or Omlyclo, so a Canadian prescription for it is off-label with no Canadian dosing table; the US table is the only published authority. Anaphylaxis is boxed in both countries. Devices differ: in Canada the 300 mg syringe and every pen strength are for 12 years and over, so a 6–11-year-old requires the 75 or 150 mg syringe or the vial. | Scene 39 |
| Dupilumab dupilumab (Dupixent) — human anti-IL-4Rα IgG4 Biologic or targeted agent | Administered therapeutically; not produced endogenously | Binds IL-4Rα, so it blocks the type I receptor (IL-4Rα + γc, used by IL-4 alone) and the type II receptor (IL-4Rα + IL-13Rα1, used by both IL-4 and IL-13): a single antibody blocks the entire STAT6 arm of type 2 immunity Atopic dermatitis from 6 months, eosinophilic asthma from 6 years, chronic rhinosinusitis with nasal polyps from 12 years, eosinophilic oesophagitis from 1 year and 15 kg, chronic spontaneous urticaria from 2 years in the USA but only from 12 years in Canada, allergic fungal rhinosinusitis from 6 years with prior sino-nasal surgery and bullous pemphigoid in adults in the USA only, and prurigo nodularis and COPD with type 2 inflammation in adults. Head and neck erythema and conjunctivitis are the characteristic adverse effects; arthralgia and psoriasiform eruptions are recognised. | IL-4; IL-13 → Blocks IL-4 and IL-13 signalling through STAT6; IL-13 can still bind the decoy IL-13Rα2, which partly accounts for the rise in free IL-13 in the blood | What it does to the tests: Blood eosinophils often rise in the first weeks to months and then decline; this is the expected result of blocking eotaxin-driven tissue recruitment while IL-5-driven marrow release continues, so the cells remain in the circulation. A rise does not represent treatment failure and is not by itself an indication for discontinuation; a sustained count over about 1.5 × 10⁹/L, and any count with new systemic symptoms, requires evaluation for eosinophilic granulomatosis with polyangiitis or hypereosinophilic disease. FeNO and total IgE fall slowly over months. TARC (CCL17) falls and correlates with atopic-dermatitis activity. CRP and ESR are unaffected and remain interpretable. Made uninterpretable: Blood eosinophils in the first months, and total IgE as a measure of disease activity. Canada and the United States: Canada (PM Oct 2026): atopic dermatitis from 6 months, asthma from 6 years, nasal polyps from 12 years, eosinophilic oesophagitis from 1 year and 15 kg, chronic spontaneous urticaria from 12 years, prurigo nodularis and COPD in adults. United States (label Apr 2026): the same, except urticaria from 2 years, plus allergic fungal rhinosinusitis from 6 years with prior sino-nasal surgery and bullous pemphigoid in adults, none of which Canada has authorised. Same: the dermatitis, polyp, oesophagitis, prurigo and COPD ages, the weight bands and the loading rules all match exactly, as do the device age limits (pen from 2 years, syringe from 6 months; under 12 a caregiver injects). Different also in asthma wording: Canada licenses severe type 2 asthma, the USA moderate-to-severe, and Canada alone offers 200 mg q2w or 300 mg q4w for a 30–60 kg child aged 6–11. No boxed warning in either country. Potential source of error: the loading dose is age-dependent and not weight-dependent; there is none under 6 years and none for 6–11-year asthma, but a 6–11-year-old with dermatitis receives a loading dose. | Scene 39 |
| Tralokinumab and lebrikizumab tralokinumab (Adbry/Adtralza) and lebrikizumab (Ebglyss) — anti-IL-13 IgG4 Biologic or targeted agent | Administered therapeutically; not produced endogenously | Neutralise IL-13 itself rather than the shared receptor chain, so IL-4 signalling through the type I receptor remains intact; the blockade is narrower than that of dupilumab Atopic dermatitis in adolescents from 12 years and in adults; the adolescent tralokinumab dose is twice as high in Canada as in the USA (see the licensing note). Useful where dupilumab-associated conjunctivitis or head-and-neck erythema is limiting, since IL-4 signalling is preserved. | IL-13 → Tralokinumab blocks IL-13 binding to both IL-13Rα1 and IL-13Rα2; lebrikizumab blocks the IL-13Rα1 heterodimer while leaving IL-13Rα2 decoy clearance intact | What it does to the tests: Changes are in the same direction as with dupilumab but are smaller: FeNO and TARC fall, and eosinophils change little. Conjunctivitis occurs but less often than with dupilumab. Canada and the United States: Tralokinumab: the adolescent dose differs by a factor of two between the two countries, and both positions are current. Canada (Adtralza, PM Mar 2026), 12 years and over: 600 mg load, then 300 mg q2w, which is the full adult dose. United States (Adbry, label Dec 2025), 12–17 years: 300 mg load, then 150 mg q2w, by prefilled syringe only, since the 300 mg autoinjector cannot deliver it. Dosing a Canadian adolescent from an American source, or the reverse, results in a twofold error. The indication and the 12-year floor are the same; Canada permits the q4w step-down in any responder, the USA only in adults under 100 kg. Lebrikizumab (Ebglyss) is the same in the two countries: 12 years and 40 kg, 500 mg at weeks 0 and 2, then 250 mg q2w to week 16; a 12-year-old under 40 kg is off-label in both countries. Different only in maintenance: the USA added 250 mg q8w in June 2026, Canada authorises q4w alone. Neither drug is authorised below 12 years in either country, and Health Canada notes that no paediatric data were submitted for tralokinumab, so there is no Canadian basis for extrapolation to younger ages. No boxed warning. | Scene 39 |
| Mepolizumab and reslizumab mepolizumab (Nucala) and reslizumab (Cinqair) — anti-IL-5 IgG Biologic or targeted agent | Administered therapeutically; not produced endogenously | Neutralise circulating IL-5, so eosinophil production, release from the marrow and survival in tissue all fall; the cells are not killed directly, so the count falls but is not abolished Mepolizumab: severe eosinophilic asthma from 6 years, hypereosinophilic syndrome from 12 years in the USA but adults only in Canada, and eosinophilic granulomatosis with polyangiitis, chronic rhinosinusitis with nasal polyps and COPD in adults. Reslizumab is intravenous and adults only. Baseline eosinophil count predicts response, so it must be measured before the first dose. | IL-5 → Free IL-5 is neutralised; eosinophil IL-5Rα signalling (JAK2/STAT5) is lost | What it does to the tests: Blood eosinophils fall by roughly 80–90% within weeks but do not reach zero; tissue eosinophils fall more slowly. CRP, ESR and IgE are unaffected. A persistently normal eosinophil count on treatment does not establish tissue control. Made uninterpretable: The blood eosinophil count as a measure of disease activity, since on treatment it reflects the drug effect. Canada and the United States: Mepolizumab (Nucala): asthma is fully concordant, from 6 years in both countries, 40 mg q4w at 6–11 years and 100 mg q4w from 12, and the 40 mg syringe is marketed in Canada. Nasal polyps, COPD and EGPA are adults-only in both. Different: hypereosinophilic syndrome is licensed from 12 years in the USA and in adults only in Canada, so use in an adolescent with idiopathic HES is off-label in Canada. Canada also specifies an eligibility threshold that the US label omits (eosinophils at or above 150/µL at initiation or 300/µL within the past year) and sets a lower inhaled-steroid floor for 6–17-year-olds than for adults. Potential source of error: the asthma dose changes in a single step at the twelfth birthday and is not weight-scaled, and the 100 mg devices cannot deliver a 40 mg dose, so an autoinjector prescribed for a 9-year-old delivers a two-and-a-half-fold overdose. The EGPA and HES dose of 300 mg is given as three separate 100 mg injections. Reslizumab (Cinqair) is identical in the two countries: adults only, 3 mg/kg intravenously q4w over 20–50 minutes, in a setting prepared for anaphylaxis, which is boxed in both countries. It is the only weight-based and only intravenous agent here and the only one with no paediatric licence in either country; the mg/kg dosing does not imply suitability for paediatric use. A malignancy warning appears in the US label; whether the Canadian monograph carries an equivalent was not confirmed. | Scene 39 |
| Benralizumab benralizumab (Fasenra) — afucosylated anti-IL-5Rα IgG1 Biologic or targeted agent | Administered therapeutically; not produced endogenously | Binds IL-5Rα, the receptor on the eosinophil, and not the cytokine: the target shown for this entry is IL-5 because the eosinophil is not a catalogued entity in this reference, but the drug leaves IL-5 itself in the circulation and depletes the cell that responds to it. Because the Fc is afucosylated and binds FcγRIIIa with very high affinity, it recruits NK-cell antibody-dependent cellular cytotoxicity: the eosinophil is killed rather than deprived of its survival signal. Basophils, which also express IL-5Rα, are depleted with them Severe eosinophilic asthma from 6 years in the USA but adults only in Canada, hypereosinophilic syndrome from 12 years (Canada also requires 40 kg), and eosinophilic granulomatosis with polyangiitis in adults. Strongyloides should be screened for and treated before initiation, as with any agent that depletes eosinophils. | IL-5 → Antibody-dependent cellular cytotoxicity through FcγRIIIa on NK cells, in addition to receptor blockade | What it does to the tests: Blood eosinophils fall to zero by the first on-treatment measurement at four weeks (and within about a day in the bronchoscopy studies of the mechanism) and remain at zero; depletion is complete, unlike that with the anti-IL-5 antibodies. Basophils also fall. A zero eosinophil count is the expected on-treatment finding and is not in itself a cause for concern, but the count can no longer be used diagnostically, including for the eosinophilia that would otherwise indicate drug reaction, parasitic infection or adrenal insufficiency. Made uninterpretable: The eosinophil count, for the duration of treatment. Canada and the United States: The asthma licence differs by twelve years. United States (label May 2026): severe eosinophilic asthma from 6 years (10 mg q4w under 35 kg and 30 mg q4w at or above it for 6–11-year-olds), then 30 mg q4w × 3 doses followed by q8w from 12 years. Canada (PM Aug 2026): asthma in adults only; Health Canada states efficacy and safety are not established below 18 years. Benralizumab for a 9-year-old is therefore on-label in the United States and off-label in Canada; the 10 mg paediatric syringe is not marketed in Canada, so the US dose cannot be delivered from Canadian stock (the 30 mg/mL syringe cannot be divided reliably). EGPA is adults-only in both, 30 mg q4w. Hypereosinophilic syndrome is from 12 years in both, but Canada additionally requires 40 kg, so a 13-year-old of 35 kg is on-label in the USA and off-label in Canada. No boxed warning in either country. Potential source of error: the q4w × 3 then q8w loading pattern applies to asthma only; EGPA and HES remain q4w indefinitely. In the USA the syringe is for clinic use and only the pen is supplied for home use; Canada permits either to be self-administered or administered by a caregiver. | Scene 39 |
| Tezepelumab tezepelumab (Tezspire) — human anti-TSLP IgG2 Biologic or targeted agent | Administered therapeutically; not produced endogenously | Blocks TSLP at the origin of the epithelial alarmin cascade, upstream of the type 2 cytokines, so it is effective in asthma independent of eosinophil count or allergic status; it is the only type 2 agent that is not restricted to a type 2 phenotype Severe asthma from 12 years regardless of phenotype, including low-eosinophil disease, and chronic rhinosinusitis with nasal polyps from 12 years in the USA but adults only in Canada. Because it acts upstream of IL-5 and IL-13, it attenuates several of the markers used to phenotype the patient, so phenotyping must precede treatment. | TSLP → Prevents TSLP binding TSLPR + IL-7Rα, so the downstream OX40L, IL-4, IL-5 and IL-13 programme is not initiated | What it does to the tests: Blood eosinophils, FeNO and total IgE all fall. IL-5 and IL-13 in blood fall. Airway hyperresponsiveness falls, an effect not reliably achieved by the other agents. Canada and the United States: Asthma is identical in the two countries and is among the most complete concordances in this reference: severe asthma from 12 years, 210 mg subcutaneously q4w, flat dose, no loading dose, no weight band and no biomarker threshold. Different for nasal polyps: licensed from 12 years in the USA since October 2025, and in adults only in Canada, which added the indication four months later and still restricted it (a deliberate divergence rather than a delay), so a 15-year-old with refractory polyposis is off-label in Canada. Canada also requires that polyps be inadequately controlled by systemic corticosteroids or surgery. No boxed warning in either country. Devices differ: in the USA the vial and syringe are for clinic administration and only the pen is supplied for home use, whereas Canada permits self- or caregiver-injection generally and does not market the vial; a Canadian adolescent may therefore receive for home use a syringe that in the United States would require clinic attendance. | Scene 39 |
| Nemolizumab nemolizumab (Nemluvio) — anti-IL-31RA IgG2 Biologic or targeted agent | Administered therapeutically; not produced endogenously | Blocks the IL-31 receptor A chain on sensory neurons, keratinocytes and immune cells, interrupting the itch signal rather than the inflammation that produced it Prurigo nodularis in adults, and atopic dermatitis from 12 years. Because it targets the itch pathway specifically, the skin signs can lag the symptomatic response. | IL-31 → Blocks IL-31 signalling through IL-31RA + OSMRβ | What it does to the tests: No reliable effect on eosinophils, IgE or the acute-phase markers, so there is no characteristic laboratory change to monitor. Arthralgia, myalgia and headache are the labelled adverse reactions. Canada and the United States: The same in the two countries, with no divergence found: atopic dermatitis from 12 years (60 mg as two 30 mg injections at the first visit, then 30 mg q4w, reducing to q8w after 16 weeks in responders, used with a topical steroid or calcineurin inhibitor) and prurigo nodularis in adults only, weight-banded at 90 kg (30 mg q4w below, 60 mg q4w at or above). No weight adjustment for adolescents in either country. No boxed warning. Canada authorised it in December 2025 and the USA in August 2024 for prurigo with dermatitis following that December. Potential sources of error: prurigo is weight-banded and dermatitis is not, so the dose rule changes with the indication in the same patient; the device requires reconstitution, unlike every other subcutaneous agent listed; and although the Canadian monograph describes a prefilled syringe, that presentation was cancelled before marketing, so only the pen is available in Canada. | Scene 39 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| Etanercept etanercept (Enbrel) — soluble TNFR2 (p75) — Fc fusion protein Biologic or targeted agent | Administered therapeutically; not produced endogenously | A decoy receptor rather than an antibody: it binds soluble TNF-α and lymphotoxin-α (TNF-β), which the monoclonal antibodies do not. It binds transmembrane TNF without the sustained cross-linking produced by the monoclonal antibodies, which is the usual, although not established, explanation for its lack of efficacy in granulomatous bowel disease and its lower rate of tuberculosis reactivation Carries the class boxed warning: serious infection including tuberculosis (testing for latent disease is required before and during treatment), invasive fungal infection (histoplasmosis, coccidioidomycosis and pneumocystosis, where the histoplasma antigen test may be negative), and lymphoma and other malignancies, some fatal, reported in children and adolescents treated with TNF blockers. Screening for latent tuberculosis and hepatitis B is required before initiation. Licensed in the USA for polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis from 2 years and for paediatric plaque psoriasis from 4 years; in Canada for polyarticular juvenile idiopathic arthritis from 4 to 17 years after an inadequate response to a disease-modifying antirheumatic drug and for chronic severe paediatric plaque psoriasis from 4 to 17 years, with no juvenile psoriatic arthritis indication. The paediatric dose in both countries is 0.8 mg/kg weekly to a maximum of 50 mg. In adults it is licensed in both countries for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and plaque psoriasis. It is not effective in Crohn disease, uveitis or sarcoidosis, which is the clearest example in this class that two drugs against the same cytokine are not interchangeable. | TNFα; TNFβ → Neutralises soluble TNF-α and TNF-β before they reach TNFR1 and TNFR2 | What it does to the tests: CRP, ESR, SAA and fibrinogen all fall, and so does the platelet count; the anaemia of inflammation improves, so haemoglobin rises. Ferritin falls. Because it attenuates the entire acute-phase response, a normal CRP on treatment cannot be used to exclude infection. Anti-nuclear and anti-dsDNA antibodies appear in a minority without clinical lupus. Made uninterpretable: CRP and ESR as infection markers. Canada and the United States: Canada (Enbrel, monograph May 2025, plus three biosimilars that carry the same indications and are not restricted): polyarticular JIA from 4 years, paediatric plaque psoriasis from 4 years, and rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and adult psoriasis in adults. United States: polyarticular JIA from 2 years and juvenile psoriatic arthritis from 2 years, neither of which is authorised in Canada, where psoriatic arthritis is an adult-only indication. Paediatric plaque psoriasis is from 4 years in both. Same: the paediatric dose is identical, 0.8 mg/kg weekly to a 50 mg ceiling, as is every adult regimen. A three-year-old with polyarticular JIA is therefore on-label in the USA and off-label in Canada, although the dose is the same in either case. Boxed in both countries, and substantively identical: serious infection and malignancy, with paediatric malignancy named explicitly, namely lymphoma and other malignancies, some fatal, reported in children and adolescents on TNF blockers. | Scene 40 |
| Infliximab, adalimumab and golimumab infliximab (Remicade), adalimumab (Humira), golimumab (Simponi), certolizumab pegol (Cimzia) — anti-TNF-α monoclonals Biologic or targeted agent | Administered therapeutically; not produced endogenously | Neutralise TNF-α only, and bind transmembrane TNF with sustained cross-linking, which delivers reverse signalling and, for the IgG1 agents, complement- and cell-mediated killing of TNF-bearing cells. This accounts for their efficacy in granulomatous disease, in which etanercept is not effective, and for their higher tuberculosis risk Carries the same class boxed warning as etanercept (serious infection including tuberculosis, invasive fungal infection, and lymphoma and other malignancies reported in children and adolescents). These agents carry the higher tuberculosis risk, as described above, so latent tuberculosis and hepatitis B screening before initiation, with repeat tuberculosis testing on treatment, is of particular importance. Licensed across Crohn disease, ulcerative colitis, juvenile idiopathic arthritis, uveitis and hidradenitis; Behçet disease is not a labelled indication for any of the four agents in Canada or the USA, so that use is off-label. The paediatric licences differ by country. Infliximab: Crohn disease from 9 years in Canada and from 6 years in the USA, and ulcerative colitis from 6 years in both. Adalimumab: polyarticular juvenile idiopathic arthritis from 2 years and ulcerative colitis from 5 years in both countries; Crohn disease from 13 years and 40 kg in Canada but from 6 years in the USA; hidradenitis suppurativa from 12 years, dosed from 30 kg, in both; and uveitis from 2 years, as chronic non-infectious anterior uveitis with methotrexate in Canada and as non-infectious intermediate, posterior and panuveitis in the USA. Golimumab: polyarticular juvenile idiopathic arthritis from 2 years by the intravenous route in both countries, with ulcerative colitis from 15 kg by the subcutaneous route and paediatric psoriatic arthritis from 2 years by the intravenous route in the USA only; the subcutaneous product has no paediatric indication in Canada. Certolizumab: polyarticular juvenile idiopathic arthritis from 2 years in the USA, with no paediatric indication in Canada. Certolizumab has the least placental transfer (negligible in most infants at birth and low in the remainder), so it is the agent that can be continued latest in pregnancy; the IgG1 agents cross from the second trimester, and a live vaccine in an exposed infant, in practice rotavirus or BCG, is deferred, usually to 6 months. | TNFα → Neutralise soluble and transmembrane TNF-α; certolizumab is a PEGylated Fab with no Fc, so it causes no Fc-mediated killing and crosses the placenta minimally | What it does to the tests: As for etanercept with respect to the acute-phase markers: CRP, ESR, SAA, fibrinogen, ferritin and the platelet count all fall, and the anaemia of inflammation improves. Faecal calprotectin falls in bowel disease. Anti-drug antibodies develop, particularly with infliximab, and drug levels with anti-drug antibodies are the standard means of investigating loss of response; concomitant methotrexate reduces them. Made uninterpretable: CRP and ESR as infection markers. Canada and the United States: Infliximab: paediatric Crohn disease is from 9 years in Canada and 6 years in the USA, so a seven-year-old is on-label in the United States and off-label in Canada, a three-year difference for the most common paediatric indication in this group. Paediatric ulcerative colitis is from 6 years in both countries, and the dose is identical for both bowel indications: 5 mg/kg intravenously at weeks 0, 2 and 6, then eight-weekly. Ankylosing spondylitis maintenance is six- to eight-weekly in Canada and six-weekly in the USA, and Canada alone advises trough-level and antibody measurement when escalating. Boxed in both countries and substantively identical for the whole class: serious infection and tuberculosis, paediatric malignancy by name, and hepatosplenic T-cell lymphoma; almost all reported cases were on concomitant azathioprine or 6-mercaptopurine, and most were adolescent or young adult males with Crohn disease or colitis. This is the boxed statement of greatest paediatric relevance in either country's labelling and should be considered when combination therapy is planned. Certolizumab is the exception in this entry: no paediatric indication in either country. | Scene 40 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| Anakinra anakinra (Kineret) — recombinant human IL-1 receptor antagonist Biologic or targeted agent | Administered therapeutically; not produced endogenously | The recombinant form of the natural antagonist catalogued in this reference as IL-1RA: it occupies IL-1R1 without signalling, so it blocks both IL-1-α and IL-1-β; this is broader than the anti-IL-1β antibodies, which is relevant where IL-1α drives the disease Licensed in the US for NOMID (neonatal-onset multisystem inflammatory disease) and for deficiency of the IL-1 receptor antagonist (DIRA) with no age or weight floor in either indication. The DIRA cohort started treatment from one month of age, which is relevant because DIRA presents in the neonatal period: the only practical lower bound is the prefilled syringe, which cannot deliver under 20 mg. Rheumatoid arthritis is the adult indication. The floor of 8 months and 10 kg is the European figure and is also the Health Canada NOMID floor, stated in the Canadian indication itself, so in Canada it governs. See the licensing note. Its wide use in systemic JIA and Still disease, macrophage activation syndrome, colchicine-resistant familial Mediterranean fever and recurrent pericarditis is off-label in the US, although well supported and recommended in the 2025 inborn-errors practice parameter for several inflammasome disorders (Scene 45). The short half-life of 4 to 6 hours is an advantage in an acutely unwell child; its effect ceases within a day of discontinuation. | IL-1α; IL-1β → Competitive blockade of IL-1R1, preventing recruitment of IL-1RAcP and NF-κB signalling | What it does to the tests: CRP, SAA, ferritin and the ESR fall rapidly, often within days; the response is sufficiently rapid to be used diagnostically in suspected macrophage activation syndrome and in the periodic fevers. Neutropenia occurs in a few per cent and requires monitoring. Injection-site reactions are almost universal early in treatment and subsequently resolve. Made uninterpretable: CRP and SAA as infection markers. Canada and the United States: The Canadian and US labels differ in their lower age and weight limits. Canada (monograph Aug 2025): NOMID from 8 months and 10 kg (the floor is in the indication itself and not in a footnote) and rheumatoid arthritis in adults. United States (label Oct 2025): NOMID with no age and no weight floor stated, and DIRA likewise with no floor, the DIRA cohort having started from one month of age. DIRA is not an authorised indication in Canada; the term does not appear in the Canadian monograph. In Canada, therefore, both DIRA and any NOMID use below 8 months or 10 kg are off-label, and NOMID typically presents within that age range. In both countries the CAPS licence covers NOMID only: treatment of familial cold autoinflammatory syndrome or Muckle-Wells syndrome with anakinra is off-label in either country. Dosing is numerically identical (start 1–2 mg/kg/day, usual maintenance 3–4, ceiling 8), and Canada alone states the maintenance range and the caveat that data above 5 mg/kg are very limited. Initiation and continuation at 1–2 mg/kg results in under-treatment. The practical lower limit in neonatal DIRA is the syringe: it is graduated 20–100 mg, so a 4 kg neonate requiring 4–8 mg cannot be dosed from it, as both labels state explicitly; this should be addressed at the outset of any neonatal treatment plan. Canada carries a Serious Warnings box (serious infections, anaphylaxis) where the USA has no boxed warning, and Canada has recently added amyloidosis and DRESS to its warnings. | Scene 40 |
| Canakinumab and rilonacept canakinumab (Ilaris) — anti-IL-1β IgG1; rilonacept (Arcalyst) — IL-1 Trap, which also binds IL-1RA Biologic or targeted agent | Administered therapeutically; not produced endogenously | Canakinumab neutralises IL-1β only and has a half-life of 22.9 to 25.7 days, so it provides sustained control with monthly dosing. Rilonacept is a fusion of the IL-1R1 and IL-1RAcP extracellular domains to an Fc, trapping IL-1β with high affinity, IL-1α with lower affinity and the natural antagonist IL-1RA as well, dosed weekly US labelling: canakinumab covers CAPS from 4 years, limited to familial cold autoinflammatory syndrome and Muckle-Wells syndrome, Still disease including systemic JIA from 2 years and 7.5 kg, and familial Mediterranean fever, TRAPS and hyper-IgD syndrome / mevalonate kinase deficiency in adult and paediatric patients without a stated age; in the USA the 2-year floor applies to Still disease and not to CAPS, and the two are readily transposed. Canadian labelling: CAPS from 2 years, dosed from 15 kg, naming familial cold autoinflammatory syndrome and Muckle-Wells syndrome and permitting use in NOMID/CINCA with the statement that improvement in central nervous system symptoms has not been confirmed; TRAPS, hyper-IgD syndrome / mevalonate kinase deficiency and familial Mediterranean fever, not recommended under 2 years; and Still disease including systemic JIA from 2 years and over 9 kg. In the EU canakinumab is licensed for CAPS from 2 years and 7.5 kg. Rilonacept is licensed in the USA from 12 years for CAPS (familial cold autoinflammatory syndrome and Muckle-Wells syndrome) and for recurrent pericarditis, and for maintenance of remission in deficiency of the IL-1 receptor antagonist from 10 kg; it is not authorised in Canada. The long half-life that makes canakinumab convenient is a disadvantage if infection supervenes. | IL-1β → Canakinumab neutralises free IL-1β; rilonacept traps IL-1β and, less avidly, IL-1α | What it does to the tests: CRP and SAA fall to normal and remain normal; SAA is the marker used to confirm that control is adequate between attacks in the periodic fevers, because a normal CRP alone does not establish it. Ferritin falls. Neutropenia is less common than with anakinra. Made uninterpretable: CRP and SAA as infection markers. Canada and the United States: The CAPS ages and dose ceilings for canakinumab differ, and the difference is large. Cryopyrin-associated periodic syndrome: from 2 years in Canada and 4 years in the USA, and Canada explicitly permits NOMID and CINCA with a CNS caveat while the US CAPS indication does not include them. The escalation ceiling diverges further: Canada allows up to 600 mg above 40 kg or 8 mg/kg between 15 and 40 kg, compared with a US paediatric ceiling of 3 mg/kg, roughly a 2.7-fold difference. Still's disease and systemic JIA are from 2 years in both countries, at 4 mg/kg to a 300 mg maximum four-weekly (identical), but the weight floor differs: above 9 kg in Canada, 7.5 kg and above in the USA. TRAPS, hyper-IgD syndrome and familial Mediterranean fever carry the same dosing in both, with Canada advising against use below 2 years and the USA stating no floor. Gout flares are a US-only indication. The CAPS and Still's disease ages must not be transposed; they differ within each country as well as between them. Neither country applies a boxed warning to canakinumab: no US boxed warning and no Canadian Serious Warnings box, with serious infection leading the ordinary warnings in both. Canada added DRESS in June 2025. | Scene 40 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| Tocilizumab and sarilumab tocilizumab (Actemra) and sarilumab (Kevzara) — anti-IL-6R IgG1 Biologic or targeted agent | Administered therapeutically; not produced endogenously | Block the IL-6 receptor, so both classical signalling (membrane IL-6R on hepatocytes and leucocytes) and trans-signalling (soluble IL-6R on any gp130-bearing cell) are inhibited. Because the hepatocyte acute-phase programme is IL-6-dependent, blockade abolishes the laboratory acute-phase response The two are not interchangeable in children. Tocilizumab covers systemic JIA and polyarticular JIA from 2 years, giant-cell arteritis and rheumatoid arthritis in both countries. For CAR T-cell-induced cytokine release syndrome the US licence is from 2 years, whereas the Canadian indication follows the populations of the authorised CAR T-cell products and safety and efficacy are stated not to be established under 3 years. For COVID-19 in hospitalised patients receiving systemic corticosteroids the US licence is from 2 years and the Canadian licence is for adults only. Sarilumab has no systemic JIA indication; its only paediatric licence is polyarticular JIA at 63 kg and above, in the USA, with no paediatric indication in Canada, and it holds no giant-cell arteritis, cytokine release syndrome or COVID-19 indication. Bowel perforation is the characteristic serious risk and presents without the CRP rise that would normally accompany it; abdominal pain on tocilizumab requires imaging rather than repeat CRP measurement. | IL-6 → Blocks IL-6 binding to IL-6Rα, so gp130 is not recruited and JAK1 → STAT3 signalling does not occur | What it does to the tests: CRP falls to normal within days and cannot be relied on to rise during treatment, irrespective of the clinical state; the same applies to ESR (through fibrinogen), SAA, haptoglobin, fibrinogen and ferritin. This is among the most consequential laboratory interactions described in this reference: a normal CRP in a child on tocilizumab provides almost no information about infection. Procalcitonin is the least affected and is the preferred marker for monitoring, because bacterial products induce CALCA through pathways that do not require IL-6; this rests, however, on observational data in cytokine release syndrome and COVID-19 rather than on the label, and procalcitonin also rises in non-infectious cytokine release syndrome, so it is the best available marker rather than a specific one. Neutropenia is common and is not usually infection-related. Transaminases rise. Lipids rise. Hepcidin falls, so the anaemia of inflammation improves and iron studies become interpretable. Measured total IL-6 rises on receptor blockade, because the cytokine is no longer cleared through its receptor; a high IL-6 on tocilizumab reflects the pharmacological effect of the drug and not failure of disease control, and for this reason interpretation in this reference is based on the treatment rather than the measured level. Made uninterpretable: CRP, ESR, SAA, fibrinogen, haptoglobin and ferritin, for the duration of treatment. Procalcitonin, clinical assessment and imaging are used instead. Canada and the United States: Sarilumab has no paediatric licence in Canada; Health Canada states that no paediatric data have been submitted. Its entire paediatric licence is American and consists solely of a weight band with no stated age: polyarticular JIA at 63 kg or more, which excludes most children who have the disease and exists because the fixed 200 mg syringe cannot be subdivided. The 63 kg indication therefore does not permit on-label prescription of sarilumab to a 65 kg adolescent in Canada. A paediatric indication cannot be inferred from the polymyalgia indication, which is authorised in Canada. Adult rheumatoid arthritis and polymyalgia rheumatica at 200 mg fortnightly are identical in both countries, and neither country licenses systemic JIA, giant-cell arteritis or cytokine release syndrome; these indications are absent in both jurisdictions. Serious infection is boxed in the USA and appears in a Serious Warnings box in Canada, which is substantively the same. The 63 kg threshold is the same value as that for etanercept, for the same device-related reason, which may cause confusion between the two drugs. | Scene 40 |
| Siltuximab siltuximab (Sylvant) — chimeric anti-IL-6 IgG1 Biologic or targeted agent | Administered therapeutically; not produced endogenously | Neutralises IL-6 itself rather than its receptor, so the same acute-phase consequences follow; it does not bind viral IL-6, and it is therefore used in HHV-8-negative rather than HHV-8-associated Castleman disease Idiopathic multicentric Castleman disease in adults; safety and efficacy in children are not established; it is not used in HHV-8-associated disease, because it does not bind viral IL-6. The same loss of infection markers as with tocilizumab applies. | IL-6 → Neutralises free IL-6 before it reaches IL-6R | What it does to the tests: Identical to tocilizumab: CRP, ESR, fibrinogen, haptoglobin and ferritin are all suppressed and uninterpretable; procalcitonin is preserved. Made uninterpretable: CRP, ESR and the other IL-6-driven acute-phase markers. Canada and the United States: Identical in both countries in every respect, and the only agent in this group with no Canada/USA divergence: idiopathic multicentric Castleman disease in patients who are HIV-negative and HHV-8-negative, 11 mg/kg intravenously every three weeks, the same laboratory treatment and retreatment criteria, no dose reduction permitted, no paediatric indication, and no boxed warning in either country. Although the disease occurs in children and adolescents, there is no paediatric indication in either country and the labels contain no paediatric dose or pharmacokinetic guidance, so paediatric use is entirely off-label and without labelled guidance. Both labels require permanent discontinuation, without re-institution, after a severe infusion reaction, anaphylaxis or cytokine release syndrome. Both warn that it masks acute inflammation and suppresses fever and CRP, which is the principal difficulty in assessing a febrile immunosuppressed child. | Scene 40 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| Ustekinumab ustekinumab (Stelara) — anti-p40 IgG1 Biologic or targeted agent | Administered therapeutically; not produced endogenously | Binds the p40 subunit shared by IL-12 and IL-23, so it blocks both the Th1 axis (IL-12 → STAT4 → IFN-γ) and the Th17 axis (IL-23 → STAT3 → IL-17); a single antibody thus blocks two pathways, which accounts for the difference between its infection profile and that of the p19-selective agents In the USA: plaque psoriasis from 6 years, psoriatic arthritis from 6 years, and Crohn disease and ulcerative colitis from 2 years, dosed from 10 kg; the US paediatric licence thus covers all four indications and not psoriasis alone. In Canada the paediatric licence is for plaque psoriasis alone, from 6 to 17 years where other systemic therapy or phototherapy has given inadequate control or is not tolerated; psoriatic arthritis, Crohn disease and ulcerative colitis are adult indications. Blockade of IL-12 as well as IL-23 distinguishes it from the newer p19 agents; the p19 agents are at least as effective in psoriasis, so the broader blockade is no longer regarded as a clinical advantage. | IL-12p40; IL-12p70; IL-23 → Prevents p40-containing cytokines binding IL-12Rβ1 | What it does to the tests: CRP and ESR fall where they were elevated by disease activity. No characteristic haematological change. The combined IL-12 and IL-23 blockade resembles inherited IL-12Rβ1 deficiency, so mycobacterial and salmonella susceptibility is the theoretical concern, although it is rarely observed in practice. Canada and the United States: Canada (Stelara, monograph Aug 2024, and nine biosimilars): plaque psoriasis from 6 years; psoriatic arthritis, Crohn disease and ulcerative colitis in adults only. Health Canada states explicitly that paediatric Crohn and colitis are not established, and Stelara I.V. has not been studied in Canadian children. United States: psoriasis from 6 years, psoriatic arthritis from 6 years, and Crohn disease and ulcerative colitis from 2 years (10 mg/kg intravenous induction in a 10–25 kg child, then 2.5 mg/kg subcutaneously), bands that appear in no Canadian monograph. Different: paediatric inflammatory bowel disease is the principal and substantial difference; American IBD guidance provides paediatric dosing that has no Canadian authorisation, and no Canadian product, originator or biosimilar, covers it. Same: the psoriasis ages and weight bands match, and neither country has a boxed warning. Health Canada's authorisation of a biosimilar is not a declaration of equivalence, and interchangeability is a provincial decision, so substitution in each province follows the provincial formulary and not the federal licence. | Scene 41 |
| Guselkumab, risankizumab and tildrakizumab guselkumab (Tremfya), risankizumab (Skyrizi), tildrakizumab (Ilumya) — anti-IL-23 p19 IgG1 Biologic or targeted agent | Administered therapeutically; not produced endogenously | Bind the p19 subunit unique to IL-23, leaving IL-12 and the Th1 axis intact; the blockade is narrower than that of ustekinumab and targets the relevant cytokine, since IL-23 maintains pathogenic Th17 cells after their induction The three are not equivalent: risankizumab covers plaque psoriasis, psoriatic arthritis, Crohn disease and ulcerative colitis, guselkumab the same four indications in both countries, but tildrakizumab is licensed in adults only, for plaque psoriasis in Canada and for plaque psoriasis and psoriatic arthritis in the USA. Guselkumab and risankizumab hold paediatric licences for plaque psoriasis and psoriatic arthritis from 6 years: guselkumab in Canada with weight-banded doses from 12 kg to under 40 kg and the adult dose from 40 kg, but in the USA only at 40 kg or more; risankizumab in both countries at 55 mg under 40 kg and 150 mg at 40 kg or more. The bowel indications of both, and all tildrakizumab indications, are adult only. Preferred over ustekinumab in psoriasis on efficacy, and the preserved IL-12 arm is a theoretical safety advantage. | IL-23 → Prevent IL-23 binding IL-23R, so STAT3-driven RORγt maintenance of Th17 is lost while IL-12 → STAT4 is preserved | What it does to the tests: CRP and ESR fall where they were elevated by disease activity. Candida infection is less frequent than with the IL-17 agents: IL-23 blockade leaves IL-17 signalling at the receptor intact and spares the IL-17 already produced by differentiated and innate sources, rather than removing the cytokine itself. Canada and the United States: Guselkumab (Tremfya): Canada has the broader licence. Both countries license psoriasis and psoriatic arthritis from 6 years, but the USA additionally requires 40 kg and has no dose below it, whereas Canada covers 12–39 kg with the variable-dose injector (20 mg at 12–15 kg rising to 45 mg at 31–39 kg). A 25 kg seven-year-old with severe psoriasis can therefore be dosed on-label in Canada and is off-label in the USA. Crohn disease and colitis are adults-only in both, with identical regimens. Canada contraindicates clinically important active infection; the USA does not. Risankizumab (Skyrizi): paediatric psoriasis and psoriatic arthritis from 6 years are identical in the two countries (55 mg under 40 kg, 150 mg at or above, weeks 0 and 4 then q12w), and paediatric IBD is authorised in neither country, despite extensive adult use. Adult Crohn differs: the USA offers an all-subcutaneous induction and 180 or 360 mg maintenance, Canada 360 mg only. Tildrakizumab (Ilumya): adults only in both countries and the only agent in this group with no paediatric authorisation in either country, so it is not a substitute for the other two in a child; psoriatic arthritis was added in the USA in late October 2026 and is not authorised in Canada. No boxed warning on any of the three in either country. | Scene 41 |
| Secukinumab, ixekizumab and bimekizumab secukinumab (Cosentyx) and ixekizumab (Taltz) — anti-IL-17A; bimekizumab (Bimzelx) — anti-IL-17A and IL-17F; brodalumab (Siliq) — anti-IL-17RA Biologic or targeted agent | Administered therapeutically; not produced endogenously | Neutralise IL-17A (and, for bimekizumab, IL-17F as well; brodalumab blocks the receptor and therefore A, F, C, E and the A/F heterodimer). IL-17 induces epithelial antimicrobial peptides, CXCL8 and G-CSF, so its blockade predictably impairs mucosal antifungal defence Secukinumab has the widest paediatric licence of any agent in these scenes. In the USA: plaque psoriasis from 6 years, psoriatic arthritis from 2 years, enthesitis-related arthritis from 4 years, and ankylosing spondylitis and hidradenitis from 12 years. In Canada: plaque psoriasis, enthesitis-related arthritis and juvenile psoriatic arthritis from 6 years, with ankylosing spondylitis, non-radiographic axial spondyloarthritis and hidradenitis in adults only. Ixekizumab covers psoriasis from 6 years in both countries; bimekizumab and brodalumab are adults only. Mucocutaneous candidiasis is the characteristic adverse effect and is the acquired phenocopy of inherited IL-17 pathway defects (IL17RA, IL17F, ACT1, and the chronic mucocutaneous candidiasis of STAT1 gain-of-function and AIRE autoantibodies). With respect to inflammatory bowel disease the class is not uniform: for secukinumab, ixekizumab and bimekizumab new or worsening disease is a labelled caution rather than a contraindication, so an effective drug need not be withheld from a child with quiescent disease, whereas for brodalumab Crohn disease is a contraindication. Brodalumab also carries a boxed warning for suicidal ideation and behaviour including completed suicides, and is available only through a restricted programme. | IL-17A; IL-17F → Neutralise IL-17A / IL-17F, or block IL-17RA, removing the ACT1 → NF-κB signal in epithelium and stroma | What it does to the tests: Mild falls in the neutrophil count are expected and follow from the IL-23 / IL-17 / G-CSF loop: reduced IL-17 lowers G-CSF and therefore the neutrophil count; this does not represent drug toxicity and is rarely clinically significant. CRP and ESR fall with disease control. Canada and the United States: Secukinumab diverges more than any other agent in this reference. Plaque psoriasis is identical: from 6 years, 75 mg under 50 kg and 150 mg at or above, loaded weekly at weeks 0 to 4. All other indications differ: psoriatic arthritis is from 2 years and 15 kg in the USA and 18 years in Canada (Canada names juvenile psoriatic arthritis separately, from 6 years); enthesitis-related arthritis from 4 years in the USA and 6 in Canada; ankylosing spondylitis from 12 years in the USA and 18 in Canada; hidradenitis from 12 years and 30 kg in the USA and 18 in Canada. The intravenous route is not available in Canada, and Canada alone requires prior hepatitis B screening. Use in a four-year-old with enthesitis-related arthritis, as described in American publications, is off-label in Canada. In addition, the US paediatric bands carry a 15 kg lower bound whereas the Canadian juvenile bands state none, so ‘under 50 kg, 75 mg’ could be misinterpreted as applying to a toddler. Ixekizumab (Taltz): paediatric psoriasis from 6 years in the two countries, with the same bands; however, only the 80 mg presentation is available in Canada, so the 20 mg and 40 mg paediatric doses must be prepared from it by a health professional at every visit, which precludes home administration below 50 kg in Canada. This is a difference in delivery and not in dose. Bimekizumab (Bimzelx): identical in the two countries, adults only, with no paediatric licence in either; no inference should be drawn from the IL-17A agents. The US label carries a suicidal-ideation warning that the Canadian monograph does not. Brodalumab is a separate case (see its own entry). | Scene 41 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| Abatacept abatacept (Orencia) — CTLA-4-Ig fusion protein Biologic or targeted agent | Administered therapeutically; not produced endogenously | Binds CD80 and CD86 on antigen-presenting cells, so the CD28 costimulatory second signal is not delivered and T cells are not fully activated; it acts at the initiation of the response rather than on any single cytokine In the USA: polyarticular JIA from 2 years (subcutaneously from 2 years, intravenously from 6 years), psoriatic arthritis from 2 years, rheumatoid arthritis in adults, and prophylaxis of acute graft-versus-host disease from 2 years. In Canada: polyarticular JIA from 6 years by intravenous infusion only, with no paediatric subcutaneous indication, rheumatoid arthritis and psoriatic arthritis in adults, and prophylaxis of acute graft-versus-host disease from 6 years. In inborn errors of immunity it is the precision agent for CTLA-4 haploinsufficiency and LRBA deficiency, where it replaces the deficient CTLA-4 inhibitory function (Scene 46). Live vaccines should not be given with it or within three months of stopping, and it should not be combined with a TNF inhibitor. Because it attenuates rather than abolishes responses, infection risk is lower than with the cytokine blockers. | Th1; Th17; Tfh → Competitive blockade of CD28 costimulation, reproducing the physiological inhibition exerted by CTLA-4 | What it does to the tests: No characteristic laboratory change; CRP and ESR fall with disease control. T-dependent vaccine responses are attenuated, so serological protection cannot be assumed and post-vaccination titres should be measured. Made uninterpretable: Vaccine serology as proof of protection. Canada and the United States: The divergence for abatacept is almost entirely paediatric. Adult rheumatoid arthritis and intravenous polyarticular JIA from 6 years at 10 mg/kg are identical. The subcutaneous route in juvenile arthritis, however, is licensed from 2 years in the USA, at 50, 87.5 or 125 mg weekly by weight, and is not authorised at any age in Canada, where the 50 mg and 87.5 mg syringes are not marketed. A Canadian child with polyarticular JIA therefore cannot receive weekly subcutaneous abatacept on-label: monthly infusions from 6 years are the only authorised route. Subcutaneous abatacept in a three-year-old, as assumed in American guidance, is off-label in Canada and the required devices are not available. Psoriatic arthritis is from 2 years in the USA and adults-only in Canada. For acute graft-versus-host disease prophylaxis the regimens differ by age, which is the most important potential source of error: Canada licenses it from 6 years at 10 mg/kg, whereas the USA licenses it from 2 years and specifies a higher regimen for 2–under-6-year-olds, 15 mg/kg then 12 mg/kg × 3; use of the 10 mg/kg dose in a three-year-old is therefore an under-dose relative to the only label that studied that age. Infusion time is 30 minutes for arthritis and 60 for graft-versus-host disease in both countries. Warnings differ in the opposite direction to that usually seen: Canada has a Serious Warnings box (anaphylaxis, infection, tuberculosis) and contraindicates use in HIV-positive and immunocompromised patients, while the US label has no boxed warning and states no contraindications. | Scene 41 |
| Rituximab rituximab (Rituxan/MabThera) — chimeric anti-CD20 IgG1 Biologic or targeted agent | Administered therapeutically; not produced endogenously | Depletes CD20-positive B cells from the pre-B stage to the memory B cell by complement-dependent and antibody-dependent killing. CD20 is lost as the cell differentiates into an antibody-secreting cell (it is low and variable on plasmablasts and absent from long-lived plasma cells), so existing antibody is initially spared and the fall in immunoglobulin is gradual; the long-lived plasma cell compartment maintains vaccine-derived antibody Carries a boxed warning with four parts: fatal infusion reactions, most often with the first infusion; severe and sometimes fatal mucocutaneous reactions; hepatitis B reactivation, which makes screening mandatory; and progressive multifocal leukoencephalopathy, including fatal cases, which is the risk of greatest importance to disclose when obtaining consent from a family. Licensed in the USA for mature B-cell non-Hodgkin lymphoma and mature B-cell acute leukaemia from 6 months, for ANCA-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) from 2 years, and in adults for non-Hodgkin lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis and pemphigus vulgaris. In Canada the reference product is licensed in adults only, for non-Hodgkin lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis and induction of remission in granulomatosis with polyangiitis and microscopic polyangiitis; it has no paediatric indication and no pemphigus vulgaris indication, so those uses are off-label in Canada. Used off-label in both countries for nephrotic syndrome, autoimmune cytopenias and neuromyelitis optica. Immunoglobulins and B-cell numbers should be measured before each course and monitored afterwards. | Transitional B cell; Naive follicular B cell; Memory B cell; Germinal-centre B cell → Complement-dependent cytotoxicity and FcγRIIIa-mediated killing of CD20+ B cells | What it does to the tests: B cells are depleted from the blood within days and return at 6 to 12 months. IgM falls first and to the greatest extent; IgG falls later and in a minority remains low for years (persistent hypogammaglobulinaemia, more likely with repeated courses, with prior immunosuppression, and in children). Specific antibody titres fall. Vaccine responses are lost while B cells are absent, so immunisation must precede treatment by at least 4 weeks where possible, and live vaccines are contraindicated. Late-onset neutropenia can occur months after the last dose. Made uninterpretable: Vaccine serology, B-cell-dependent diagnostic testing, and any attempt to diagnose an antibody deficiency while the drug is active; the immunological evaluation must precede treatment. Canada and the United States: Canada (Rituxan, monograph Jun 2023; Rituxan SC also marketed): adult lymphoma and leukaemia, adult rheumatoid arthritis after a TNF inhibitor, and ANCA-associated vasculitis in adults, induction only. United States: the same adult indications plus paediatric mature B-cell lymphoma and B-cell acute leukaemia from 6 months at 375 mg/m² with chemotherapy, granulomatosis with polyangiitis and microscopic polyangiitis from 2 years with a defined follow-up regimen (250 mg/m² in children), and pemphigus vulgaris in adults, none of which Canada has authorised. Different also in what is boxed: the USA boxes severe mucocutaneous reactions and hepatitis B reactivation alongside infusion reactions and PML, while Canada boxes infusion reactions, PML and an experienced-prescriber requirement but neither of the other two, although hepatitis B screening appears elsewhere in the monograph. Canada contraindicates prior or current PML and hypersensitivity to murine protein; the US label states no contraindications. Same: neither country restricts distribution. Hypogammaglobulinaemia that can persist for years and prolonged B-cell aplasia are recognised in children; immunoglobulins should be measured before and after treatment in either country. | Scene 41 |
| Belimumab belimumab (Benlysta) — human anti-BAFF (BLyS) IgG1 Biologic or targeted agent | Administered therapeutically; not produced endogenously | Neutralises soluble BAFF, the survival factor on which transitional and naive B cells depend, so the autoreactive transitional cells that normally die at that checkpoint are not rescued; the effect is selective pressure on the newly formed B-cell pool rather than depletion Systemic lupus erythematosus from 5 years and lupus nephritis from 5 years in both countries. The licensed routes differ: in Canada paediatric lupus nephritis is treated by the intravenous route only, subcutaneous use in lupus nephritis being restricted to adults, while subcutaneous use in paediatric systemic lupus erythematosus is from 15 kg; in the USA subcutaneous dosing from 15 kg is licensed from 5 years for both indications. The complement and anti-dsDNA response is used to monitor treatment. | BAFF → Neutralises BAFF before it reaches BAFF-R, TACI and BCMA | What it does to the tests: Naive and transitional B cells fall over months; memory B cells and plasma cells are relatively spared, so immunoglobulins fall only modestly. Anti-dsDNA titres fall and complement C3 and C4 rise towards normal as consumption diminishes; this is one of the few agents listed that raises complement levels. Canada and the United States: The same in the two countries for the relevant ages: systemic lupus from 5 years, and 10 mg/kg intravenously every two weeks for three doses then monthly. The subcutaneous paediatric bands represent a true difference in dosing and not a difference in wording: Canada has three (weekly at 50 kg and above, every ten days at 30–under-50 kg, fortnightly at 15–under-30 kg) and the USA has two (weekly at 40 kg and above, fortnightly at 15–under-40 kg). A 35 kg eleven-year-old is dosed every ten days in Canada and every fourteen in the USA. Lupus nephritis also diverges: it is licensed subcutaneously from 5 years in the USA and not below 18 years in Canada, so a Canadian child with nephritis remains on monthly infusions. Warnings again differ in the opposite direction: Canada boxes infusion reactions, serious infection including PML, and depression and suicidality, whereas the USA has no boxed warning but includes an instruction to assess for depression and suicide risk before initiation and to monitor during treatment. Since August 2026 the USA contraindicates prior anaphylaxis, Stevens-Johnson syndrome or toxic epidermal necrolysis to belimumab; Canada does not list these. | Scene 41 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| Anifrolumab anifrolumab (Saphnelo) — anti-IFNAR1 IgG1 Biologic or targeted agent | Administered therapeutically; not produced endogenously | Blocks the type I interferon receptor, so the type I interferons (the IFN-α subtypes, IFN-β, IFN-ω and the less-studied IFN-κ and IFN-ε) are blocked together. The interferon signature that defines a large subgroup of lupus is suppressed Moderate-to-severe systemic lupus erythematosus in adults; no paediatric licence. Its mechanism is the converse of that of the type I interferonopathies (STING, TREX1, IFIH1), in which the same pathway is pathologically activated. | IFNα2; IFNβ; IFNω → Blocks IFNAR1, preventing JAK1/TYK2 → STAT1/STAT2/IRF9 (ISGF3) assembly | What it does to the tests: The 21-gene interferon signature is neutralised by at least 80% from about week 4 and through the first year, which is the pharmacodynamic measure reported in the label; where the assay is available it is the marker used for monitoring. Anti-dsDNA falls and C3 and C4 rise with disease control. Herpes zoster is the characteristic infection and respiratory viral infections are more frequent, which is the predictable consequence of type I interferon blockade. Made uninterpretable: The interferon signature as a measure of disease rather than of drug. Canada and the United States: The same in the two countries: adults only, for active autoantibody-positive systemic lupus on standard therapy, 300 mg intravenously over 30 minutes every four weeks, with a subcutaneous option of 120 mg weekly by autoinjector added in 2026 (April in the USA, March in Canada). Health Canada states that no paediatric data are available to it, so no paediatric indication exists; the USA likewise has not established paediatric use. Neither country recommends it in severe active lupus nephritis or severe CNS lupus. No boxed warning in either country. Switching between routes requires a washout in either country: about two weeks from the last infusion before the first injection, and three to four weeks in the reverse direction. | Scene 42 |
| Emapalumab emapalumab (Gamifant) — anti-IFN-γ IgG1 Biologic or targeted agent | Administered therapeutically; not produced endogenously | Neutralises free and receptor-bound IFN-γ, the cytokine that drives the macrophage activation of haemophagocytic lymphohistiocytosis; it is the only agent in this reference directed at that final common pathway Licensed in the USA only; it is not authorised in Canada, where the submission was withdrawn by the sponsor in January 2021 before a decision was issued. Primary haemophagocytic lymphohistiocytosis refractory to, intolerant of or recurrent on conventional therapy, from birth, and also HLH / macrophage activation syndrome in known or suspected Still disease where glucocorticoids have failed or MAS has recurred, which makes it directly relevant to systemic JIA as described elsewhere in this reference. The label names the organisms favoured by neutralisation of IFN-γ as mycobacteria, herpes zoster and Histoplasma capsulatum: latent tuberculosis is evaluated and tested for before initiation and treated if present, and prophylaxis is given against herpes zoster, Pneumocystis jirovecii and fungal infection. Salmonella susceptibility is a feature of the inherited IFN-γ-axis phenotype rather than of this drug. | IFNγ → Neutralises IFN-γ before and after it engages IFN-γR1 | What it does to the tests: CXCL9 (MIG) falls and is the marker used for monitoring; CXCL9 is interferon-induced and reflects IFN-γ activity better than ferritin. Total IFN-γ measured by immunoassay rises, because the drug–cytokine complex is still detected; this is expected and is not treatment failure. Ferritin, soluble CD25 and the transaminases fall with response. Made uninterpretable: Measured IFN-γ levels. CXCL9 is used instead. Canada and the United States: Not authorised in Canada; the product was not left unexamined: the submission for primary haemophagocytic lymphohistiocytosis was cancelled by the sponsor in January 2021 before Health Canada issued a decision, with clinical deficiencies identified that would have prevented approval. No Canadian decision was issued, so Canadian access is through the Special Access Programme only, which is the most important consideration regarding this drug in Canadian paediatric immunology practice. Whether a new submission has been filed since, and current Special Access availability, were not confirmed. United States (label Mar 2026): primary HLH in adults and children of any age with refractory, recurrent or progressive disease or intolerance of conventional therapy, and (added June 2025) HLH/macrophage activation syndrome in known or suspected Still's disease including systemic JIA, where glucocorticoids have failed or MAS has recurred. The two indications use different regimens, which is a potential source of prescribing error. Zoster, Pneumocystis and fungal prophylaxis are given, and the IFN-γ-dependent tests become uninterpretable. | Scene 42 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| Eculizumab and ravulizumab eculizumab (Soliris) and ravulizumab (Ultomiris) — anti-C5; pozelimab (Veopoz) — anti-C5, licensed for CHAPLE disease alone Biologic or targeted agent | Administered therapeutically; not produced endogenously | Bind C5 and prevent its cleavage, so neither the C5a anaphylatoxin nor the C5b that nucleates the membrane attack complex is generated. All upstream events (C3 cleavage, C3b opsonisation, the amplification loop) continue unaffected Eculizumab and ravulizumab: paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome, and generalised myasthenia gravis and NMOSD in adults. Paediatric cover differs by agent and country: ravulizumab is licensed for both haemolytic indications from one month of age in both countries; eculizumab is licensed for both in children from 5 kg in Canada, whereas in the USA its paediatric use is established for atypical haemolytic uraemic syndrome and for generalised myasthenia gravis from 6 years, and paediatric safety and effectiveness in paroxysmal nocturnal haemoglobinuria are not established. Pozelimab is not interchangeable with them: its only licensed indication is CD55-deficient protein-losing enteropathy (CHAPLE disease) from one year of age, the condition described in this reference under the complement regulators, and it has none of the other three indications; it is licensed in the USA and is not authorised in Canada. All three carry a boxed warning for serious meningococcal infection and are available only through a restricted programme. The class creates an acquired terminal-pathway defect, so meningococcal ACWY and B vaccination at least two weeks before initiation, with antibiotic prophylaxis, is mandatory; these are the same precautions described in this reference for inherited C5 to C9 deficiency. Vaccination does not eliminate the risk; breakthrough meningococcal disease occurs in vaccinated patients. | C5; C5a → Blocks C5 convertase cleavage of C5; ravulizumab adds pH-dependent recycling for 8-weekly dosing | What it does to the tests: CH50 and AH50 both become undetectable: C5 is a terminal component and both haemolytic assays require C5 to C9, so its blockade abolishes both; this finding confirms adequate blockade and does not indicate a complement deficiency. C3 and C4 are unchanged, because the blockade is distal to them, so a normal C3 and C4 on treatment provides no information about drug effect. Free eculizumab levels and the modified Ham test are used where available. LDH falls in paroxysmal nocturnal haemoglobinuria; extravascular haemolysis with C3 loading on red cells may continue. Made uninterpretable: CH50 as a test for complement deficiency, and C3/C4 as a measure of blockade. Canada and the United States: Eculizumab shows the most marked reversal of the usual pattern in this reference, in the direction opposite to that generally assumed. Paroxysmal nocturnal haemoglobinuria: Canada has a paediatric indication, down to 5 kg since August 2025, and the USA does not; US paediatric PNH use is off-label. Generalised myasthenia gravis differs in the opposite direction: from 6 years in the USA, adults only in Canada. Atypical HUS is the same in both, with identical weight bands from 5 kg and STEC-HUS excluded; neuromyelitis optica is adults only in both. Ravulizumab is identical in the two countries (PNH and atypical HUS from one month, myasthenia and neuromyelitis optica in adults, with every weight band, loading dose and interval matching), except that IgA nephropathy is a US-only accelerated approval in adults. Pozelimab is not authorised in Canada: no Health Canada record exists under any status, so a Canadian child with CHAPLE disease requires the Special Access Programme. In the USA it is licensed for CHAPLE only, from one year. Vaccination: meningococcal ACWY and B at least two weeks before the first dose in both countries, with antibiotic cover if treatment cannot be delayed; Canada additionally mandates prophylaxis for every child under two years until two weeks after vaccination, which the US label does not. Two eculizumab biosimilars are marketed in the USA and none in Canada. | Scene 42 |
| Pegcetacoplan pegcetacoplan (Empaveli in Canada and the USA; Aspaveli elsewhere) — PEGylated C3-binding peptide Biologic or targeted agent | Administered therapeutically; not produced endogenously | Binds C3 and C3b, blocking cleavage at the level of the convertase itself, so it inhibits the alternative amplification loop as well as the terminal pathway; this proximal blockade also prevents the C3 loading responsible for extravascular haemolysis on C5 inhibitors Carries a boxed warning for serious infection caused by encapsulated bacteria and is available only through a restricted programme. Licensed for paroxysmal nocturnal haemoglobinuria in adults, and for C3 glomerulopathy and primary immune-complex MPGN from 12 years. Blockade at C3 abolishes opsonisation as well as the terminal pathway, so the encapsulated-organism risk is broader than with C5 blockade: pneumococcal, meningococcal and Haemophilus influenzae type b vaccination are all required. | C3 → Binds C3/C3b, preventing convertase cleavage of C3 | What it does to the tests: Measured C3 rises steeply, which is the most common source of misinterpretation with this drug: with convertase cleavage blocked, C3 is no longer consumed, and drug-bound C3 accumulates. The label reports a mean rise from 94 mg/dL at baseline to 380 mg/dL by week 16 in paroxysmal nocturnal haemoglobinuria, and from 62 to 371 mg/dL by week 26 in C3 glomerulopathy. A C3 of several hundred mg/dL on this drug reflects the pharmacological effect of treatment and is neither an artefact nor evidence of a different diagnosis. CH50 and AH50 both fall. Haemoglobin rises further than on C5 blockade in paroxysmal nocturnal haemoglobinuria, because extravascular haemolysis is also prevented. Made uninterpretable: The C3 level as a measure of disease, and both pathway assays. Canada and the United States: The same in the two countries for the relevant age: C3 glomerulopathy and immune-complex MPGN from 12 years, and paroxysmal nocturnal haemoglobinuria in adults with no paediatric indication in either. Trade names differ: Empaveli in the USA, Aspaveli elsewhere. Vaccination is broader than for the anti-C5 agents because blockade of C3 abolishes opsonisation as well as the terminal pathway: pneumococcal and meningococcal ACWY and B at least two weeks before the first dose in both countries, and Canada additionally requires Haemophilus influenzae type b per NACI. The direction of the C3 result should be noted: C3 rises steeply on treatment, because the drug prevents consumption, so a rising C3 is the expected response and does not represent treatment failure. | Scene 42 |
| Iptacopan and danicopan iptacopan (Fabhalta) — factor B inhibitor; danicopan (Voydeya) — factor D inhibitor Biologic or targeted agent | Administered therapeutically; not produced endogenously | Oral small molecules that block the alternative pathway specifically, at factor B or at factor D, the two components of the amplification loop, leaving the classical and lectin pathways functional Adults only. Paroxysmal nocturnal haemoglobinuria (iptacopan as monotherapy, danicopan added to a C5 inhibitor for extravascular haemolysis), and C3 glomerulopathy for iptacopan in both countries, with IgA nephropathy for iptacopan in the USA only. Both carry a boxed warning for serious infection with encapsulated organisms and both are available only through a restricted programme; vaccination against meningococcus, pneumococcus and Haemophilus influenzae type b is required before initiation, as for any alternative-pathway blockade. | Factor B; Factor D → Inhibit factor B or factor D, preventing assembly and activity of the alternative C3 convertase C3bBb | What it does to the tests: AH50 falls to near zero while CH50 is relatively preserved, the converse of classical-pathway blockade with sutimlimab, in which CH50 falls and C4 recovers. It is not the converse of C5 blockade: C5 is a terminal component and both haemolytic assays require C5 to C9, so a C5 inhibitor abolishes CH50 and AH50 together (Scene 30). Measured C3 also rises as consumption ceases (the iptacopan label reports 23 to 80 mg/dL by day 14 in C3 glomerulopathy), although less steeply than on pegcetacoplan. The near-zero AH50 is inferred from the pathway as described in this reference rather than taken from the label, which uses an alternative-pathway activity assay and plasma Bb as its pharmacodynamic markers. Made uninterpretable: AH50, and the C3 level as a measure of disease. Canada and the United States: Iptacopan (Fabhalta) is the same in the two countries: paroxysmal nocturnal haemoglobinuria and C3 glomerulopathy in adults at 200 mg twice daily, with no paediatric indication at any age in either. Different: IgA nephropathy is a US-only indication (full approval July 2026) and is not authorised in Canada. Danicopan (Voydeya) is identical in the two countries: add-on to ravulizumab or eculizumab in adults with residual extravascular haemolysis, 150 mg rising to 200 mg three times daily, with no paediatric use in either country. Different only in risk-management arrangements: the USA operates a formal risk-management programme for danicopan and the Canadian monograph describes none, whereas Canada alone instructs tapering on discontinuation and names Haemophilus influenzae type b in its warnings box. Each requires pneumococcal and meningococcal vaccination two weeks beforehand, with Hib recommended in Canada. Neither is currently authorised for children, which is the relevant consideration in paediatric practice. | Scene 42 |
| Avacopan and sutimlimab avacopan (Tavneos) — C5aR1 antagonist; sutimlimab (Enjaymo) — anti-C1s IgG4 Biologic or targeted agent | Administered therapeutically; not produced endogenously | Avacopan blocks C5aR1, the C5a receptor on the neutrophil, rather than C5a itself (the target shown is C5a because that is the catalogued entity), so the chemotactic and priming signal is lost while the membrane attack complex is preserved; the terminal-pathway infection risk is therefore not created. Sutimlimab blocks C1s and so inhibits the classical pathway at its first enzyme Avacopan: ANCA-associated vasculitis in adults, where it allows steroid sparing; hepatotoxicity requiring scheduled liver-function monitoring, hepatitis B reactivation and angioedema are its labelled cautions. Sutimlimab: cold agglutinin disease in adults, licensed in the USA and not authorised in Canada; it carries the same encapsulated-organism requirement as the other complement agents, namely vaccination against Streptococcus pneumoniae, Haemophilus influenzae type b and Neisseria meningitidis serogroups A, C, W, Y and B at least two weeks before the first dose, because blockade of C1s abolishes classical-pathway opsonisation, and vaccination does not eliminate the risk. Avacopan is the only complement agent listed that does not create a terminal-pathway defect. | C5a; C1r / C1s → Avacopan: competitive antagonism of C5aR1. Sutimlimab: blocks C1s protease activity in the C1 complex | What it does to the tests: Avacopan: no routine complement assay changes, since C5 cleavage is unaffected and CH50 remains normal; liver enzymes require scheduled monitoring. Sutimlimab: C4 rises towards normal as classical-pathway consumption ceases (the label reports a return to about 0.2 g/L within a week), and CH50 falls; haemolysis markers improve in cold agglutinin disease. Made uninterpretable: For sutimlimab, CH50 and C4 as measures of disease. Canada and the United States: Avacopan (Tavneos) is identical in the two countries: adults with severe active ANCA-associated vasculitis, 30 mg twice daily with food, no paediatric indication, no boxed warning and no restricted programme in either country, and four-weekly liver tests for the first six months. The discontinuation thresholds are expressed differently: Canada specifies interruption at three to five times the upper limit and consideration of discontinuation above eight times, whereas the USA adds an explicit alkaline-phosphatase and bilirubin trigger and an intensified monitoring schedule for patients of Japanese descent. Canada alone recommends Pneumocystis prophylaxis. Sutimlimab is not authorised in Canada (no Health Canada record under any status), so cold agglutinin disease has no authorised complement inhibitor in Canada and access is through the Special Access Programme. In the USA it is adults only. Mechanistically it differs from the other agents: it inhibits C1s, so it is the only proximal classical-pathway agent listed; it leaves the alternative pathway and the AH50 intact and does not carry the terminal complement meningococcal risk profile, but its label nevertheless requires full meningococcal and pneumococcal cover. | Scene 42 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| JAK inhibitors tofacitinib (Xeljanz), baricitinib (Olumiant), upadacitinib (Rinvoq), abrocitinib (Cibinqo), ruxolitinib (Jakafi/Opzelura) — oral JAK inhibitors Biologic or targeted agent | Administered therapeutically; not produced endogenously | Not biologics, but agents that act on the same pathways at the intracellular side of the membrane: every cytokine in this reference that signals through JAK-STAT is blocked simultaneously, according to the JAK selectivity of the drug. Ruxolitinib and baricitinib are JAK1/2-selective, tofacitinib JAK1/3, upadacitinib and abrocitinib JAK1-selective; the TYK2 arm is blocked only partially by these agents, and the selective TYK2 inhibitor deucravacitinib is not included here. Cytokines that use other receptor families (TNF, IL-1, IL-17, IL-18) are not affected Paediatric licences exist across the class and differ by country. Tofacitinib: polyarticular-course JIA and psoriatic arthritis from 2 years and 10 kg in the USA, with an oral solution for children under 40 kg; in Canada polyarticular JIA and juvenile psoriatic arthritis only in children of 40 kg or more, with the 5 mg tablet. Abrocitinib: atopic dermatitis from 12 years in both countries. Upadacitinib: atopic dermatitis from 12 years and 40 kg in both countries, with polyarticular JIA and psoriatic arthritis from 2 years in the USA only. Baricitinib: severe alopecia areata from 12 years in the USA, and adults only in Canada. Topical ruxolitinib: atopic dermatitis from 2 years and nonsegmental vitiligo from 12 years in both countries. Systemic ruxolitinib covers myelofibrosis, polycythaemia vera and acute and chronic graft-versus-host disease (from 12 years) in both countries, with haemophagocytic lymphohistiocytosis off-label. The class boxed warning covers serious infection, mortality from any cause, malignancy including lymphoma, major adverse cardiovascular events and thrombosis, and derives from an adult rheumatoid-arthritis safety trial in patients over 50 with a cardiovascular risk factor, so it applies to children with caution rather than directly. In inborn errors of immunity these are the precision agents for the JAK/STAT gain-of-function disorders and the interferonopathies (Scene 44): ruxolitinib or baricitinib for STAT1 gain-of-function, ruxolitinib or tofacitinib for STAT3 gain-of-function, baricitinib or tofacitinib for SOCS1 haploinsufficiency, and ruxolitinib, baricitinib or tofacitinib for CANDLE, SAVI, Aicardi-Goutières syndrome and USP18 deficiency. | IL-6; IFNγ; IFNα2; IL-4; IL-13; IL-2; IL-23 → Inhibit JAK1, JAK2, JAK3 or TYK2 kinase activity, so STAT phosphorylation does not occur downstream of the γc, gp130, type I and type II interferon and IL-12-family receptors | What it does to the tests: CRP and ESR fall through the IL-6/gp130 arm, so the same loss of infection markers as with tocilizumab applies, although less completely. Haemoglobin, neutrophils, lymphocytes and platelets all fall through the JAK2 arm (erythropoietin and thrombopoietin signalling) and the γc arm. NK and B-cell numbers fall. Lipids and CK rise. Herpes zoster reactivation is the characteristic infection and is the predictable consequence of simultaneous blockade of type I and type II interferon signalling. Made uninterpretable: CRP and ESR, partially, as infection markers. Canada and the United States: Abrocitinib (Cibinqo) is among the most complete concordances in this reference: atopic dermatitis from 12 years in both countries, with the same dose options, the same dose reduction at age 65 and the same risk-stratified 100 mg starting dose. Oral ruxolitinib: acute and chronic graft-versus-host disease from 12 years in the two countries, myelofibrosis and polycythaemia in adults in the two countries, and no indication below 12 in either. The brand differs (Jakavi in Canada, Jakafi in the USA), Canada carries an infection-focused Serious Warnings box where the US label has no boxed warning, and the extended-release form has no Canadian counterpart. Topical ruxolitinib (Opzelura): atopic dermatitis from 2 years and vitiligo from 12 years in both countries, the ages now being identical; the US indication, however, restricts dermatitis use to non-immunocompromised patients and to short-term non-continuous use, a restriction absent from the Canadian indication. In paediatric immunology this is the material difference: in the USA topical ruxolitinib is explicitly off-label in an immunocompromised child. Deucravacitinib (Sotyktu) is a TYK2 allosteric inhibitor rather than a classical jakinib, adults only in both, and psoriatic arthritis is not in the Canadian monograph. The class warnings (serious infection, mortality, malignancy, major cardiovascular events, thrombosis) appear in both countries, boxed in the USA and in a Serious Warnings box in Canada, with four Canadian headings against five American. | Scene 42 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| Mavorixafor and plerixafor mavorixafor (Xolremdi) and plerixafor (Mozobil in the USA; generic Plerixafor Injection in Canada) — CXCR4 antagonists Biologic or targeted agent | Administered therapeutically; not produced endogenously | Block CXCR4, the receptor and not the ligand: the target shown for this entry is SDF-1 because that is the catalogued entity, but the drug binds CXCR4 and does not affect SDF-1 itself. CXCR4 retains mature neutrophils and stem cells in the marrow against the SDF-1 (CXCL12) gradient. Release from this retention is the treatment of WHIM syndrome, in which a truncated CXCR4 cannot be inactivated and the cells are retained; this myelokathexis is a defect of retention and not of production Mavorixafor is licensed in the USA for WHIM syndrome from 12 years and is not authorised in Canada; plerixafor is licensed for stem-cell mobilisation, in adults in both countries and in Canada also in children from 1 year with lymphoma or solid malignant tumours, whereas paediatric safety and effectiveness are not established in the USA, and is used off-label in WHIM. In Canada the Mozobil brand was cancelled after marketing on 31 October 2025 and plerixafor is supplied as generic Plerixafor Injection. Both are teratogenic, so pregnancy must be excluded and contraception used. The 2025 inborn-errors practice parameter recommends both for WHIM with the blood count as the monitoring marker. The mechanism is the direct converse of the WHIM defect, which accounts for the rapidity of the response. | SDF-1 → Competitive antagonism of CXCR4, so the SDF-1 retention signal is lost and cells leave the marrow | What it does to the tests: The absolute neutrophil count and the lymphocyte count rise within hours of dosing, because the cells were present but retained in the marrow. A normal count on treatment therefore reflects release and not production. Canada and the United States: Mavorixafor is not authorised in Canada (no Health Canada record under any status and no filing found), so a Canadian patient with WHIM syndrome can obtain it only through the Special Access Programme. In the USA it is licensed for WHIM from 12 years; the dose is banded at 50 kg rather than by age, and the requirement for an overnight fast with no food for half an hour afterwards is a significant barrier to adherence in an adolescent. Plerixafor shows the other major reversal of the usual pattern in this reference, with the broader authorisation in Canada: Health Canada has an authorised paediatric indication (1 to under 18 years, lymphoma or solid tumours, 0.24 mg/kg eight to twelve hours before apheresis for up to three days), whereas the US label states that paediatric safety and effectiveness are not established and records that effectiveness was not demonstrated in its paediatric trial. Reliance on the FDA position that effectiveness is not established in children would lead to incorrect refusal of a therapy that is on-label in Canada. The paediatric timing window and duration also differ from the adult eight-to-twelve hours and three days against ten to eleven hours and four days, and the US indication covers only lymphoma and myeloma where Canada's paediatric one includes solid tumours. Adult mobilisation dosing is the same in both. | Scene 43 |
| G-CSF (filgrastim) filgrastim, pegfilgrastim, lenograstim — recombinant G-CSF Biologic or targeted agent | Administered therapeutically; not produced endogenously | The only agent listed that supplies a cytokine rather than blocking one: recombinant G-CSF drives granulopoiesis, shortens marrow transit and releases the marrow reserve, which accounts for its efficacy in severe congenital neutropenia, in cyclic neutropenia and after chemotherapy Severe chronic neutropenia, whether congenital, cyclic or idiopathic, and chemotherapy-induced neutropenia are the labelled uses of filgrastim in both countries; autoimmune neutropenia is not a labelled indication in either, and in Canada efficacy in autoimmune neutropenia of infancy is stated not to have been established, so that use is off-label. The labelled starting dose in congenital neutropenia is 12 micrograms/kg daily, as a single or divided dose, in Canada and 6 micrograms/kg twice daily in the USA; in cyclic or idiopathic neutropenia it is 5 micrograms/kg daily in both. Pegfilgrastim has no paediatric indication in Canada. In severe congenital neutropenia the long-term MDS/AML risk (about 22% at 15 years, with a hazard of about 2.3% per year after the first 10 years) is the reason for annual marrow surveillance, and a higher G-CSF requirement indicates higher risk; whether G-CSF causes the transformation or is a marker of the more severe underlying defect is not established. | G-CSF → Agonist at G-CSFR (CSF3R) → JAK2 → STAT3/STAT5, the same receptor shown in the granulopoiesis scene | What it does to the tests: The neutrophil count rises within 24 to 48 hours, with a left shift and toxic granulation that can be mistaken for sepsis. Alkaline phosphatase, LDH and uric acid rise. The CD64 index on neutrophils rises, so neutrophil CD64 as a sepsis marker is confounded during G-CSF treatment. Bone pain is common. Made uninterpretable: Neutrophil CD64 as a sepsis marker; the blood film, which has a reactive appearance as an expected effect of treatment. Canada and the United States: Filgrastim is substantively the same in the two countries, including paediatric use in severe chronic neutropenia at the same starting doses: 12 µg/kg/day in congenital, 5 µg/kg/day in cyclic or idiopathic disease and 5 µg/kg/day for chemotherapy-induced neutropenia. Canada alone specifies the exclusions of neonates and autoimmune neutropenia of infancy; the USA alone licenses the acute radiation syndrome, and Canada alone an HIV-associated neutropenia indication. Pegfilgrastim is the difference carrying the greatest risk: the US label contains a full paediatric weight-band table from under 10 kg and establishes effectiveness from 8 months, whereas the Canadian monographs for both the originator and its biosimilar state that Health Canada has not authorised a paediatric indication and contain no paediatric dose. Pegfilgrastim in a Canadian child is entirely off-label, and use of the US weight bands constitutes a regimen with no supporting Canadian label. Lenograstim is marketed in neither country (no Health Canada record under any status and no US licensed biologic), so it is a European and Japanese agent and any dose quoted from that literature has no supporting North American label; Canadian practice is filgrastim and pegfilgrastim only. Splenic rupture and sickle-cell crisis appear in a formal Canadian Serious Warnings box and in ordinary warnings in the USA, with the same content but different prominence. Long-term counselling regarding myelodysplasia and leukaemic transformation in congenital neutropenia is required, which the US label places in its paediatric section. | Scene 43 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| JAK inhibitors in JAK/STAT gain-of-function ruxolitinib, baricitinib and tofacitinib used as precision therapy in inborn errors of immunity Precision therapy for inborn errors of immunity | Administered therapeutically, matched to the molecular defect | The same drugs as in Scene 42, used for a different purpose: correction of a signalling defect rather than suppression of an inflammatory disease. In a JAK/STAT gain-of-function disorder the pathway is constitutively active, so inhibition of the kinase upstream of the STAT restores near-normal signalling; this is the only medical therapy, other than transplantation, that addresses the underlying lesion Dosing in these disorders is not established by trial and is taken from cohort experience; none of these uses is licensed in Canada or the USA. Ruxolitinib: in the published cohort of STAT1 and STAT3 gain-of-function disease the dose was 0.4 to 2 mg/kg/day, or 15 mg/m² per dose twice daily, started at half the goal dose and increased by 25% weekly until the goal dose was reached (Forbes LR et al. J Allergy Clin Immunol 2018;142:1665-1669). On the basis of retrospective experience, escalation to 30 mg/m² twice daily, to a maximum of 25 mg twice daily, is also described; 50 mg/m² per dose has been tolerated in children, but long-term data at that dose are inadequate. Tofacitinib: the one patient treated in that cohort was dosed as labelled for rheumatoid arthritis. Baricitinib: the published proposal for CANDLE and SAVI is by body weight and renal function (Kim H et al. Clin Pharmacol Ther 2018;104:364-373). With an estimated glomerular filtration rate of 120 mL/min/1.73 m² or more, the initial dose is 2 mg three times daily under 20 kg, 3 mg twice daily at 20 to 40 kg and 4 mg twice daily over 40 kg; the first escalation is to 2 mg four times daily, to 3 mg, 2 mg and 3 mg as three daily doses, and to 5 mg twice daily respectively; and a second escalation, to 6 mg twice daily, is proposed only over 40 kg. With a lower filtration rate the initial dose is 2 mg twice daily at all weights. Mean exposure at the doses reached was 1.83 times that of adults taking 4 mg daily for rheumatoid arthritis. A regimen of 2 mg daily, increased to 4 mg daily within 4 to 6 weeks according to clinical response and tolerance, with 2 mg daily in children under 9 years, may also be used. The dose is titrated every 4 to 6 weeks according to clinical response. Aciclovir prophylaxis is suggested because of the herpesvirus risk, with review every 4 to 6 months for opportunistic infection, cardiovascular and thromboembolic disease, malignancy and liver disease. Treatment is lifelong or until transplant. Early introduction may determine whether the disease resolves. | IFNγ; IFNα2; IFNβ; IL-6 → Inhibit the JAK upstream of the overactive STAT, lowering STAT phosphorylation to nearer normal | For: STAT1 gain-of-function (ruxolitinib or baricitinib); STAT3 gain-of-function (ruxolitinib or tofacitinib); STAT4 gain-of-function and STAT5b gain-of-function (ruxolitinib); SOCS1 haploinsufficiency (baricitinib or tofacitinib); and the interferonopathies: USP18 deficiency, SAVI, Aicardi-Goutières syndrome and CANDLE (ruxolitinib, baricitinib or tofacitinib) Follow: CXCL9 and Th17 numbers in STAT1 gain-of-function; double-negative T cells in STAT3 gain-of-function; IL-6 in STAT4; eosinophilia in STAT5b; CXCL9 in SOCS1 deficiency; and an interferon-activity score in the interferonopathies. CXCL9 (MIG) is an interferon-induced chemokine and therefore reflects IFN-γ activity better than ferritin Graded: Strong recommendation for STAT3 gain-of-function, SOCS1 deficiency and the interferonopathies; conditional for STAT1, STAT4 and STAT5b gain-of-function. Certainty of evidence moderate to very low; there are no clinical trials in these disorders, and the evidence is at cohort and case-report level throughout What it does to the tests: The biomarkers listed above fall with response and are those recommended for monitoring. The laboratory adverse effects are those of the class: cytopenias, raised transaminases and raised triglycerides, so a blood count with differential, a liver panel and a chemistry panel are monitored, with viral PCR for reactivation. Because these agents also block IL-6 signalling, the CRP response is attenuated, as with tocilizumab. Made uninterpretable: CRP and ESR, partially, as infection markers. | Scene 44 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| IL-1 blockade in the inflammasomopathies anakinra, rilonacept and canakinumab used as precision therapy in inborn errors of immunity Precision therapy for inborn errors of immunity | Administered therapeutically, matched to the molecular defect | The three IL-1 agents of Scene 40, matched here to the defects that drive IL-1 production. They are not equivalent: anakinra blocks IL-1α as well as IL-1β and has a terminal half-life of 4 to 6 hours with probably better central nervous system penetration; rilonacept traps IL-1β and, less avidly, IL-1α and the natural antagonist IL-1RA, with a half-life of about 7 days; canakinumab neutralises IL-1β alone with a half-life of 22.9 to 25.7 days Children generally require higher doses than adults, and patients with severe phenotypes require higher doses than those with mild disease. In familial Mediterranean fever, raising canakinumab from 150 mg to 300 mg every 4 weeks converted many partial responses into complete responses, and dose escalation also improved response in TRAPS and in mevalonate kinase deficiency. IL-1 blockade also reduces proteinuria. In milder disease with normal markers between episodes, on-demand anakinra can shorten or prevent attacks rather than continuous treatment. Data in pregnancy and breastfeeding are limited for all three. Treatment is lifelong. | IL-1α; IL-1β → Receptor blockade (anakinra), ligand trapping (rilonacept) or neutralisation of IL-1β (canakinumab) | For: CAPS (familial cold autoinflammatory syndrome, Muckle-Wells syndrome and NOMID/CINCA, from NLRP3) with all three agents in practice, although the licences are narrower: anakinra is licensed for NOMID alone in both countries (in Canada from 8 months and 10 kg), canakinumab for familial cold autoinflammatory syndrome and Muckle-Wells syndrome (from 4 years in the USA; from 2 years in Canada, where use in NOMID/CINCA is also permitted), and rilonacept for familial cold autoinflammatory syndrome and Muckle-Wells syndrome from 12 years in the USA only, so the remaining uses are off-label; TRAPS (TNFRSF1A), familial Mediterranean fever (MEFV) and mevalonate kinase deficiency (MVK) with canakinumab; deficiency of the IL-1 receptor antagonist (DIRA, IL1RN) with anakinra or rilonacept, both licensed for this in the USA only, anakinra being off-label for DIRA in Canada and rilonacept not authorised there; PAPA syndrome (PSTPIP1), FCAS2 (NLRP12) and Majeed syndrome (LPIN2) with anakinra or canakinumab; NOCARH (CDC42) with anakinra; FCAS4 (NLRC4) with canakinumab; the uses in PAPA syndrome, FCAS2, Majeed syndrome, NOCARH and FCAS4 are off-label in both countries Follow: CRP and serum amyloid A throughout, with the white cell and neutrophil count and proteinuria in CAPS, TRAPS, FMF and mevalonate kinase deficiency, and ferritin added in NOCARH and NLRC4 disease. Serum amyloid A is the relevant marker between attacks: a normal CRP does not establish that inflammation is controlled, and sustained SAA elevation is the precursor of AA amyloid Graded: Strong recommendation with high certainty for CAPS, TRAPS, FMF and mevalonate kinase deficiency; strong with moderate certainty for DIRA; conditional with low certainty for PAPA, FCAS2, Majeed syndrome, NOCARH and FCAS4 What it does to the tests: CRP, SAA, the neutrophil count and proteinuria all fall, often within days; the response is sufficiently rapid that a trial of IL-1 blockade is used diagnostically while a molecular diagnosis is awaited, in preference to awaiting genetic results and accepting the morbidity of the delay. Anakinra causes neutropenia in a few per cent. Injection-site reactions are almost universal early in anakinra treatment and subsequently resolve. Made uninterpretable: CRP and SAA as infection markers. | Scene 45 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| Leniolisib leniolisib (Joenja) — oral selective PI3Kδ inhibitor Precision therapy for inborn errors of immunity | Administered therapeutically, matched to the molecular defect | The first drug developed for a single inborn error of immunity. In activated PI3K-delta syndrome a gain-of-function in PIK3CD, or loss of its regulatory subunit in PIK3R1, renders PI3Kδ constitutively active; leniolisib inhibits that catalytic subunit selectively and restores the lymphocyte compartment towards normal Fetal harm is possible, and medication interactions occur, so concurrent drugs should be reviewed. Treatment is lifelong. The randomised trial enrolled patients of 12 to 75 years, and the original 2023 licence followed it. The US licence was extended in September 2026 down to 4 years at 27 kg or more, with weight-banded dosing: 40 mg twice daily at 27 to under 38 kg, 50 mg twice daily at 38 to under 45 kg, and 70 mg twice daily at 45 kg and above and for all patients of 12 years and over. The Canadian licence was not extended: it remains 12 years and 45 kg, with only the 70 mg strength authorised, which is recorded as approved but not yet as marketed, and no weight bands (see the licensing note before an age is quoted). Children under 27 kg have no approved dose in either country; a US supplemental application for children of 4 years and over weighing 13 to under 27 kg has been accepted for priority review, with a target action date of 30 January 2027, and remains pending, so no dose can currently be quoted for that band. | IgM; Transitional B cell; Plasmablast; CD8 Tem / Temra → Selective inhibition of the PI3Kδ catalytic subunit p110δ, lowering AKT–mTOR signalling in lymphocytes | For: Activated PI3K-delta syndrome, both APDS1 (PIK3CD gain-of-function) and APDS2 (PIK3R1 loss); from 4 years and 27 kg in the USA, but from 12 years and 45 kg in Canada, which requires both Follow: Serum IgM, which is characteristically high in APDS and falls markedly on treatment; transitional B cells; and CD8 and CD4 terminally differentiated effector memory (TEMRA) cells Graded: Strong recommendation, high certainty; one of two agents in this group, with interferon gamma-1b in chronic granulomatous disease (PMID 1846940), supported by a randomised placebo-controlled trial What it does to the tests: In the phase 3 trial, lymphadenopathy and spleen size fell, as did transitional B cells, CD38+ plasmablasts, switched and unswitched memory B cells, CD57+ senescent CD8 T cells and CD8 TEMRA cells, while total CD4 counts rose and CD4 TEMRA cells fell. Serum IgM fell markedly. A blood count and immunoglobulins are the monitoring specified in the label. Made uninterpretable: Serum IgM as a measure of disease rather than of treatment. Canada and the United States: The Canadian and US criteria differ. Canada: activated PI3K-delta syndrome from 12 years and 45 kg (both conditions are required); only the 70 mg strength is authorised, and it is recorded as approved but not yet as marketed, so there is no weight-banded dosing in Canada. United States (label Sep 2026): from 4 years and 27 kg, with 40, 50 and 70 mg tablets and weight bands (40 mg twice daily at 27 to under 38 kg, 50 mg at 38 to under 45 kg, 70 mg at 45 kg and above, and 70 mg twice daily for any patient aged 12 or over). Two specific consequences follow. A 13-year-old weighing 40 kg is on-label in the USA and off-label in Canada, because Canada requires both the age and the weight. A 7-year-old of 30 kg cannot be treated according to the label in Canada and cannot receive a reduced dose of the Canadian product, because the 70 mg tablet is film-coated and oval with no scoring or splitting instructions in either monograph. To obtain the paediatric strengths, a Canadian prescriber would apply to the Health Canada Special Access Programme for the US 40 mg or 50 mg tablets, documenting the weight band and the absence of an authorised Canadian 40 mg or 50 mg product. A further US supplemental application, for lower doses in children of 4 years and over weighing 13 to under 27 kg, has been accepted for priority review with a target action date of 30 January 2027; no dose for that band is authorised. A Canadian reimbursement recommendation could not be verified: the review page of Canada's Drug Agency, last updated October 2024, records the review as suspended, whereas a BC PharmaCare call for public input (29 July to 25 August 2026) states that the drug has been or will be reviewed by Canada's Drug Agency. | Scene 46 |
| Abatacept and belatacept in CTLA-4 and LRBA disease abatacept (Orencia) and belatacept (Nulojix) — CTLA-4-Ig fusion proteins Precision therapy for inborn errors of immunity | Administered therapeutically, matched to the molecular defect | Replacement of a deficient inhibitory mechanism rather than suppression of a normal one. CTLA-4 competes with CD28 for CD80 and CD86; LRBA is required to recycle CTLA-4 rather than direct it to degradation, so loss of either leaves CD28 costimulation unopposed. A CTLA-4–Ig fusion protein supplies the missing competitor Live vaccines must not be given during treatment or within three months of stopping, and it should not be combined with a TNF inhibitor. Treatment is lifelong. It controls the disease and is not curative: transplantation remains the curative option in severe disease. | Tfh → Binds CD80 and CD86, restoring the competition for CD28 that is lost as a result of the defect | For: CTLA-4 haploinsufficiency and LRBA deficiency: the lymphoproliferation, enteropathy, autoimmune cytopenias and interstitial lung disease of those disorders Follow: Circulating T follicular helper cells and soluble CD25, both of which fall on treatment in most patients Graded: Strong recommendation, moderate certainty What it does to the tests: Circulating Tfh and soluble CD25 fall. In LRBA deficiency with refractory interstitial lung disease, lung function improved within six months of initiation; chronic diarrhoea, lymphoproliferation and autoimmune cytopenias improved on long-term follow-up. The label specifies no monitoring blood tests. Made uninterpretable: Vaccine serology as proof of protection, as with abatacept in any indication. | Scene 46 |
| Elapegademase elapegademase (Revcovi) — PEGylated recombinant bovine adenosine deaminase Precision therapy for inborn errors of immunity | Administered therapeutically, matched to the molecular defect | Enzyme replacement rather than a signalling inhibitor. In adenosine deaminase deficiency the toxic substrates deoxyadenosine and dAXP accumulate and are toxic to lymphocytes; enzyme replacement clears them, and lymphocyte counts, neutrophil counts and infection frequency improve Licensed in the USA for adenosine deaminase severe combined immune deficiency in paediatric and adult patients; it is not authorised in Canada. Treatment is started as soon as absent enzyme activity is demonstrated, without awaiting the genetic result. Initial dosing in the parameter is 0.4 mg/kg/week intramuscularly, divided into two doses, for infants and 0.2 mg/kg/week for older children and adolescents, which may be given weekly; the label applies the same two figures to a different distinction (0.4 mg/kg/week, calculated on ideal or actual body weight, whichever is greater, and divided twice weekly for a minimum of 12 to 24 weeks until immune reconstitution, for any patient new to enzyme replacement irrespective of age, and 0.2 mg/kg/week as the minimum starting dose for those transitioning from pegademase at a weekly dose of 30 U/kg or less or of unknown size), so a late-diagnosed older child started at 0.2 would be underdosed. Treatment history as well as age should determine the dose. The dose is increased by 0.033 mg/kg/week if the trough plasma ADA remains under 30 mmol/h/L or trough dAXP exceeds 0.02 mmol/L; higher doses may be needed in ADA-associated pulmonary alveolar proteinosis or hepatitis. The parameter names vidarabine and deoxycoformycin as interacting; the label states that interaction potential has not been studied. Enzyme replacement does not fully reconstitute immunity, so antimicrobial prophylaxis and immunoglobulin replacement usually continue, and it is a bridging therapy to transplantation or gene therapy rather than definitive treatment. | No catalogued node is acted on directly → Replaces adenosine deaminase activity in plasma, clearing plasma deoxyadenosine and lowering erythrocyte deoxyadenosine nucleotides (dAXP) | For: Adenosine deaminase deficiency, including ADA-SCID Follow: Plasma ADA activity and erythrocyte dAXP, with blood counts and lymphocyte subsets Graded: Strong recommendation, high certainty What it does to the tests: Lymphocyte and neutrophil counts rise and infections decrease; trough erythrocyte dAXP (deoxyadenosine nucleotides) falls below 0.02 mmol/L within 3 to 6 months, and a trough dAXP above 0.02 mmol/L is an indication for dose escalation. The US label specifies that trough erythrocyte dAXP is maintained below 0.02 mmol/L from two months after the start of treatment and monitored at least twice a year. Plasma ADA, erythrocyte dAXP, blood counts and lymphocyte subsets are measured at least every 6 months. Antibody function can wane on long-term therapy, in part from neutralising antibodies to the drug. | Scene 46 |
| Interferon gamma-1b interferon gamma-1b (Actimmune) — recombinant human IFN-γ Precision therapy for inborn errors of immunity | Administered therapeutically, matched to the molecular defect | The converse of emapalumab: a cytokine supplied rather than blocked. In chronic granulomatous disease it reduces the frequency and severity of serious infection without restoring the oxidative burst, and in the IFN-γ-axis defects it supplies or augments the signal that the defect has weakened Dosing is by body surface area, and the rule for small infants is the most frequent source of error: 50 micrograms/m² three times a week where the surface area is above 0.5 m², but 1.5 micrograms/kg per dose three times a week where it is 0.5 m² or below; a young infant dosed by the per-square-metre figure is substantially underdosed. In chronic granulomatous disease it is given alongside trimethoprim-sulfamethoxazole and itraconazole; in disseminated mycobacterial disease the per-square-metre dose is added to antimycobacterial therapy. It does not replace antimicrobial prophylaxis. It is licensed in the USA for chronic granulomatous disease, with paediatric use established from 1 year, and for severe malignant osteopetrosis, from 1 month; its use in Mendelian susceptibility to mycobacterial disease is off-label, and it is not authorised in Canada. | IFNγ → Agonist at the IFN-γ receptor, driving JAK1/JAK2 and STAT1 in macrophages | For: Chronic granulomatous disease as prophylaxis against all infections, and the Mendelian susceptibility to mycobacterial disease group: IL-12p40, IL-12Rβ1, IL-12Rβ2 and IL-23R deficiency, autosomal dominant partial IFN-γR1 or R2 deficiency, STAT1 loss-of-function, TYK2, IRF8 and ISG15 deficiency, and IFN-γ deficiency itself Follow: Clinical infection frequency; there is no validated laboratory marker of response Graded: Strong recommendation in chronic granulomatous disease with moderate certainty; strong with very low certainty in the IFN-γ-signalling defects What it does to the tests: Raised liver enzymes and renal toxicity are the laboratory adverse effects, with fever; liver enzymes, a chemistry panel and a blood count with differential are monitored. Treatment is lifelong or until transplant. | Scene 46 |
| Oral fucose oral L-fucose supplementation Precision therapy for inborn errors of immunity | Administered therapeutically, matched to the molecular defect | Direct supplementation of a deficient sugar. Leukocyte adhesion deficiency type II is a defect of GDP-fucose transport, so the selectin ligands on which rolling depends are not synthesised; oral fucose permits their synthesis, and the rolling step of Scene 33 is restored Not every patient responds, and the neurological features do not improve with the haematological ones. The white cell count is the practical measure of response to supplementation. | No catalogued node is acted on directly → Substrate supplementation restoring fucosylation of selectin ligands, including sialyl-Lewis X | For: Leukocyte adhesion deficiency type II (SLC35C1), which also causes short stature, developmental delay and the Bombay blood phenotype Follow: The white cell count with differential: the persistent leucocytosis of a rolling defect falls as the ligands return Graded: Strong recommendation, low certainty; some but not all patients respond What it does to the tests: Selectin ligands reappear on neutrophils, the white cell count normalises and infections improve in responders. Discontinuation reverses both: the ligands are lost and the leucocytosis returns, which demonstrates the mechanism as clearly as the response itself. | Scene 46 |
| Cobalamin and folate in the transport defects hydroxocobalamin, cyanocobalamin and high-dose intravenous folinic acid Precision therapy for inborn errors of immunity | Administered therapeutically, matched to the molecular defect | Several defects of vitamin B12 and folate transport or metabolism present with the features of severe combined immunodeficiency (poor T-cell proliferation to mitogen, hypogammaglobulinaemia and absent antibody responses) and respond to vitamin replacement, with the best outcomes when treatment begins early. They are the most important treatable mimics in this group TCN2 deficiency is treated with cyanocobalamin or hydroxocobalamin; SLC46A1 deficiency with high-dose intravenous folinic acid; MTHFD1 deficiency and cblF disease (LMBRD1) with hydroxocobalamin and folinic acid together. Treatment is lifelong. Total plasma homocysteine, methylmalonic acid and folate should be measured before a diagnosis of SCID is made in an infant with an SCID-like presentation. | No catalogued node is acted on directly → Bypasses the defective transporter by supplying the vitamin at a dose that reaches the cell | For: Transcobalamin II deficiency (TCN2); proton-coupled folate transporter deficiency (SLC46A1); MTHFD1 deficiency; and cblF disease (LMBRD1) Follow: Vitamin B12 and folate levels, total plasma homocysteine and methylmalonic acid, and the blood count Graded: Strong recommendation, low certainty What it does to the tests: The immunological abnormalities (low or absent T-cell proliferation, hypogammaglobulinaemia and impaired antibody responses) return to normal with treatment. The blood count, vitamin B12 and folate are monitored, together with total plasma homocysteine and methylmalonic acid. | Scene 46 |
| Entity | Made / induced by | Function and clinical correlate | Receptor → signalling | Detail | Scene |
|---|---|---|---|---|---|
| Immunoglobulin replacement immunoglobulin replacement therapy (IgRT) — intravenous or subcutaneous IgG Precision therapy for inborn errors of immunity | Administered therapeutically, matched to the molecular defect | Not a cytokine therapy, but the treatment received by most patients with the antibody deficiencies described in this reference. It supplies pooled donor IgG and only IgG: it does not replace IgA or IgM, so mucosal protection is not restored and a low IgA is not corrected The population target is a minimum and not an individual goal: the dose is individualised to the level at which the individual patient ceases to have infections (the biologic trough), which in X-linked agammaglobulinaemia has ranged from 800 to 1300 mg/dL and in common variable immunodeficiency from 500 to 1700 mg/dL. Dose is adjusted for weight change beyond 5%. A low or absent IgA is not a contraindication, and the choice of route is a conditional recommendation made with the patient rather than part of the strong one. Treatment is continuous, and lifelong for most but not all patients: a planned trial off therapy is explicitly permitted in selected cases, specifically specific antibody deficiency in children and transient hypogammaglobulinaemia of infancy, which are the paediatric situations in which the question arises. | IgG1; IgG2; IgG3; IgG4 → Passive replacement of IgG, with the FcRn recycling of Scene 28 conferring the three-week half-life that permits three- to four-weekly dosing | For: Inborn errors with defective humoral immunity: X-linked agammaglobulinaemia, common variable immunodeficiency, class-switch recombination defects, combined immunodeficiencies and others in which antibody production or function is lost Follow: The serum IgG trough, with a blood count and chemistry panel Graded: Strong recommendation. Certainty moderate for the starting dose and the monitoring, high for the trough target, low for the recommendation that it is continuous and lifelong What it does to the tests: The starting dose is 400 to 600 mg/kg per month: intravenously every 3 to 4 weeks, or the same monthly dose divided into weekly or two-weekly subcutaneous infusions (the labelled conversion from the intravenous dose differs by product and by country: in the USA the weekly-equivalent intravenous dose is multiplied by 1.37 for Hizentra, Xembify and subcutaneous Gamunex-C and Gammagard Liquid and by 1.30 for Cuvitru and Cutaquig, to match bioavailability, and is unchanged for facilitated subcutaneous HyQvia; in Canada it is unchanged for Hizentra, Cuvitru and HyQvia, while the Canadian monographs of Xembify and Cutaquig, neither of which is recorded as marketed, apply 1.37 and 1.30; the figures of 1.35 and 1.53 are not labelled conversion factors, 1.53 being the mean individual dose adjustment in the US pharmacokinetic study of Hizentra). The target is a serum IgG above 800 mg/dL: pneumonia falls by about a quarter for every additional 100 mg/dL of trough, and a trough of 500 carries about five times the pneumonia rate of 1000, with no further benefit above 1000. IgG is measured every 6 to 12 months when stable, and monthly when there are breakthrough infections, in pregnancy, with protein loss, on immunosuppression, with significant weight change or where adherence is uncertain. The trough is sampled before the intravenous infusion; on subcutaneous dosing the level peaks at 3 to 5 days and steady state takes 4 to 6 months. Made uninterpretable: All IgG-based serology, including vaccine responses and infectious serology: the result reflects the donor pool and not the patient. Any assessment of antibody production must precede the first infusion or follow a washout. Canada and the United States: The monthly dose is concordant; the trough target and the subcutaneous conversion are not, and both are likely sources of error in a Canadian chart. The monthly dose is identical (the practice parameter's 400–600 mg/kg/month is the same as the Canadian 0.4–0.6 g/kg every four weeks), except that Canadian guidance specifies adjusted body weight in adults whereas children are generally dosed on actual weight, which diverges only in the obese adolescent. Trough target: the practice parameter sets above 800 mg/dL (a strong recommendation on high-certainty evidence); Canadian guidance sets ‘at least the lower limit of the age-specific serum IgG reference range’, which in a two-year-old is roughly 500 mg/dL and is substantially lower. Recording 800 as the sole target in a Canadian chart conflicts with the criteria applied by the local transfusion service, so both targets should be known; the American figure is the one supported by outcome evidence. Subcutaneous conversion: the 1.37 factor (1.35–1.53 across products) derives from US labelling. Canadian labelling and Canadian guidance use 1:1: the monthly dose is divided by four for the weekly subcutaneous dose and then titrated to trough. Access differs in kind: in the USA this is a prescription drug supplied through specialty pharmacy; in Canada it is a blood product, free to the patient, released by transfusion medicine against a utilisation guideline, with brand allocation determined by national contracts and shortage plans, so brand continuity cannot be assured, and there is a dedicated national brand-switching statement because switching is expected. Objective measures of effectiveness should be set at the outset and reviewed by six months and at least annually thereafter. | Scene 47 |
| Antimicrobial prophylaxis targeted antimicrobial prophylaxis in inborn errors of immunity Precision therapy for inborn errors of immunity | Administered therapeutically, matched to the molecular defect | Prophylaxis in these disorders is directed at the organisms to which the specific defect confers susceptibility and is not given broadly. The correspondence between defect and organism follows the principle applied throughout this reference: the deficient pathway predicts the infection Where hypersensitivity to trimethoprim-sulfamethoxazole is suspected, desensitisation is preferred to discontinuation, since the alternatives provide incomplete coverage. The azoles interact with many drugs, including the agents in these scenes. Prophylaxis complements, and does not replace, immunoglobulin replacement or precision therapy. | No catalogued node is acted on directly → Antimicrobial rather than immunological | For: Chronic granulomatous disease; SCID and congenital athymia; antibody deficiencies; terminal complement defects and asplenia; STAT3 and IL-6-pathway hyper-IgE syndrome; chronic mucocutaneous candidiasis (STAT1 gain-of-function, APECED, CARD9, IL-17 and IL-17R defects); Mendelian susceptibility to mycobacterial disease; combined immunodeficiency with severe T-cell defects Follow: Infection frequency; adherence and drug interactions are of greater importance than any laboratory measure Graded: Strong recommendation, high quality of evidence for the recommendation overall; the individual regimens range from strong with high certainty down to conditional with very low certainty What it does to the tests: Trimethoprim-sulfamethoxazole for chronic granulomatous disease, covering Staphylococcus aureus, Burkholderia, Nocardia and Serratia: 5 mg/kg of the trimethoprim component, with a maximum dose of 160 mg of trimethoprim twice daily; whether 5 mg/kg is a single or a total daily dose is not specified, and a 2018 review gives 5 mg/kg per day to a maximum of one double-strength tablet (160 mg of trimethoprim) daily. Prophylaxis reduces bacterial infections by approximately half. For Pneumocystis prophylaxis in SCID and congenital athymia the same agent is given two to three times a week (5 mg/kg, maximum 160 mg of trimethoprim), and in combined immunodeficiency with severe T-cell defects twice daily, as a conditional rather than a strong recommendation; pentamidine, atovaquone and dapsone are alternatives. Itraconazole for Aspergillus in chronic granulomatous disease: 5 mg/kg daily, to a maximum of 100 mg daily under 50 kg and 200 mg daily over 50 kg. The placebo-controlled trial, which enrolled patients aged 5 years and over, used fixed doses of 100 mg daily under 13 years of age or under 50 kg and 200 mg daily from 13 years or from 50 kg. Itraconazole has no paediatric indication in Canada or the USA; the oral solution is better absorbed than the tablets, which should be taken with a meal. Fluconazole for Candida at 3 mg/kg in SCID and congenital athymia, or 3 to 6 mg/kg/day in infants with SCID, and at 5 mg/kg in chronic mucocutaneous candidiasis and in hyper-IgE syndrome. In STAT3 hyper-IgE syndrome the named regimen is trimethoprim-sulfamethoxazole at 5 to 6 mg/kg/day of the trimethoprim component divided twice daily, with itraconazole added where pneumatoceles are present; coccidioidomycosis prophylaxis is advised in endemic regions for STAT3 hyper-IgE syndrome and STAT1 gain-of-function. Aciclovir for HSV and VZV, at 12.5 mg/kg twice daily in SCID and congenital athymia before immune reconstitution and at 20 to 40 mg/kg, to a maximum of 400 mg, twice daily in combined immunodeficiency with severe T-cell defects; ganciclovir or valganciclovir is used as treatment rather than as prophylaxis, for established CMV infection or for symptoms consistent with CMV infection while PCR results are pending. Azithromycin 5 mg/kg daily to a maximum of 250 mg, or 500 mg three days a week, for respiratory infection in antibody deficiency and for environmental mycobacteria in MSMD, with amoxicillin or trimethoprim-sulfamethoxazole as alternatives. Daily amoxicillin or penicillin in terminal complement defects and asplenia, to at least 5 years of age and able to be continued for life, particularly after an episode of sepsis; cephalexin or azithromycin is used in penicillin allergy, and an allergy evaluation is preferred before a second-line drug is adopted. Meningococcal and pneumococcal vaccination at diagnosis is at least as important as the antibiotic. Aciclovir should not be given concurrently with ganciclovir or valganciclovir. Perioperative decolonisation for Staphylococcus aureus is advised in chronic granulomatous disease, leukocyte adhesion deficiency and hyper-IgE syndrome. Canada and the United States: None of these uses is a licensed indication in Canada or the USA; all represent guideline practice and are off-label. Dosing is effectively the same in the two countries because both follow the same guidelines and literature; the paediatric formulations available differ, and this is the principal source of practical risk, so the available suspension should be confirmed before a weight-based dose is prescribed. For trimethoprim-sulfamethoxazole in chronic granulomatous disease, the recommended regimen is 5 mg/kg of the trimethoprim component with a maximum dose of 160 mg twice daily; the recommendation does not state whether 5 mg/kg is a single dose or a total daily dose. A 2018 review of the management of chronic granulomatous disease gives 5 mg/kg per day of the trimethoprim component, to a maximum of one double-strength tablet (160 mg of trimethoprim) daily. Where hypersensitivity to trimethoprim-sulfamethoxazole is a concern, drug desensitisation is suggested; the alternatives, second- or third-generation cephalosporins or trimethoprim alone, leave gaps in the coverage of Staphylococcus aureus, Burkholderia, Nocardia and Serratia. | Scene 47 |
| Vaccination in inborn errors of immunity live and non-live vaccines in IEI and their household contacts Precision therapy for inborn errors of immunity | Administered therapeutically, matched to the molecular defect | Vaccination is not contraindicated as a whole: live replicating vaccines are withheld in severe cellular, phagocytic or humoral defects, whereas non-live vaccines are given and are of value even where the antibody response is expected to be poor, because the T-cell response may be preserved Household contacts may receive live vaccines, with two exceptions: oral poliovirus vaccine and replication-competent smallpox/mpox vaccine. After a household infant has received oral rotavirus vaccine, hand washing after nappy changes is advised for a month. Contact with a blistering rash after varicella vaccination or shingles should be avoided. COVID-19 vaccination is strongly recommended including on immunoglobulin replacement, where T-cell and serological responses were better than expected; HPV vaccination is recommended for all patients with an inborn error of immunity from 9 to 45 years. The first dose of rotavirus vaccine must be given by 14 weeks and 6 days of age, with the series completed by 8 months, which is often before the immunological diagnosis is established; the question should therefore be resolved early rather than deferred by default. Meningococcal and pneumococcal vaccination is recommended at diagnosis in complement deficiency, asplenia and the TLR-pathway defects, alongside the antibiotic prophylaxis. Seasonal inactivated influenza vaccination is recommended with a standing on-demand antiviral prescription for exposure in patients of 3 months and over. With respect to grading, during immunoglobulin replacement the recommendations for mRNA COVID-19 and inactivated influenza vaccination are conditional with low certainty, and those for recombinant zoster and for HPV conditional with very low certainty, although the narrative text recommends them. | No catalogued node is acted on directly → Immunisation | For: All inborn errors of immunity, and their household contacts Follow: Vaccine-specific antibody titres, where immunoglobulin replacement has not made them uninterpretable Graded: Strong recommendation to follow current public-agency and professional-society schedules, with low certainty, because those schedules change more rapidly than any practice parameter and supersede it What it does to the tests: All live viral vaccines, including live attenuated influenza and dengue, and all live bacterial vaccines (BCG, typhoid) are contraindicated in severe inborn errors: SCID, congenital athymia, combined immunodeficiency, IFN-α and IFN-γ deficiency, the IL-12 axis defects, antibody deficiencies and chronic granulomatous disease. Chronic granulomatous disease is a clinically important partial exception: the contraindication applies to live bacterial vaccines, and a child with CGD who is not immunosuppressed may receive live viral vaccines, so MMR and varicella are not withheld on the basis of the CGD diagnosis alone. Vaccine-strain rotavirus infection has occurred in newborns with SCID diagnosed before newborn screening, BCG has caused disseminated or localised granulomatous disease in SCID, IFN-γ-pathway defects and chronic granulomatous disease, and vaccine-strain rubella has been found in skin granulomas in ataxia-telangiectasia, combined immunodeficiency and also humoral defects. Isolated T-cell lymphopenia with preserved function is a distinct situation in which live vaccines may be given; the suggested thresholds are CD4 above 400/µL, CD8 above 200/µL, naive CD4 above 20% of CD4, and a protective tetanus response. In a patient who no longer requires immunoglobulin replacement (for example, in transient hypogammaglobulinaemia of infancy), catch-up live viral vaccines are deferred until 8 months after the last infusion (the ACIP interval for a replacement dose of 300–400 mg/kg before a measles- or varicella-containing vaccine), which is also the point at which serology again becomes interpretable. Made uninterpretable: Vaccine serology in any patient on immunoglobulin replacement. | Scene 47 |
| Immune reconstitution: transplant and gene therapy allogeneic haematopoietic stem cell transplantation and ex vivo gene therapy Precision therapy for inborn errors of immunity | Administered therapeutically, matched to the molecular defect | The only curative options. All other treatments in Scenes 44 to 47 control a disease or replace a product; transplantation and gene therapy replace the defective cell itself, and several of the precision agents are accordingly described in the parameter as treatment until transplant rather than as definitive therapy Timing is among the most important determinants of outcome: survival exceeds 90% when SCID is identified by newborn screening, and transplantation before 3.5 months of age gives better outcomes than later transplantation; this is the rationale for newborn screening and the reason the procedure is urgent rather than elective. Thymus transplantation, rather than haematopoietic transplant, is the procedure for congenital athymia; in the USA allogeneic processed thymus tissue (Rethymic) has been licensed since 8 October 2021 for immune reconstitution in paediatric patients with congenital athymia, and is not indicated for severe combined immunodeficiency, while no such product is authorised in Canada. Gene therapy has been licensed in Europe for adenosine deaminase deficiency (Strimvelis, since May 2016) and in the USA for two further disorders: etuvetidigene autotemcel (Waskyra), approved on 9 December 2025 for Wiskott-Aldrich syndrome with a mutation in the WAS gene, from 6 months of age, where transplantation is appropriate and no suitable HLA-matched related donor is available; and marnetegragene autotemcel (Kresladi), given accelerated approval on 26 March 2026 for paediatric patients with severe leukocyte adhesion deficiency type I due to biallelic ITGB2 variants who have no HLA-matched sibling donor, with continued approval contingent on confirmatory evidence of clinical benefit. None of these gene therapies is authorised in Canada. The parameter lists ADA alongside X-linked SCID, Artemis deficiency and RAG1 deficiency as disorders in which it is accessed through open clinical trials, a statement that predates the two US approvals, so availability depends on location. | No catalogued node is acted on directly → Replacement of the haematopoietic compartment, from a donor or from the patient’s own corrected cells | For: Severe combined immunodeficiency and congenital athymia; severe combined and phagocyte defects; severe immune dysregulation; and selected disorders in which medical control is inadequate Follow: Lymphocyte subsets, chimerism and immune reconstitution testing after the procedure Graded: Strong recommendation with high certainty that SCID is treated by transplant or gene therapy; strong with moderate certainty for cultured thymus tissue implantation in congenital athymia; conditional with moderate certainty that it is done at an experienced centre What it does to the tests: Blood products given before or around transplant must be irradiated, leucoreduced and CMV-negative (not only CMV-safe), and lymphocyte-depleted; this requirement applies from the time a severe cellular defect is suspected and not from the time it is confirmed. | Scene 47 |
The catalogue read the other way round: every producing cell type and the mediators it releases. A mediator appears under each of its main sources, so totals exceed 95. The rows added at the end are the cell subsets, antibody-secreting cells, complement-producing tissues and acute-phase outputs of Scenes 19–47.
Full explanations for all 47 scenes above, in order. Match the scene title here to the title bar above each diagram.
A pathogen or damage signal hits a macrophage/dendritic cell. Three receptors from two families — the TNF receptors, plus the IL-1 and IL-18 receptors of the IL-1 family — all converge on the same transcription factor, NF-kB, through different adaptor proteins. IL-1RA physically occupies the IL-1 receptor without triggering it. IL-10 arrives at a completely different receptor; its STAT3 signal switches on a suppressive gene programme that represses NF-kB target genes and destabilizes pro-inflammatory mRNAs — drawn here as a block on the pro-inflammatory genes, not on the adaptors. (IL-10 also induces SOCS3, but its anti-inflammatory effect persists without it.)
The macrophage from Scene 1 secretes IL-12 and IL-27. Both, together with IL-23, bind to a T cell or NK cell. IL-12 and IL-23 share the IL-12Rbeta1 chain (and the p40 subunit); IL-27 is a relative that uses its own WSX-1/gp130 receptor. Each fires a different STAT and gene programme: IL-12→STAT4 drives Th1, IL-23→STAT3 expands and stabilizes Th17, and IL-27 first supports Th1 (STAT1/T-bet), then restrains Th17 and induces IL-10. IL-18 arrives through the older, non-JAK IL-1-family route and synergizes with IL-12 on the same IFN-gamma gene. The IFN-gamma that comes out closes two loops at once: a positive loop back to the macrophage, which primes it for more IL-12 alongside CD40 and type I interferon signals, and a negative loop that induces IL-18BP to cap IL-18. There is a third arm the diagram does not draw, and it matters clinically: IFN-gamma also signals back on the T cell itself, where STAT1 induces T-bet, and T-bet switches on both the IFN-gamma gene and IL-12Rβ2, the inducible chain. So the MSMD genes (IFNGR1, IFNGR2, STAT1, IL12B, IL12RB1) sit on both arms — a receptor or STAT1 defect blocks Th1 commitment itself, not just macrophage killing. Follow both all the way around.
Unlike the Th1 core, the Th2 cytokines mostly act on different target cells rather than converging on one. IL-4 and IL-13 share a receptor chain and the same STAT6 endpoint: on epithelium it drives mucus, eotaxin and periostin; in T and B cells it drives GATA3 and the IgE switch. The two receptor forms are not interchangeable by cell type — the type I receptor (IL-4Rα + γc) sits on haematopoietic cells only, since epithelium carries no γc, so epithelium answers through the type II receptor (IL-4Rα + IL-13Rα1) alone. That is why blocking IL-4Rα with dupilumab takes out both arms at once, while an anti-IL-13 antibody leaves type I signalling intact. IL-5 and IL-9 use the same STAT5 machinery as the survival cytokines in Scene 5, but on eosinophils and mast cells respectively. IL-31 is the odd one out — its receptor is expressed on sensory neurons, making it a major driver of Th2-associated itch.
IL-6, IL-23 (detailed in Scene 2), and IL-21 all converge on STAT3 to lock in Th17 identity. IL-21 is special: Th17 cells secrete it themselves, and it signals back on the very same cell — a proposed autocrine amplification loop — though mice lacking IL-21 or its receptor mount intact Th17 responses to infection, so the loop is not settled, separate from the IL-12/IL-18/IFN-gamma loop in Scene 2. The two output cytokines, IL-17A and IL-22, land on the same epithelial cell but take completely different routes to get there: IL-17A never touches a JAK.
IL-2, IL-7, and IL-15 share the common gamma chain and JAK1/JAK3/STAT5 — the same machinery IL-9 uses in Scene 3. IL-15 is drawn differently on purpose: it is usually trans-presented, held on a dendritic cell's own IL-15Ralpha and handed directly to the responding lymphocyte, rather than floating free like other cytokines. IFN-alpha's antiviral cascade builds a three-part complex (ISGF3) instead of a simple dimer. IL-6's most classic site isn't an immune cell at all — it's the liver. GM-CSF acts on myeloid progenitors, but its non-redundant job is in the lung (alveolar macrophages).
Everything so far has been one cell secreting, another cell's receptor firing a kinase cascade into its own nucleus. Chemokines do something different: they form a physical concentration gradient in the tissue, and leukocytes read that gradient through a 7-transmembrane GPCR, not a JAK, and crawl up it. Four lanes below show four different cell types reading four different (overlapping) chemokine sets. The fifth vignette, SDF1alpha, is the odd one out — its main job is to hold cells in place and guide homing, rather than inflammatory recruitment.
The initial signals in an allergic response often originate from damaged epithelium rather than from T cells. IL-33 (an IL-1-family trefoil stored in the nucleus) and IL-25 (an IL-17-family cystine knot produced by tuft cells) both activate ILC2s and Th2 memory cells through NF-κB, so the first IL-5 and IL-13 can appear before any antigen-specific T cell is involved. TSLP signals through the JAK-STAT pathway: STAT5 is its main signal, whereas in the dendritic cell OX40L is induced via NF-κB and CCL17 via STAT6, which together enable the dendritic cell to prime naive T cells toward Th2. HMGB1 is the generic damage signal released by any necrotic cell and feeds back into the innate alarm response of Scene 1.
IFN-α (Scene 5) is not the only antiviral interferon. IFN-β and IFN-ω use the same IFNAR receptor and the same ISGF3 programme. IFN-β is the first interferon produced after a virus is sensed, and one of the genes it induces, IRF7, enables virus-sensing cells to produce substantially more IFN-α/β; this positive feedback loop is drawn in pink. The type III interferons IL-28A and IL-29 (IFN-λ2 and IFN-λ1) activate the same ISGF3 programme through a different receptor, IFNLR1 + IL-10R2, which is expressed mainly on barrier epithelium and hepatocytes. They protect the surfaces at which viruses enter while causing less systemic inflammation.
Not every member of a cytokine family activates a pathway. Free IL-12p40 (and its p80 homodimer) occupies IL-12Rβ1 without signalling and competes with both IL-12 and IL-23. IL-35, produced by regulatory cells, signals through an unusual STAT1:STAT4 pair to suppress the target T cell and convert it into a new IL-35 producer, so suppression is propagated from cell to cell (infectious tolerance, shown as the pink loop). The two soluble receptors act by ligand capture: sCD137 binds 4-1BB ligand and sFas binds Fas ligand, so the ligand does not reach the receptor on the cell and the signal shown in dashed grey is not transmitted.
IL-17F is the less potent counterpart of IL-17A (Scene 4): it uses the same receptor pair and the same Act1/NF-κB pathway and induces a smaller neutrophil programme. IL-20 and IL-24 belong to the IL-10 family and share two receptor combinations on keratinocytes, driving proliferation through STAT3; IL-24, induced by IL-13, also lowers filaggrin, linking Th2 inflammation to the barrier defect of atopic dermatitis. IL-11 and LIF are gp130-family relatives of IL-6. IL-11 is produced by fibroblasts and acts on the same fibroblasts (an autocrine loop), and its fibrotic programme depends largely on ERK. LIF supports mouse embryonic stem cells, implantation, acute-phase proteins and neurons.
Haematopoiesis in the bone marrow is regulated through two classes of growth-factor receptor. IL-3, G-CSF and TPO use cytokine receptors with JAKs, as do the survival cytokines of Scene 5: IL-3 acts on progenitors, basophils, mast cells and pDCs, G-CSF on neutrophils (it rises when IL-17 is high), and TPO on megakaryocytes and platelets. M-CSF and IL-34 (sharing CSF1R), SCF (KIT) and Flt-3 ligand (FLT3) instead bind receptor tyrosine kinases: the ligand pairs two receptor chains, which phosphorylate each other and activate PI3K/AKT and RAS/MAPK. KIT is the mast-cell receptor mutated in systemic mastocytosis.
Tissue repair and remodelling use the same receptor-tyrosine-kinase mechanism. EGF and TGFα share EGFR on epithelium and keratinocytes; FGF-2 requires heparan sulfate as a co-receptor; the PDGFs pair different PDGFR chains (BB binds all three combinations) to recruit fibroblasts, pericytes and smooth muscle; VEGF-A acts on endothelial VEGFR2 to induce new vessel formation and vascular permeability, whereas VEGFR1 acts mainly as a decoy receptor. In the airway these mediators underlie mucus metaplasia, smooth-muscle growth and vascular remodelling.
Three TNF-family trimers determine B-cell fate. BAFF maintains survival of naive B cells through BAFF-R, which degrades TRAF3 and releases NIK to activate the non-canonical NF-κB pathway; excess BAFF permits survival of autoreactive B cells (the target of belimumab). APRIL maintains survival of long-lived plasma cells through BCMA and drives IgA switching through TACI. CD40 ligand drives class switching and germinal-centre formation through CD40; most of this help derives from membrane CD40L on T cells, and most circulating soluble CD40L derives from platelets.
Cytotoxic cells kill by two mechanisms. Death ligands (FasL, TRAIL) bind a death receptor that recruits FADD and caspase-8, which activates caspase-3; soluble FasL is weakly cytotoxic compared with the membrane form. Granule-mediated killing delivers perforin, which inserts into the target membrane in a calcium-dependent manner and forms pores, and granzymes, which enter through those pores. Granzyme B cleaves BID to trigger the mitochondrial pathway and also activates caspase-3 and -7 directly. Granzyme A causes caspase-independent death by a mechanism that is not settled: single-strand DNA nicking after cleavage of the SET complex, and pyroptosis through cleavage of gasdermin B in gasdermin-B-expressing cells such as epithelium, have both been proposed.
These lanes extend Scene 6. ENA-78 and GCP-2 act with IL-8 and GROα as neutrophil chemoattractants (through CXCR2, and additionally CXCR1 for GCP-2) and are induced by IL-1 and TNF (ENA-78 also by IL-17). MIG and I-TAC act with IP-10 on CXCR3, the receptor that recruits Th1 cells, CTLs and NK cells into tissue; MIG is produced predominantly in response to IFN-γ, and serum CXCL9 is therefore used as a measure of IFN-γ activity.
CC chemokines are promiscuous in their receptor usage, so the relationships are presented as a table rather than a diagram. Each row shows every receptor engaged by one chemokine, and each column shows every chemokine to which a given cell type responds. These four chemokines mainly recruit monocytes and T cells through CCR1 and CCR2, and also recruit eosinophils through CCR3. MCP-3 also binds CCR5 but acts as an antagonist at that receptor.
The chemokines of allergic tissue fall into two groups: CCR3 ligands that recruit eosinophils and basophils (the eotaxins and MCP-4), and CCR4 / CCR8 ligands that recruit Th2 cells and Tregs (TARC, MDC, I-309). Eotaxin-3 is also an antagonist at CCR1, CCR2 and CCR5, so it attracts eosinophils while blocking monocyte and Th1 recruitment. IL-16 is included because it attracts CD4+ cells, but it is not a chemokine and signals through CD4.
Homeostatic chemokines direct cells to specific tissues. CCR7 ligands recruit naive T cells and mature DCs into the lymph-node T zone; CXCL13 recruits B cells and Tfh cells into follicles; CCL20 recruits CCR6+ cells to epithelia; CCL27 (skin) and CCL28 (mucosa) act through CCR10 to direct memory T cells and IgA plasmablasts to the appropriate barrier. Lymphotactin acts in the opposite direction: an activated CD8 T cell or NK cell recruits an XCR1+ cDC1. Fractalkine is both a chemokine and an adhesion molecule, anchored on inflamed endothelium, where it captures patrolling monocytes.
The fate of a naive CD4 T cell is not fixed: the cytokines present at priming determine the effector subset, and each subset is defined by a transcription factor, a set of effector cytokines and a homing pattern. IL-12 with IL-18 induces Th1 and IFN-γ; IL-4 induces Th2 and the IL-4, IL-5, IL-13 programme underlying allergic disease; IL-1β with IL-6 and IL-23 induces Th17 and the neutrophil-recruiting IL-17 programme; IL-4 with TGF-β induces Th9; and IL-6 with TNF-α and aryl-hydrocarbon-receptor ligands induces Th22, which produces IL-22 without IL-17. Th9 and Th22 are better regarded as differentiation states than as fixed lineages. The lanes beneath show the cross-regulation: IFN-γ suppresses Th2 and Th17, IL-4 suppresses Th1, and IL-4 is required for Th9 as well as Th2. IL-4 also restrains Th17, which is shown as a suppression marker on the Th17 entry rather than as a lane, and the IL-13-driven keratinocyte IL-24 of Scene 10 is named in the footer because it does not act between two of these cells.
The same naive cell can alternatively differentiate into a helper of B cells or a regulatory cell. In the current working model, Tfh cells are induced in humans mainly by IL-12, although the human inducer is not established, with IL-21 as an autocrine amplifier; they express CXCR5, enter the follicle and deliver IL-21, IL-4 and CD40 ligand, which determine the isotype of the antibody response. Tfr cells are regulatory cells that enter the follicle with them and limit the response. Thymic Tregs depend on IL-2 and STAT5 for FoxP3 stability; peripherally induced Tregs are generated in the gut by TGF-β with retinoic acid and are the population on which oral tolerance and oral immunotherapy depend. Tr1 cells do not express FoxP3: they are induced by IL-27 and IL-10 and suppress through large amounts of IL-10. IL-2 is required for Treg survival but represses Bcl-6, and therefore restrains the follicular programme.
CD8 T cells differentiate along corresponding lines. A cDC1 cross-presenting antigen with IL-12 and type I interferon induces a Tc1 cytotoxic lymphocyte expressing perforin, granzymes, Fas ligand and IFN-γ; IL-4 instead induces Tc2 and IL-6 with IL-23 induces Tc17, which are found in allergic and psoriatic tissue respectively. Memory subsets are distinguished by the signals that maintain them: IL-7 and IL-15 maintain stem-cell-like and central-memory cells, persistent antigen with IL-15 produces effector-memory and terminally differentiated Temra cells, and TGF-β with local IL-15 retains tissue-resident memory cells through CD69 and CD103. These resident cells account for the recurrence of a fixed drug eruption and of a herpes lesion at the same site.
Four lymphocyte populations respond within hours rather than days. Invariant NKT cells recognize lipid presented by CD1d and release IFN-γ, IL-4 and IL-13 together, so they influence the response before any conventional T cell is primed. MAIT cells recognize riboflavin metabolites presented by MR1 and can also be activated by IL-12 with IL-18 alone, without a receptor signal. γδ T cells are not MHC-restricted. NK cells are included for comparison: IL-15 maintains their survival, IL-12 and IL-18 induce IFN-γ, and CD16 allows bound IgG to direct their cytotoxicity, which is the point at which antibody and cellular cytotoxicity converge. PLZF is the shared developmental transcription factor of the innate-like T-cell lineages.
This matrix is the index to the four preceding scenes. Each row shows every lymphocyte on which one cytokine acts; each column shows every cytokine to which a subset responds or which it produces. Three entries merit comment. IL-2 both expands effector T cells and sustains the Tregs that restrain them, while repressing Bcl-6 and thereby restraining Th17 and Tfh. IL-10 suppresses Th1 cells and is also produced by them, which constitutes the self-limiting arm of a Th1 response. CD40 ligand appears almost entirely as a product of activated T cells rather than as a signal acting on them, because its targets are the B cell and the dendritic cell.
A B cell leaving the marrow is transitional and survives only if tonic B-cell-receptor signalling is matched by BAFF; this is the last checkpoint against autoreactivity, and excess BAFF therefore permits survival of autoreactive cells. Surviving cells become naive follicular B cells, the pool from which T-dependent responses arise. Marginal-zone B cells respond to polysaccharide with little or no T-cell help, using the B-cell receptor together with Toll-like receptors and complement receptor CD21; they therefore protect against encapsulated bacteria, and that protection is weak in young children and absent after splenectomy. B-1 cells are the source of natural IgM in mouse; the human equivalent is contested. Regulatory B cells are defined by IL-10 production rather than by lineage.
In the germinal centre a B cell moves between the dark zone, where AID mutates its immunoglobulin genes, and the light zone, where it must capture antigen from follicular dendritic cells and obtain help from a Tfh cell. That help, consisting of CD40 ligand and IL-21, both maintains survival of the cell and selects the isotype. Cells that receive little help become memory cells; those that receive most become plasmablasts; and plasmablasts that reach a CXCL12 marrow niche with APRIL, BAFF and IL-6 become long-lived plasma cells that maintain serum titres for years. The long-lived fraction does not express CD20, and anti-CD20 treatment therefore spares existing antibody while depleting the cells that would generate new specificities.
Class switching requires two signals: a CD40 signal (or a TACI signal from BAFF or APRIL in the absence of T-cell help) to induce AID, and a cytokine to select the isotype. CD40 ligand is drawn as a ring rather than a filled circle because it permits switching without selecting an isotype. IL-4 and IL-13 open the ε and γ4 regions and therefore induce IgE and IgG4; the addition of IL-10 shifts the same cell from IgE toward IgG4, as occurs during successful allergen immunotherapy. IFN-γ induces IgG1 and IgG3 and suppresses IgE. TGF-β with APRIL or BAFF induces IgA, and gut retinoic acid favours IgA2. Polysaccharide acting through TACI induces IgM and IgG2 without germinal centres; this is the response that matures last in childhood.
Each isotype is defined by the effector functions of its constant region. IgM is the strongest activator of the classical complement pathway, but only after antigen binding converts the pentamer from its planar star form into the staple conformation that exposes its C1q binding sites. Among the IgG subclasses the order of complement activation is IgG3 then IgG1, with IgG2 weak and IgG4 inactive; IgG2 is bound almost exclusively by the H131 allotype of FcγRIIa, which accounts for the relevance of that polymorphism to pneumococcal infection. IgG4 preferentially binds the inhibitory receptor and exchanges half-molecules, so it cannot cross-link antigen, which defines a blocking antibody. IgA engages FcαRI on neutrophils and is transported into secretions by pIgR. IgE engages FcεRI, on which it persists for weeks. Every range in this scene is a typical adult value: in children, the IgG nadir at three to six months, the late maturation of the polysaccharide response and the rise of total IgE through childhood make an age-matched range essential.
An antibody exerts effector function only when its Fc is bound by a cellular receptor. FcγRI is the only high-affinity IgG receptor and is therefore occupied by circulating IgG; it is expressed on neutrophils only after IFN-γ or G-CSF, which accounts for the rise in neutrophil CD64 within hours of bacterial infection. FcγRIIa is the main phagocytic receptor. FcγRIIb is the only inhibitory Fc receptor and the only one expressed by B cells, so IgG immune complexes inhibit further antibody production. FcγRIIIa on NK cells is the receptor for antibody-dependent cellular cytotoxicity, and its V158F polymorphism predicts the response to IgG1 therapeutic antibodies. FcεRI retains IgE on mast cells for weeks and triggers immediate hypersensitivity; CD23 regulates the quantity of IgE produced. FcRn and pIgR do not signal; they are transport receptors, which accounts for the three-week half-life of IgG, its transfer across the placenta and the delivery of secretory IgA to the mucosal surface.
The classical and lectin pathways differ only in the molecule that recognizes the target. C1q binds the Fc of antibody already bound to a surface and activates C1r and then C1s; mannose-binding lectin, a ficolin or collectin-11 binds microbial carbohydrate and activates MASP-2, which has the same function as C1s. Either protease cleaves C4 to C4b, which binds the surface covalently, and C2 to C2a, and C4b with C2a forms the C3 convertase. C1 inhibitor is the inhibitor of both initiating proteases and, of equal importance, of plasma kallikrein and factor XIIa; its loss therefore causes bradykinin angioedema rather than a complement-deficiency syndrome. Low C4 with a normal C3 is the classic screening pattern for that condition, whereas low C4 with low C3 indicates classical-pathway consumption.
The alternative pathway requires no recognition molecule: C3 hydrolyses spontaneously, factor D cleaves the factor B bound to it, and the resulting convertase cleaves further C3 to C3b. Properdin stabilizes that loop five- to ten-fold, and as a result the alternative pathway generates most of the C3b and membrane attack complex in any response, irrespective of the initiating pathway. A second C3b converts the convertase into a C5 convertase, and C5 is cleaved into C5a, the most potent neutrophil chemoattractant in the body, and C5b, which recruits C6 to C9 to form a pore. Host cells are protected by factor H, factor I, DAF, MCP, CR1 and CD59. The two functional assays together localize a defect: absent CH50 with normal AH50 indicates C1, C2 or C4; the reverse indicates factor D, factor B or properdin; absence of both indicates C3 or a terminal component.
Deficiency of each regulator has a characteristic presentation, and the pattern is usually more informative than the measured level. C1 inhibitor deficiency causes angioedema. In factor H the phenotype depends on the domain affected: C-terminal mutations, which impair host-surface recognition, cause atypical haemolytic uraemic syndrome, whereas loss of N-terminal regulatory function causes C3 glomerulopathy. Factor I deficiency results in complete consumption of C3, so the presentation is secondary C3 deficiency with pyogenic infection. The membrane regulators are lost together in paroxysmal nocturnal haemoglobinuria, in which an acquired PIGA mutation eliminates both DAF and CD59 from a stem-cell clone, and separately in CHAPLE disease, in which inherited CD55 loss causes protein-losing enteropathy. Neonatal complement levels are roughly half to two-thirds of adult levels, so age-matched ranges are as important here as for immunoglobulins.
Complement fragments act only when recognized by a cellular receptor, and the fragment present determines which cell responds. CR1 binds intact C3b, and erythrocyte CR1 is the main route by which immune complexes reach the liver and spleen. Once factor I has cleaved C3b, iC3b is the ligand for CR3 and CR4, so that single cleavage transfers the particle from one receptor to another. The final fragment, C3d, is bound by CR2 on B cells, where it lowers the activation threshold by orders of magnitude: this is the point at which innate complement directly amplifies an antibody response, and it is also the receptor by which Epstein–Barr virus enters the cell. The anaphylatoxin receptors are GPCRs of the same family as the chemokine receptors, and C5aR1 on the neutrophil converts complement activation into neutrophil recruitment.
Neutrophil numbers are regulated at four points, each associated with a distinct disease. G-CSF drives production. The marrow then holds about ninety per cent of the neutrophils of the body in reserve, retained by stromal CXCL12 acting on CXCR4 and released when G-CSF lowers CXCL12 and raises the CXCR2 ligands; in WHIM syndrome gain-of-function CXCR4 fixes this balance in favour of retention. In tissue, TNF-α and IL-1β induce selectins and chemokines on endothelium and C5a is generated by complement activation; the cell rolls, adheres firmly through LFA-1 and CR3, and migrates out of the vessel, and the leukocyte adhesion deficiencies disrupt successive steps of this sequence. Finally the cell undergoes apoptosis and is ingested, which switches the macrophage to IL-10 and TGF-β production and actively terminates the response. The number of cells cleared is itself sensed: when few apoptotic neutrophils are ingested, IL-23 rises, IL-17 follows, and IL-17 raises G-CSF, which is the loop that accounts for the rise in G-CSF in neutropenia.
A neutrophil kills unopsonized targets far less efficiently, although it recognizes some targets directly, including fungal beta-glucan through Dectin-1 and CR3, so antibody and complement largely determine which targets are ingested. IgG is bound by FcγRIIa and FcγRIIIb, and FcγRI is expressed only after IFN-γ or G-CSF. C3b is bound by CR1 and, after cleavage by factor I, iC3b by CR3; C5a activates the same CR3 by inside-out signalling, so complement provides both the activating signal for adhesion and the opsonized particle. Ingestion assembles the NADPH oxidase on the phagosome and discharges the granules into it; in chronic granulomatous disease the oxidase is absent and granulomas form. When the target cannot be ingested the cell can instead release an extracellular trap, which captures organisms but also externalizes the MPO and PR3 of ANCA disease, the nucleosomes of lupus, and the citrullinated histones that are the source of rheumatoid autoantibodies.
Almost all inflammatory markers in clinical use are products of a single circuit. Infection, trauma, surgery or autoinflammation activates macrophages and monocytes, which release IL-6 with IL-1-beta and TNF-alpha, and the hepatocyte responds to IL-6 through gp130, JAK1 and STAT3. A coordinated change in plasma-protein synthesis follows: CRP, serum amyloid A, fibrinogen, haptoglobin, ferritin, hepcidin, alpha-1 antitrypsin and ceruloplasmin rise, while albumin, transferrin and transthyretin fall simultaneously and for the same reason. Several complement proteins are also acute-phase reactants, so a C3 or C4 level can be normal during consumption. The dependence on a single signal is of clinical importance: during IL-6 blockade, in IL6R or STAT3 defects, and in liver failure, the IL-6-dependent reactants (CRP, fibrinogen and therefore the ESR, haptoglobin and SAA) cannot rise, so a normal CRP in those settings provides no information about infection. Two markers are exempt and are used instead: procalcitonin still rises, and ferritin can still rise steeply, because it is also driven by IL-1-beta, IFN-gamma and IL-18. A rising ferritin with an unchanged CRP in a child on tocilizumab is a clinically significant finding and not an artefact.
These four markers differ sufficiently in behaviour that their combined measurement is more informative than any single marker. CRP is produced only by hepatocytes, only in response to IL-6, and has a fixed half-life of about nineteen hours, so the level reflects the current rate of synthesis; it is also an effector molecule, binding phosphocholine on damaged membranes and on pneumococcus and then activating complement through C1q, and thus acts as an antibody-independent opsonin. Serum amyloid A rises earlier and falls more rapidly, and can rise about 1000-fold in a day, as can CRP; sustained elevation is the precursor of AA amyloid, which makes SAA, rather than CRP, the marker of adequately treated periodic fever. Procalcitonin is induced by bacterial products and suppressed by interferon, so it discriminates bacterial from viral illness better than CRP, and it is the only marker in this group that IL-6 blockade does not abolish. Fibrinogen rises slowly and is the principal protein determining the ESR.
The ESR is not a protein: it is the distance that red cells fall in a tube in one hour. Sedimentation is faster when plasma proteins bridge red cells into rouleaux, and the principal protein responsible is fibrinogen, followed by immunoglobulin. The properties of the test follow from this mechanism. Because fibrinogen takes a day or two to rise and days to weeks to fall, the ESR lags the CRP in both directions. Because any factor that alters red cells or plasma proteins alters sedimentation, the ESR can be high in the absence of inflammation (anaemia, pregnancy, age, any hypergammaglobulinaemia) and can remain normal despite active inflammation when fibrinogen is consumed or the red cells do not form rouleaux, as in sickle-cell disease or disseminated intravascular coagulation. Discordance between the two tests is informative: a high CRP with a normal ESR indicates inflammation of less than a day in duration; a high ESR with a normal CRP indicates a resolving process, a paraprotein, or anaemia. In lupus the two classically diverge, so a high CRP in that setting should raise the possibility of infection rather than flare.
Iron sequestration is a regulated component of the inflammatory response and is mediated by the same IL-6 signal that raises CRP. IL-6 acting through STAT3 raises hepcidin; hepcidin degrades ferroportin, the only route by which iron leaves a cell; dietary iron therefore cannot cross the enterocyte and recycled iron cannot leave the macrophage. Serum iron and transferrin saturation fall, transferrin falls because it is a negative acute-phase protein, and ferritin rises for two unrelated reasons simultaneously: inflammation raises its transcription and retained iron raises its translation. The result is the anaemia of inflammation, and in practice the standard iron panel can no longer be interpreted in the usual way: a normal or high ferritin does not exclude iron deficiency, a low transferrin does not indicate iron overload, and the response to oral iron is poor until the inflammation is treated. A ferritin of several thousand has a different significance and suggests haemophagocytosis or macrophage activation syndrome.
The seven agents differ in the level of the type 2 pathway at which they act. Omalizumab binds free IgE at the site used by FcεRI, so IgE can no longer bind to mast cells; receptor-bound IgE is not displaced, which accounts for an onset of effect over weeks as FcεRI density falls. Dupilumab binds IL-4Rα and thereby blocks IL-4 and IL-13 together, whereas tralokinumab and lebrikizumab block IL-13 alone. Mepolizumab and reslizumab neutralise IL-5 and deprive the eosinophil of its survival signal; benralizumab binds IL-5Rα with an afucosylated Fc and directs NK-cell killing of the eosinophil, so the count falls to zero rather than being reduced. Tezepelumab is the only agent acting upstream of the type 2 cytokines, at TSLP, which accounts for its efficacy in the absence of a type 2 phenotype. Nemolizumab blocks the IL-31 receptor and treats itch rather than inflammation. Two laboratory effects are contrary to expectation and account for most errors of interpretation: total IgE rises on omalizumab, because the assay detects drug–IgE complexes, and blood eosinophils rise in the first months of dupilumab treatment, because marrow release continues while eotaxin-driven tissue entry is blocked.
These agents act on the three cytokines that drive the hepatic acute-phase response and therefore share one consequence: they lower the markers used to detect infection. The degree differs, and the difference is clinically relevant. TNF and IL-1 blockade attenuate the response; IL-6 blockade abolishes it, so CRP cannot rise on tocilizumab, sarilumab or siltuximab irrespective of the clinical state. Procalcitonin is the exception and is preserved, because bacterial products induce it independently of IL-6; it is the marker to be used. Within TNF blockade the agents are not interchangeable: etanercept is a decoy receptor that also binds lymphotoxin-α and binds transmembrane TNF without sustained cross-linking, which accounts for its lack of efficacy in granulomatous bowel disease, in which the monoclonal antibodies are effective, and for its lower tuberculosis risk. Anakinra blocks IL-1α as well as IL-1β and has a half-life of hours, which makes it the preferred IL-1 agent in an acutely unwell child; canakinumab persists for weeks, which is a disadvantage if infection supervenes. One agent in this group restores the interpretability of a test rather than removing it: IL-6 blockade lowers hepcidin, so the anaemia of inflammation improves and iron studies become interpretable.
Ustekinumab binds the p40 subunit shared by IL-12 and IL-23 and therefore blocks the Th1 and Th17 axes together; guselkumab, risankizumab and tildrakizumab bind p19 and block IL-23 alone, leaving IL-12 intact. The IL-17 agents act one step further downstream, and their adverse effects are predictable from the pathways described in this reference: IL-17 drives the epithelial antimicrobial programme, so mucocutaneous candidiasis is the acquired phenocopy of inherited IL-17 pathway defects, and IL-17 drives G-CSF, so neutrophil counts fall mildly. Inflammatory bowel disease is a labelled caution for secukinumab, ixekizumab and bimekizumab, and a contraindication for brodalumab, which also carries a boxed warning for suicidal ideation and behaviour. The cell-directed agents do not target a cytokine. Abatacept blocks the CD28 second signal, so vaccine responses are attenuated and serological protection cannot be assumed. Rituximab depletes CD20-positive B cells but spares the long-lived plasma cell, so IgM falls first and IgG falls later and in a minority remains low for years; the immunological evaluation and vaccinations must therefore precede the first dose. Belimumab removes BAFF from the newly formed B-cell pool and is one of the few agents listed that raises complement levels, as consumption diminishes.
The complement agents are the clearest example in this reference of a drug that reproduces an inherited phenotype: blockade of C5 reproduces terminal-pathway deficiency, with the same meningococcal risk and the same vaccination and prophylaxis requirements, and vaccination does not eliminate the risk. The assay that changes indicates the level of blockade. C5 blockade leaves C3 and C4 unaffected, so a normal C3 on treatment provides no information about drug effect, and because C5 is a terminal component its blockade abolishes CH50 and AH50 together. Iptacopan and danicopan abolish AH50 and spare CH50, which is the converse of classical-pathway blockade with sutimlimab and not of C5 blockade. Measured C3 rises steeply on pegcetacoplan, to several hundred mg/dL, because the C3 bound by the drug is no longer consumed, so a high C3 in that setting reflects the effect of treatment; because that agent abolishes opsonisation, pneumococcal and Hib cover are also required. Sutimlimab raises C4 towards normal and carries the same encapsulated-organism vaccination requirement as the other agents. Avacopan is the exception: blockade of C5aR1 leaves the membrane attack complex intact and creates no terminal-pathway defect. Of the interferon agents, anifrolumab suppresses the lupus interferon signature, and emapalumab neutralises IFN-γ in haemophagocytic lymphohistiocytosis, in which measured IFN-γ rises on treatment because the assay still detects the drug–cytokine complex, so CXCL9 is the marker used for monitoring. The JAK inhibitors are not biologics but block every JAK-STAT cytokine in this reference simultaneously, and do not affect TNF, IL-1, IL-17 and IL-18.
The two neutrophil agents have converse actions, corresponding to the defects in Scene 33. Mavorixafor blocks CXCR4 and releases the neutrophils retained in the marrow in WHIM syndrome, so the count rises within hours, because the cells were present but retained. Recombinant G-CSF has the opposite action for the opposite defect and drives production; its effects include a left shift and toxic granulation that can be mistaken for sepsis, and a raised neutrophil CD64 that confounds CD64 as a sepsis marker. The final entry states the principle of which every other entry in these five scenes is an example. A test in a patient receiving a biologic addresses one of three questions, of which only the first concerns the patient: whether the test still reflects the disease, whether it now reflects the drug, or whether the drug has rendered it uninterpretable. A zero eosinophil count on benralizumab, an undetectable CH50 on eculizumab and a rising total IgE on omalizumab are all measures of drug effect. A CRP on tocilizumab cannot answer the clinical question. Two corollaries follow: the baseline should be measured before the first dose, and when a marker is abolished an alternative marker should be specified.
The agents in Scenes 39 to 43 suppress a pathway that functions normally but is overactive. These four scenes differ: each agent is matched to a molecular defect, in accordance with the 2025 inborn errors of immunity practice parameter. In a JAK/STAT gain-of-function disorder the lesion is a signalling molecule that cannot be inactivated, so inhibition of the upstream kinase restores rather than suppresses signalling; it is the only medical therapy, other than transplantation, that addresses the lesion. Ruxolitinib or baricitinib is used for STAT1 gain-of-function, monitored by CXCL9 and Th17 numbers; ruxolitinib or tofacitinib for STAT3 gain-of-function, monitored by double-negative T cells, with the strongest recommendation in the group; ruxolitinib for STAT4 and STAT5b; and baricitinib or tofacitinib for SOCS1 haploinsufficiency, in which the inhibitor rather than the kinase is deficient but the functional result is the same. The same drugs treat the type I interferonopathies (USP18 deficiency, SAVI, Aicardi-Goutières syndrome and CANDLE), monitored by an interferon-activity score, the measure also used to monitor anifrolumab in lupus. There are no clinical trials in any of these disorders and the evidence is at cohort and case-report level, as the gradings indicate; early introduction may nevertheless determine whether the disease resolves. Dosing is derived from cohort experience, aciclovir prophylaxis is suggested because of the herpesvirus risk, and treatment is lifelong or until transplant. The converse condition should be distinguished: STAT1 loss-of-function affects the same molecule in the opposite direction and is treated with IFN-γ and not with a JAK inhibitor.
The inflammasome disorders are the clearest example of a disease explained by a single cytokine and controlled by its blockade. The three IL-1 agents are not interchangeable: anakinra blocks IL-1α as well as IL-1β, is cleared in 4 to 6 hours and probably has better central nervous system penetration, which is relevant in NOMID; rilonacept traps both, and IL-1RA as well, with a half-life of about a week; canakinumab neutralises IL-1β alone and persists for 22.9 to 25.7 days, which is convenient unless infection supervenes. All three are strongly recommended with high certainty in CAPS, and canakinumab in TRAPS, familial Mediterranean fever and mevalonate kinase deficiency; anakinra or rilonacept is recommended in deficiency of the IL-1 receptor antagonist, which is the most direct precision therapy in this reference, since anakinra is the molecule that is deficient in the disease. The evidence is weaker but the mechanism is the same in PAPA syndrome, NLRP12 disease, Majeed syndrome, NOCARH and NLRC4 disease. Two practical considerations apply to all of these disorders: the marker for monitoring between attacks is serum amyloid A rather than CRP, because sustained SAA elevation is the precursor of AA amyloid and a normal CRP does not establish control; and because the response is rapid, a trial of IL-1 blockade is used diagnostically without awaiting genetic results.
Six agents are each matched to one lesion. Leniolisib inhibits the PI3K-delta that is constitutively active in activated PI3K-delta syndrome; with interferon gamma-1b in chronic granulomatous disease, it is one of two agents in this group supported by a randomised placebo-controlled trial; it is licensed in the USA from 4 years and 27 kg, with weight-banded dosing under 12 years, and in Canada from 12 years and 45 kg, and its response markers are entities in this reference: serum IgM, which is characteristically high in APDS and falls markedly, transitional B cells, plasmablasts and the CD8 TEMRA compartment. CTLA-4–Ig supplies the inhibitory function lost in CTLA-4 haploinsufficiency and LRBA deficiency, monitored by circulating Tfh cells and soluble CD25; it is the same molecule that, in Scene 41, suppresses a normal immune system. Elapegademase replaces adenosine deaminase and should be started as soon as absent enzyme activity is demonstrated, without awaiting the genetic result, as a bridging therapy to transplantation or gene therapy. Interferon gamma-1b is the converse of emapalumab: the cytokine is administered rather than neutralised, three times a week in chronic granulomatous disease and in the Mendelian susceptibility to mycobacterial disease group. Oral fucose restores the selectin ligands in leukocyte adhesion deficiency type II, and they are lost again on discontinuation. The defects of cobalamin and folate transport and metabolism (TCN2, SLC46A1, MTHFD1 and cblF) can present with a picture resembling severe combined immunodeficiency and respond to cobalamin or folate replacement, most completely when treatment begins early; neurological impairment can persist when treatment is late. Total plasma homocysteine, methylmalonic acid and folate should therefore be measured before a diagnosis of SCID is made in an infant with an SCID-like presentation, because serum vitamin B12 can be normal in transcobalamin deficiency; on treatment, the blood count, vitamin B12 and folate are monitored.
Precision agents treat a minority of these patients; the measures described here are those received by the remainder. Immunoglobulin replacement is started at 400 to 600 mg/kg a month, intravenously every three to four weeks or divided into weekly or two-weekly subcutaneous infusions, with a target IgG above 800 mg/dL; pneumonia falls by about a quarter for each additional 100 mg/dL of trough, and a trough of 500 carries about five times the pneumonia rate of 1000, with no further benefit above 1000. The population target is a minimum and not an individual goal: the dose is individualised to the level at which the individual patient ceases to have infections. It supplies IgG only, so mucosal IgA protection is not restored, and all IgG-based serology then reflects the donor pool; the immunological evaluation must therefore precede the first infusion. Prophylaxis is directed at the organisms to which the specific defect confers susceptibility: trimethoprim-sulfamethoxazole and itraconazole with interferon gamma in chronic granulomatous disease, Pneumocystis and Candida cover in severe T-cell defects, azithromycin for respiratory infection in antibody deficiency and for environmental mycobacteria, and daily penicillin or amoxicillin in terminal complement defects and asplenia. Vaccination is not contraindicated as a whole: live replicating vaccines are withheld in severe cellular, phagocytic and humoral defects (vaccine-strain rotavirus, BCG and rubella have all caused disease), but patients with isolated T-cell lymphopenia and preserved function may receive them, household contacts may receive live vaccines other than oral polio and replication-competent smallpox/mpox vaccine, and COVID-19 and HPV vaccination are recommended for all patients. Transplantation and gene therapy are the only curative treatments, and several agents in the earlier scenes are accordingly described as treatment until transplant rather than as definitive therapy.
Seventeen regulatory circuits appear across the scenes above: ten feedback loops, one effector arm, one resolution switch, one coordinated hepatic output, two mutual-antagonism circuits, one competitive block, and the complement amplification loop. A loop means the output of a pathway eventually changes the input to that same pathway — trace each loop back to its start to confirm it closes.
Most interleukins and interferons in this atlas signal through Janus kinases (JAK1/2/3, TYK2) phosphorylating STAT transcription factors — every blue/purple cascade drawn above. The TNF superfamily, the IL-1 and IL-17 families, the receptor-tyrosine-kinase growth factors (M-CSF, IL-34, SCF, Flt-3L, EGF, TGFα, FGF-2, PDGF, VEGF-A), cytotoxic granule proteins, and all chemokines do not — every amber (NF-κB), olive (receptor tyrosine kinase), red (death receptor / granule), grey (decoy / CD4) or teal (chemokine) cascade above. "Suppression" via JAK-STAT is almost always indirect: a STAT drives transcription of a suppressor gene (most often SOCS1/SOCS3) that then caps further cytokine signalling. The Clinical correlate column below is a compressed pointer, not a full account — for clinical presentation, cytokine profile, and diagnostic workup on each of these, see the companion Pathway → Phenotype Chart.
| Cytokine | JAKs | Primary STAT(s) | Net effect | Clinical correlate if disrupted | Main scene |
|---|---|---|---|---|---|
| TSLP | JAK1, JAK2 | STAT5 | Induction — Th2-priming programme in DCs | Tezepelumab (anti-TSLP) approved for severe asthma and CRSwNP; TSLP variants associate with asthma; CRLF2 rearrangement in Ph-like ALL | Scene 7 |
| IL-10 | JAK1, TYK2 | STAT3 | Suppression — STAT3-induced programme represses NF-κB target genes | Ligand or receptor LOF (IL10, IL10RA, IL10RB) → very early-onset inflammatory bowel disease | Scene 1 |
| IL-35 | JAK1, JAK2 | STAT1 + STAT4 heterodimer | Suppression — iTr35 conversion, anti-proliferative | No monogenic disease; constitutive production by human Tregs is still debated | Scene 9 |
| IL-12p70 | JAK2, TYK2 | STAT4 | Induction — T-bet, drives Th1 | LOF (IL12B/IL12RB1) → MSMD; STAT4 GOF → disabling pansclerotic morphea (JAK-inhibitor responsive) | Scene 2 |
| IL-27 | JAK1, JAK2, TYK2 | STAT1 and STAT3 (dual, sequential) | Both — early STAT1 supports Th1; late STAT1+3 suppresses Th17, induces IL-10 | Biallelic IL27RA LOF → severe but self-limited primary EBV infection (infectious mononucleosis) | Scene 2 |
| IFNγ | JAK1, JAK2 | STAT1 (GAF) | Induction — macrophage activation, IL-12 amplification | Receptor LOF (IFNGR1/2) → MSMD, severity tracks AD-partial vs AR-complete inheritance | Scene 2 |
| IFNα2 | JAK1, TYK2 | STAT1/STAT2 + IRF9 (ISGF3) | Induction — antiviral genes | LOF (IFNAR/STAT1/2/IRF9) → severe/fatal viral infection; pathway dysregulation → type I interferonopathies (SAVI, CANDLE, AGS) | Scene 5 |
| IFNβ | JAK1, TYK2 | STAT1/STAT2 + IRF9 (ISGF3) | Induction — antiviral genes; IRF7 amplification | IFN-β therapy for relapsing MS; IFNAR1 / IFNAR2 LOF → severe disease from live vaccines and viruses | Scene 8 |
| IFNω | JAK1, TYK2 | STAT1/STAT2 + IRF9 (ISGF3) | Induction — antiviral genes | Neutralizing autoantibodies to IFN-α and/or IFN-ω in ~10–20% of critical COVID-19 pneumonia and in almost all APS-1 (AIRE) patients | Scene 8 |
| IL-28A | JAK1, TYK2 | STAT1/STAT2 + IRF9 (ISGF3) | Induction — antiviral genes at barriers | Variants at the neighbouring IFNL3 (IL28B) / IFNL4 genes, not IL-28A itself, predict spontaneous and treatment-induced hepatitis C clearance | Scene 8 |
| IL-29 | JAK1, TYK2 | STAT1/STAT2 + IRF9 (ISGF3) | Induction — antiviral genes at barriers | Pegylated IFN-λ1 tested in hepatitis D and COVID-19; no monogenic disease | Scene 8 |
| IL-4 | JAK1, JAK3 (type I) / JAK1, JAK2, TYK2 (type II) | STAT6 | Induction — GATA3, IgE class switch | Common IL4RA variants (e.g., Q576R; functional effect debated) associate with atopy/asthma; pathway overactivity → atopic dermatitis (dupilumab) | Scene 3 |
| IL-5 | JAK1, JAK2 | STAT5 (shares beta-c with GM-CSF) | Induction — eosinophil genes | Pathway overactivity → hypereosinophilic syndrome (mepolizumab and benralizumab FDA-approved for HES; benralizumab also approved for EGPA) | Scene 3 |
| IL-9 | JAK1, JAK3 | STAT5 (also STAT1/3) | Induction — mast cell growth genes | No dedicated monogenic disease; shares the γc/JAK3 machinery with the SCID genes | Scene 3 |
| IL-13 | JAK1, JAK2, TYK2 | STAT6 | Induction — Th2 effector genes | Same overactivity axis as IL-4 → atopic dermatitis (dupilumab, tralokinumab, lebrikizumab) and asthma (dupilumab) | Scene 3 |
| IL-31 | JAK1, JAK2 | STAT3 (mainly; also STAT1/5) | Induction — pruritus signalling genes | Pathway overactivity → chronic pruritus in atopic dermatitis and prurigo nodularis (nemolizumab) | Scene 3 |
| IL-21 | JAK1, JAK3 | STAT3 (also STAT1) | Induction — Th17 autocrine loop, B cell help | IL21R LOF → combined immunodeficiency with Cryptosporidium cholangitis / liver disease; IL21 LOF → very-early-onset IBD with CVID-like features | Scene 4 |
| IL-22 | JAK1, TYK2 | STAT3 | Induction — epithelial antimicrobial genes | Falls with broader STAT3 defects; no isolated IL-22 monogenic disease described | Scene 4 |
| IL-23 | JAK2, TYK2 | STAT3 | Induction — stabilizes RORγt+ Th17 / ILC3; IL-17 and IL-22 genes | Pathway overactivity → psoriasis, IBD (guselkumab, risankizumab); IL23R reduced-function variant is protective | Scene 2, 4 |
| IL-20 | JAK1, TYK2 | STAT3 | Induction — keratinocyte proliferation | Over-expressed in psoriatic skin and RA synovium; no monogenic disease | Scene 10 |
| IL-24 | JAK1, TYK2 | STAT3 | Induction — keratinocyte proliferation; ↓ filaggrin | Raised in atopic-dermatitis and psoriasis lesions; no monogenic disease | Scene 10 |
| IL-2 | JAK1, JAK3 | STAT5 | Induction — proliferation genes | IL2RA (CD25) LOF → IPEX-like immune dysregulation | Scene 5 |
| IL-7 | JAK1, JAK3 | STAT5 | Induction — survival genes | IL7R LOF → SCID, T-B+NK+ phenotype | Scene 5 |
| IL-15 | JAK1, JAK3 | STAT5 | Induction — NK/memory CD8 survival (trans-presented) | No dedicated monogenic disease; shares JAK3 with the SCID genes | Scene 5 |
| IL-6 | JAK1, JAK2, TYK2 | STAT3 | Induction — acute-phase genes (hepatocyte); Th17 support | STAT3 node shared with Job syndrome; drives CRP/SAA in autoinflammation; tocilizumab target | Scene 4, 5 |
| IL-11 | JAK1 (JAK2, TYK2) | STAT3 | Induction — fibrotic (largely ERK-dependent) and megakaryocyte genes | IL11RA LOF → craniosynostosis with delayed tooth eruption; recombinant IL-11 (oprelvekin) once used for chemotherapy thrombocytopenia | Scene 10 |
| LIF | JAK1 (JAK2, TYK2) | STAT3 | Induction — mouse ES-cell self-renewal / acute-phase genes | LIFR LOF → Stüve–Wiedemann syndrome (bowed long bones, dysautonomia, hyperthermia) | Scene 10 |
| IL-3 | JAK2 | STAT5 | Induction — progenitor, basophil, mast-cell genes | CD123 targeted by tagraxofusp (BPDCN); no monogenic disease | Scene 11 |
| GM-CSF | JAK2 | STAT5 | Induction — myeloid genes | Receptor LOF or anti-GM-CSF autoantibodies → pulmonary alveolar proteinosis | Scene 5 |
| G-CSF | JAK1, JAK2 | STAT3 (also STAT5) | Induction — neutrophil granule / release genes | Acquired CSF3R truncations in severe congenital neutropenia herald AML; CSF3R T618I → chronic neutrophilic leukaemia; filgrastim | Scene 11 |
| TPO | JAK2 | STAT5 (also STAT3) | Induction — megakaryocyte growth genes | MPL LOF → congenital amegakaryocytic thrombocytopenia; JAK2 V617F / MPL W515 → ET and myelofibrosis; TPO-receptor agonists for ITP | Scene 11 |
| Cytokine | Pathway class | Receptor | Signalling | Clinical correlate if disrupted | Main scene |
|---|---|---|---|---|---|
| IL-1α | NF-κB family | IL-1R1 + IL-1RAcP (IL-1R2 / CD121b is a membrane and soluble decoy) | MyD88 / IRAK4 / TRAF6 → NF-κB, MAPK | Shares IL-1R1 with IL-1β (anakinra blocks both); MyD88/IRAK4 LOF → pyogenic infection with blunted fever | Scene 1 |
| IL-1β | NF-κB family | IL-1R1 + IL-1RAcP (IL-1R2 / CD121b is a membrane and soluble decoy) | MyD88 / IRAK4 / TRAF6 → NF-κB, MAPK | NLRP3 GOF → CAPS (anakinra, canakinumab, rilonacept); IL-1 blockade in Still’s disease and gout | Scene 1 |
| IL-18 | NF-κB family | IL-18Rα + IL-18Rβ | MyD88 / IRAK → NF-κB | NLRC4 GOF → very high free IL-18 and macrophage activation syndrome; serum IL-18 marks MAS risk in Still’s / sJIA | Scene 1, 2 |
| TNFα | NF-κB family | TNFR1 (p55), TNFR2 (p75) | TRADD / TRAF2 / RIPK1 → NF-κB, MAPK; or caspase-8 death | Dominant TNFRSF1A mutations → TRAPS; anti-TNF therapy unmasks latent TB | Scene 1 |
| TNFβ | NF-κB family | TNFR1, TNFR2, HVEM (and LTβR as LTα1β2) | TRADD / TRAF2 → NF-κB | LTα / LTβR needed for lymphoid-organ development (mouse knockouts lack lymph nodes); shares TNFR1 with TNF-α | Scene 1 |
| HMGB1 | NF-κB family | RAGE; TLR4 (disulfide form); CXCR4 when complexed with CXCL12 (reduced form) | TLR4 → MyD88 → NF-κB; RAGE → MAPK / NF-κB | Late mediator and biomarker of lethal sepsis and sterile injury; no monogenic disease | Scene 7 |
| IL-33 | NF-κB family | ST2 (IL1RL1) + IL-1RAcP; soluble ST2 is a decoy | MyD88 / IRAK → NF-κB, MAPK | IL33 and IL1RL1 are leading asthma GWAS loci; anti-IL-33 / anti-ST2 antibodies are in COPD and asthma trials | Scene 7 |
| IL-17E/IL-25 | NF-κB family | IL-17RA + IL-17RB | Act1 → TRAF6 → NF-κB | No monogenic disease; raised in asthmatic airways and atopic-dermatitis lesions | Scene 7 |
| IL-17A | NF-κB family | IL-17RA + IL-17RC | Act1 → TRAF6 → NF-κB, C/EBPβ | Receptor / adaptor LOF (IL17RA, IL17RC, ACT1 / TRAF3IP2) → chronic mucocutaneous candidiasis; overactivity → psoriasis (secukinumab, ixekizumab) | Scene 4 |
| IL-17F | NF-κB family | IL-17RA + IL-17RC (as homodimer or IL-17A/F heterodimer) | Act1 → TRAF6 → NF-κB, C/EBPβ | Dominant IL17F LOF → chronic mucocutaneous candidiasis; bimekizumab blocks IL-17A and IL-17F (psoriasis, hidradenitis) | Scene 10 |
| BAFF | NF-κB family | BAFF-R (BR3), TACI, BCMA | TRAF3 degradation → NIK → non-canonical NF-κB (p52 / RelB) | TNFRSF13C (BAFF-R) LOF → CVID-like B lymphopenia; belimumab (anti-BAFF) for SLE; BAFF high in SLE and Sjögren’s | Scene 13 |
| APRIL | NF-κB family | TACI, BCMA (plus heparan sulfate proteoglycans) | TRAF → canonical and non-canonical NF-κB | TNFRSF13B (TACI) variants in ~8–10% of CVID (risk modifiers); BCMA is a CAR-T / bispecific target in myeloma; anti-APRIL agents in IgA nephropathy | Scene 13 |
| sCD40L | NF-κB family | CD40 (also αIIbβ3 and Mac-1 integrins) | TRAF2/3/5/6 → canonical and non-canonical NF-κB | CD40LG LOF → X-linked hyper-IgM syndrome (Pneumocystis, Cryptosporidium cholangitis); plasma sCD40L tracks platelet activation | Scene 13 |
| IL-1RA | Antagonist / decoy | IL-1R1 (occupies without recruiting IL-1RAcP) | Competitive block — no signal | IL1RN LOF → DIRA (neonatal pustulosis, osteitis); anakinra is recombinant IL-1RA | Scene 1 |
| IL-12p40 | Antagonist / decoy | IL-12Rβ1 (as free p40 or p40 homodimer) | Occupies IL-12Rβ1 without STAT activation — competitive antagonist of IL-12 / IL-23 (mainly in mice) | IL12B LOF → MSMD (loses IL-12 and IL-23); ustekinumab targets p40 (psoriasis, Crohn’s) | Scene 9 |
| sCD137 | Antagonist / decoy | Binds 4-1BBL (CD137L) — decoy | No signal; blocks 4-1BB co-stimulation | TNFRSF9 (membrane 4-1BB) LOF → EBV-driven lymphoproliferation; 4-1BB agonists studied in cancer immunotherapy | Scene 9 |
| sFas | Antagonist / decoy | Binds FasL — decoy | No signal; blocks Fas-mediated apoptosis | Raised in SLE and several cancers; FAS germline / somatic LOF → ALPS | Scene 9 |
| M-CSF | Receptor tyrosine kinase | CSF1R (c-FMS) | Receptor tyrosine kinase → PI3K / AKT, ERK | CSF1R LOF → adult-onset leukoencephalopathy (ALSP); CSF1R inhibitor pexidartinib for tenosynovial giant-cell tumour | Scene 11 |
| IL-34 | Receptor tyrosine kinase | CSF1R (also PTPRZ1, syndecan-1) | Receptor tyrosine kinase → PI3K / AKT, ERK | No monogenic disease; raised in RA synovium | Scene 11 |
| SCF | Receptor tyrosine kinase | KIT (CD117) | Receptor tyrosine kinase → PI3K / AKT, MAPK, (STAT) | KIT D816V → systemic mastocytosis (avapritinib, midostaurin); KIT LOF → piebaldism; anti-KIT antibody trials in chronic urticaria | Scene 11 |
| Flt-3 Ligand | Receptor tyrosine kinase | FLT3 (CD135) | Receptor tyrosine kinase → PI3K / AKT, RAS / MAPK, STAT5 | FLT3-ITD / TKD mutations in ~30% of AML (midostaurin, gilteritinib); serum Flt-3L rises in marrow aplasia | Scene 11 |
| EGF | Receptor tyrosine kinase | EGFR (ErbB1) | Receptor tyrosine kinase → RAS / MAPK, PI3K / AKT, PLCγ | EGFR LOF → neonatal inflammatory skin and bowel disease; EGFR inhibitors cause acneiform rash and paronychia | Scene 12 |
| TGFα | Receptor tyrosine kinase | EGFR (ErbB1) | Receptor tyrosine kinase → RAS / MAPK, PI3K / AKT | ADAM17 LOF (cannot shed TGF-α or TNF-α) → neonatal inflammatory skin and bowel disease; over-expressed in psoriasis | Scene 12 |
| FGF-2 | Receptor tyrosine kinase | FGFR1–4 + heparan sulfate | Receptor tyrosine kinase → RAS / MAPK, PI3K, PLCγ | Raised in asthmatic airways after allergen challenge; no monogenic disease | Scene 12 |
| PDGF-AA | Receptor tyrosine kinase | PDGFRα homodimer | Receptor tyrosine kinase → PI3K, PLCγ, RAS / MAPK | FIP1L1-PDGFRA fusion → myeloid neoplasm with eosinophilia (imatinib-responsive); PDGFRA GOF → GIST | Scene 12 |
| PDGF-AB/BB | Receptor tyrosine kinase | PDGFRαα, PDGFRαβ, PDGFRββ (BB binds all three; AB binds αα and αβ) | Receptor tyrosine kinase → PI3K, PLCγ, RAS / MAPK | PDGFRB fusions (e.g., ETV6-PDGFRB) → myeloid neoplasm with eosinophilia (imatinib-responsive); becaplermin (rhPDGF-BB) for diabetic ulcers | Scene 12 |
| VEGF-A | Receptor tyrosine kinase | VEGFR2 (KDR) + neuropilin-1; VEGFR1 (FLT1) as a high-affinity sink | Receptor tyrosine kinase → PLCγ / ERK, PI3K / AKT / eNOS | Anti-VEGF therapy (bevacizumab, intravitreal agents); serum VEGF is a diagnostic marker of POEMS syndrome | Scene 12 |
| sFasL | Death receptor | Fas (CD95) | FADD → caspase-8 → caspase-3 (soluble form is a weak killer) | Serum sFasL >200 pg/mL is a diagnostic biomarker of ALPS; FASLG LOF → ALPS-FASLG; Fas–FasL in SJS/TEN keratinocyte death | Scene 14 |
| TRAIL | Death receptor | DR4 (TRAIL-R1), DR5 (TRAIL-R2); decoys DcR1, DcR2, OPG | FADD → caspase-8 → caspase-3; also NF-κB | No monogenic disease; serum TRAIL (with IP-10, CRP) separates viral from bacterial infection in host-response assays | Scene 14 |
| Perforin | Cytotoxic granule | Inserts into the target-cell membrane (Ca²⁺-dependent) | Forms pores → delivers granzymes | Biallelic PRF1 LOF → familial HLH type 2; perforin flow cytometry in the HLH work-up | Scene 14 |
| Granzyme A | Cytotoxic granule | Enters through perforin pores (extracellular actions via unknown receptors) | Cleaves SET complex → single-strand DNA nicks (caspase-independent); cleaves gasdermin B | Raised in sepsis and RA synovial fluid; no monogenic disease | Scene 14 |
| Granzyme B | Cytotoxic granule | Enters through perforin pores | Cleaves BID and caspase-3/7 → mitochondrial apoptosis | No monogenic disease; extracellular granzyme B rises with cytotoxic activation (e.g., SJS/TEN blister fluid) | Scene 14 |
| IL-8 | Chemokine GPCR | CXCR1, CXCR2 | Gαi → PI3K, Rho GTPases, Ca²⁺ flux | CXCR2 / IL-8 axis drives neutrophilic airway disease; no monogenic disease | Scene 6 |
| GROα | Chemokine GPCR | CXCR2 | Gαi → PI3K, Rho GTPases, Ca²⁺ flux | No monogenic disease | Scene 6 |
| ENA-78 | Chemokine GPCR | CXCR2 | Gαi → PI3K, Rho GTPases, Ca²⁺ flux | Raised in neutrophilic lung inflammation; no monogenic disease | Scene 15 |
| GCP-2 | Chemokine GPCR | CXCR1, CXCR2 | Gαi → PI3K, Rho GTPases, Ca²⁺ flux | No monogenic disease | Scene 15 |
| IP-10 | Chemokine GPCR | CXCR3 | Gαi → PI3K, Ca²⁺ flux | Host-response marker of viral infection (with TRAIL, CRP); raised in IFN-driven diseases | Scene 6 |
| MIG | Chemokine GPCR | CXCR3 | Gαi → PI3K, Ca²⁺ flux | Serum CXCL9 reflects IFN-γ activity in HLH / MAS and was used to track emapalumab response | Scene 15 |
| I-TAC | Chemokine GPCR | CXCR3 (highest affinity); ACKR3 scavenger | Gαi → PI3K, Ca²⁺ flux | Raised in allograft rejection; C57BL/6 laboratory mice lack functional CXCL11 | Scene 15 |
| MCP-1 | Chemokine GPCR | CCR2 | Gαi → PI3K, Ca²⁺ flux | No monogenic disease; the classical-monocyte recruitment axis in atherosclerosis and fibrosis | Scene 6 |
| MCP-2 | Chemokine GPCR | CCR1, CCR2, CCR3, CCR5 (CCR8 in mice) | Gαi → PI3K, Ca²⁺ flux | No monogenic disease | Scene 16 |
| MCP-3 | Chemokine GPCR | CCR1, CCR2, CCR3 (CCR5 antagonist) | Gαi → PI3K, Ca²⁺ flux | No monogenic disease | Scene 16 |
| MIP-1α | Chemokine GPCR | CCR1, CCR5 | Gαi → PI3K, Ca²⁺ flux | No monogenic disease; homozygous CCR5 Δ32 (no surface CCR5) → near-complete R5 HIV-1 resistance; heterozygotes progress more slowly | Scene 6 |
| MIP-1β | Chemokine GPCR | CCR5 | Gαi → PI3K, Ca²⁺ flux | No monogenic disease; homozygous CCR5 Δ32 → R5 HIV-1 resistance | Scene 6 |
| MIP-1δ | Chemokine GPCR | CCR1, CCR3 | Gαi → PI3K, Ca²⁺ flux | No monogenic disease | Scene 16 |
| MPIF-1 | Chemokine GPCR | CCR1 | Gαi → PI3K, Ca²⁺ flux | No monogenic disease | Scene 16 |
| RANTES | Chemokine GPCR | CCR1, CCR3, CCR5 | Gαi → PI3K, Ca²⁺ flux | No monogenic disease; CCR5 antagonist maraviroc blocks R5 HIV | Scene 6 |
| Eotaxin | Chemokine GPCR | CCR3 | Gαi → PI3K, Ca²⁺ flux | No monogenic disease | Scene 6 |
| Eotaxin-2 | Chemokine GPCR | CCR3 | Gαi → PI3K, Ca²⁺ flux | Raised in late-phase asthmatic airways; no monogenic disease | Scene 17 |
| Eotaxin-3 | Chemokine GPCR | CCR3 (also a CX3CR1 agonist and a CCR1, CCR2, CCR5 antagonist) | Gαi → PI3K, Ca²⁺ flux | CCL26 is the most up-regulated gene in eosinophilic-oesophagitis biopsies; falls with effective therapy | Scene 17 |
| MCP-4 | Chemokine GPCR | CCR1, CCR2, CCR3 | Gαi → PI3K, Ca²⁺ flux | Raised in atopic-dermatitis skin and asthmatic airways; no monogenic disease | Scene 17 |
| TARC | Chemokine GPCR | CCR4 | Gαi → PI3K, Ca²⁺ flux | Serum TARC is the best-validated biomarker of atopic-dermatitis severity; also raised in classic Hodgkin lymphoma and DRESS | Scene 17 |
| MDC | Chemokine GPCR | CCR4 | Gαi → PI3K, Ca²⁺ flux | Raised in atopic dermatitis and asthma; mogamulizumab (anti-CCR4) treats mycosis fungoides / Sézary syndrome (ATLL in Japan) | Scene 17 |
| I-309 | Chemokine GPCR | CCR8 | Gαi → PI3K, Ca²⁺ flux | CCR8 is a tumour-Treg depletion target in oncology trials; no monogenic disease | Scene 17 |
| SDF-1 | Chemokine GPCR | CXCR4 (ACKR3 = scavenger) | Gαi → PI3K, Ca²⁺ flux | CXCR4 GOF → WHIM syndrome (oral CXCR4 antagonist mavorixafor approved 2024, 12 years and over); plerixafor mobilizes stem cells | Scene 6 |
| 6Ckine | Chemokine GPCR | CCR7 | Gαi → PI3K, Ca²⁺ flux; integrin activation | No monogenic disease; CCR7 on tumour cells favours lymph-node metastasis | Scene 18 |
| MIP-3β | Chemokine GPCR | CCR7 | Gαi → PI3K, Ca²⁺ flux | No monogenic disease | Scene 18 |
| BCA-1 | Chemokine GPCR | CXCR5 | Gαi → PI3K, Ca²⁺ flux | Plasma CXCL13 is a germinal-centre activity marker; CSF CXCL13 marks Lyme neuroborreliosis and CNS lymphoma | Scene 18 |
| MIP-3α | Chemokine GPCR | CCR6 (its only chemokine receptor; β-defensin-2 is also reported to bind CCR6) | Gαi → PI3K, Ca²⁺ flux | Keratinocyte CCL20 sustains psoriatic Th17 infiltration; CCR6 variants associate with RA | Scene 18 |
| CTACK | Chemokine GPCR | CCR10 | Gαi → PI3K, Ca²⁺ flux | Serum CCL27 tracks atopic-dermatitis severity | Scene 18 |
| CCL28 | Chemokine GPCR | CCR10, CCR3 | Gαi → PI3K, Ca²⁺ flux | No monogenic disease | Scene 18 |
| Lymphotactin | Chemokine GPCR | XCR1 | Gαi → PI3K, Ca²⁺ flux | No monogenic disease; XCR1 is a target for DC-directed vaccines | Scene 18 |
| Fractalkine | Chemokine GPCR | CX3CR1 | Gαi + direct adhesion (membrane-anchored on a mucin stalk; ADAM10/17 shed) | CX3CR1 variants (V249I / T280M) associate with atherosclerosis and macular degeneration | Scene 18 |
| IL-16 | Other (CD4) | CD4 (with CD9) — not a GPCR | CD4-associated Lck signalling → migration, IL-2Rα (CD25) expression | Raised in asthmatic airways after allergen challenge; no monogenic disease | Scene 17 |
The suppression mechanism worth naming explicitly: JAK-STAT cytokines frequently cap their own or each other's signalling by inducing SOCS (suppressor of cytokine signalling) proteins. IFN-gamma induces SOCS1; IL-6, IL-10, and IL-27 induce SOCS3. Once expressed, SOCS proteins bind JAKs or receptor docking sites and block further STAT activation — SOCS3 mainly caps signalling from the gp130 family (IL-6, IL-27), which is why IL-6 and IL-10 give opposite outcomes through the same STAT3. IL-10's own anti-inflammatory effect does not depend on SOCS3: it comes from a STAT3-induced suppressive gene programme (Scene 1).
The signalling vocabulary used throughout this atlas. For clinical/genetic terminology (disease names, inheritance patterns, diagnostic tests), see the glossary in the companion Pathway → Phenotype Chart.